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Abstract
Virtually all studies on the molecular regulation of axonal growth have been carried 
out on axotomised neurons that regenerate axons in culture and are dependent on neurotrophic 
factors not only for survival but also for axonal growth. The technical difficulty of obtaining 
and culturing early, newly differentiated neurons that initiate axonal growth for the first time 
in culture has meant that developmentally relevant de novo axonal growth has been almost 
ignored. Numerous studies have shown that axonal regeneration from embryonic and 
postnatal neurotrophic factor-dependent neurons is regulated by a variety of signalling 
pathways that influence the assembly and stability of key components of the cytoskeleton in 
growth cones. Depending on neuron type, these can include MEK, PI3 kinase, GSK3, NF-kB 
and calcium signalling. The extent to which these pathways are important for de novo axonal 
growth, and how their importance changes as axonal growth becomes responsive to 
neurotrophic factors during early development is not known.
I have used the experimentally advantageous placode-derived sensory neurons of the 
chicken embryo to study the molecular basis of de novo, neurotrophic factor independent 
axonal growth and to compare this neurotrophic factor-dependent axonal growth at later 
stages of development. These neurons can be dissected from the earliest stages in their 
development and cultures can be established in which neurons extend axons for the first time. 
Previous work has shown that at this stage of development, axonal growth is independent of 
neurotrophic factors and its rate is correlated with target distance. For example, neurons of 
the nodose ganglion have the most distant targets, the fastest axonal growth rate and survive 
longest before becoming dependent on the neurotrophic factor BDNF for survival, whereas 
neurons of the vestibular ganglion have the nearest targets, slowest axonal growth rate and 
survive for the shortest time before acquiring BDNF dependence.
My initial studies focused on the role of the extracellular calcium-sensing receptor 
(CaSR), a G protein coupled receptor that has recently been shown to regulate axonal growth 
from sympathetic neurons during the stage when neurons are innervating their targets. I 
found that during the stage of development when the earliest axons of placode-derived 
sensory neurons are growing to their targets, nodose ganglion neurons (which have the fastest 
axon growth rates) express the highest levels of the CaSR, and vestibular neurons (which have 
the slowest axon growth rates) express the lowest levels of the CaSR. Experimental 
manipulation of CaSR activation in cultured nodose neurons at the stage in development when 
their axons are normally growing to their targets markedly affects axon growth rate
1
(enhancing activation increases growth rate whereas reducing activation has the opposite 
effect). In contrast, similar manipulations of CaSR activation in cultured vestibular neurons 
have no effects on axonal growth rate. These findings suggest that the CaSR plays an 
important role in the regulation of de novo axonal growth rate. Manipulating CaSR activation 
in older, BDNF-dependent nodose neurons at the stage in development when these neurons 
are innervating their targets also demonstrated a role for the CaSR in promoting axonal 
growth at this stage.
Having demonstrated a role for the CaSR in promoting axonal growth at these two 
successive stages of development, I then characterised the intracellular signalling pathways 
that mediate the effects of the CaSR on axonal growth at these stages. Using Western blot 
analysis and pharmacological inhibitors of PI3-kinase, GSK3 and MEK1/2, I discovered a 
clear switch in the signalling pathways that are involved in promoting axon elongation 
between early BDNF-independent stages of de novo axon growth to later BDNF-dependent 
stages of axon growth. Whereas PI3-kinase signalling plays a pivotal role in transducing 
CaSR-enhanced, neurotrophin-independent axon growth, GSK3 signalling plays a major role 
in transducing the growth enhancing effects of CaSR activation on BDNF-promoted axonal 
growth from older BDNF-dependent nodose neurons. My findings suggest that PI3-Kinase 
and GSK3 signalling are not linked in developing nodose neurons, but are regulated 
independently of each other. Furthermore, Western analysis also suggests the operation of a 
novel activation mechanism of GSK3 in axon growth in BDNF-dependent nodose neurons 
that involves tyrosine phosphorylation of GSK3 rather than serine phosphoryation following 
CaSR activation. In all, my studies have revealed several novel and unexpected aspects of 
regulation of axonal growth by the CaSR during the early stages of neuronal development.
2
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Chapter 1 
Introduction
1 .Introduction
The work of this thesis focuses on two key aspects of neuronal development, the regulation of de 
novo axonal growth in early, neurotrophic factor-independent neurons and the control of neuronal 
growth in axotomized, neurotrophic factor dependent-neurons. This research was carried out on the 
cranial sensory neurons of the vestibular and nodose ganglia of the embryonic chicken peripheral 
nervous system. I will therefore begin this introductory chapter with a brief overview of the anatomy 
and development of the peripheral nervous system, with an emphasis on the cranial sensory neurons. 
I will describe growth cone structure and function, and provide an overview of some of the key 
extracellular signalling proteins, especially neurotrophic factors, that influence the growth of 
neuronal processes and regulate the survival of neurons during development. I will introduce the 
extracellular calcium sensing receptor (CaSR), as the influence of this receptor on neurite growth 
forms a major part of the research described in this thesis. Finally, I will outline the main 
intracellular signalling pathways that mediate the effects of neurotrophic factors and the CaSR, with 
a particular emphasis on the pathways I have studied in this thesis, namely, the glycogen synthase 
kinase-3 (GSK3), phosphoinositol 3-kinase (PI 3-kinase) and mitogen-activated protein (MAP- 
kinase) pathways.
2. Organization o f the peripheral nervous system
The peripheral nervous system consists of somatic and autonomic divisions. The somatic division is 
comprised of sensory neurons and the axons of motoneurons. Sensory neurons, whose cell bodies 
reside within cranial sensory ganglia and dorsal root ganglia, convey sensory information from skin, 
muscles, joints and viscera to the CNS. Motoneurons, whose cell bodies reside within the spinal cord 
and brainstem of the CNS, innervate skeletal muscle. The autonomic division is comprised of three 
subdivisions: the sympathetic, parasympathetic and enteric nervous systems. The sympathetic and 
parasympathetic subdivisions use a disynaptic pathway to influence their target tissues. The cell 
bodies of preganglionic neurons reside within the brainstem and spinal cord. The axons of 
preganglionic neurons synapse with postganglionic neurons whose cell bodies reside in paravertebral 
and prevertebral sympathetic ganglia and in terminal and cranial parasympathetic ganglia. The 
enteric nervous system is comprised of a network of sensory, visceral motor and intemeurons that are 
predominantly embedded in plexi lining the digestive system. Enteric sensory neurons detect 
intestinal stretch and the chemical composition within the lumen of the digestive system. This 
information is processed by intemeurons that regulate motor neuron functions like peristalsis, control 
of blood vessel diameter and secretion of digestive enzymes. Although the enteric nervous system
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operates in a predominantly autonomous manner, its function is modulated to a certain extent by 
input from the sympathetic and parasympathetic divisions of the ANS.
Cranial sensory ganglia are associated with 5 of the 12 pairs cranial nerves. The trigeminal ganglion 
of cranial nerve V (trigeminal nerve) is comprised of neurons that innervate mainly thermoreceptors 
and nociceptors in the face, oral cavity and nasal cavity and periodontal mechanoreceptors of teeth. 
Most of the neurons of the geniculate ganglion of cranial nerve VII (facial nerve) innervate taste buds 
of the anterior two thirds of the tongue, and small number innervate the skin of the external ear. The 
vestibular and cochlear ganglia (the latter known as the spiral ganglion in mammals) of cranial nerve 
VIII (vestibulocochlear nerve) innervate the hair cells of the organs of hearing and balance. The 
petrosal ganglion (inferior glossopharyngeal ganglion) of cranial nerve IX (glossopharyngeal nerve) 
contains the cell bodies of visceral afferent neurons that innervate the oropharynx, carotid body and 
the taste buds of the posterior third of the tongue. The superior glossopharyngeal ganglion of cranial 
nerve EX (vagus nerve) contains somatic sensory neurons that innervate a portion of the skin of the 
external ear. The nodose ganglion (inferior vagal ganglion) of cranial nerve X contains visceral 
afferent neurons that innervate the pharynx, larynx and viscera of the thorax and abdomen. The 
jugular ganglion (superior vagal ganglion) of cranial nerve X contains somatic sensory neurons that 
innervate the external auditory meatus. In addition to the above cranial sensory ganglia, there are two 
further populations of primary sensory neurons associated with cranial nerves. These are the 
olfactory neurons (cranial nerve I) resident within the olfactory epithelium and the proprioceptive 
neurons of the trigeminal mesencephalic nucleus (cranial nerve V) that innervate the muscles of 
mastication. The optic nerve (cranial nerve II), although traditionally classified as part of the 
peripheral nervous system, is more appropriately considered to be a CNS tract as it and the retina 
originate from the diencephalon during development.
3. Development of the peripheral nervous system
The cells of the peripheral nervous system are derived from two sources: the neural crest and 
ectodermal thickenings in the cranial region called placodes. The neural crest gives rise to all of the 
glial cells of the peripheral nervous system, namely, the Schwann cells of peripheral nerves and the 
satellite cells of peripheral ganglia. All postganglionic autonomic neurons, enteric neurons and the 
majority of sensory neurons of the peripheral nervous system are derived from the neural crest. 
Neurogenic placodes only give rise to the neurons in certain cranial sensory ganglia or parts of these
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ganglia and to olfactory neurons and their supporting cells in the olfactory and vomeronasal epithelia. 
Newly bom neurons extend axons that are guided to their target organs and tissues by a variety of 
guidance cues. Shortly after axons reach their targets, a substantial proportion of neurons is 
eliminated by a phase of cell death that serves to match the number of neurons to the functional 
requirements of their targets and the circuits in which they participate. After this period of naturally- 
occurring neuronal death, there is an ongoing phase of growth and elaboration of neural processes, 
synaptogenesis and refinement of neural connections.
3.1 Neural crest
The neural crest is a transient component of the ectoderm formed during the final stages of 
neurulation. It is comprised of cells at the margins of the approaching neural folds that do not 
become incorporated into the neural tube, but migrate away from the dorsal aspect of neural tube 
following neural tube closure to give rise to wide variety of cell types in addition to neurons and glial
cells of the peripheral nervous system. In chick embryos, the neural crest is specified during the
early stages of neurulation. Fate mapping experiments designed to reveal the prospective fate of 
various regions of the chick epiblast (the structure that develops out of the inner cell mass that 
differentiates into the three layer embryonic disc) have shown that prospective neural crest cells are 
located in the narrow margin of the epiblast between the prospective neural plate and epidermis 
(Rosenquist, 1981). The mechanisms by which the precursors of the neural crest cells are formed 
during development are unknown. One possibility is that some cells, particularly those of the 
marginal zone between the neural plate and presumptive epidermis, are relatively distant from the 
neural inducing signals produced by the mesoderm (Rosenquist, 1981) and consequently become 
assigned to a neural crest cell fate as a result of differential neural induction of the dorsal ectoderm 
by this underlying mesoderm (Mazzoni et al., 1999). Detailed fate mapping of neural crest cells, 
predominantly in the chick, has determined that they migrate along characteristic pathways to form 
specific cell types depending on their rostral-caudal position along the neuroaxis. For example, 
whereas melanocytes arise from the whole length of the neural crest, various types of peripheral 
nervous system neurons have distinct levels of origin along the neural axis (Figure 1.1).
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Fig. 1.1: Fate map of the derivates of the neural crest The levels of origin of the main derivates of the neural crest are indicated 
along the neural axis at 2 developmental stages: 7 somite stages and 28 somite stages. Illustration adapted from (Le Douarin, 
2004)
The molecular regulation of neural crest formation is incompletely understood. Both BMP 
and FGF signalling have been implicated in neural crest induction (Selleck and Bronner- 
Fraser, 1995), (D’Amico-Martel and Noden, 1983). A prevailing model for neural crest 
induction suggests that a gradient of BMP signalling subdivides the ectoderm into different 
domains: epidermis forms at high levels of BMP signalling, neural plate forms where BMP 
signalling is low and neural crest form at intermediate levels. Since both the neural crest and 
the placodes are induced by FGF signalling, an additional signal is considered to divide neural 
crest cells from placodal ectoderm, namely, the Wnts (Litsiou et al., 2005). Mouse embryos in 
which (3-catenin has been inactivated have malformed neural crest derivates, including the 
DRG and various craniofacial regions, implicating Wnt signalling in neural crest formation 
and differentiation (Brault et al., 2001), whereas stabilizing of p-catenin modulates the 
production of neural crest cells and melanocytes (Voigt and Papalopulu, 2006)
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3.2 Neurogenic Placodes
Certain cranial sensory neurons originate from the olfactory, trigeminal, otic and epibranchial 
placodes. These placodes are regions of columnar epithelium that form at distinct locations in the 
head close to the neural tube between the 10-30 somite stage of development (Alvarez and 
Navascues, 1990). The olfactory placode forms in the anterior-most position next to the forebrain, 
and gives rise to the olfactory epithelium (and vomeronasal epithelium of mammals) and its 
contained neurons (Brunjes and Frazier, 1986). Fate-mapping experiments in chicken embryos have 
revealed that the trigeminal placode, which is located near the anterior/mid hindbrain region, gives 
rise to the neurons of the distal (ventrolateral) parts of the ophthalmic and maxillo-mandibular lobes 
of the trigeminal ganglion. The otic placode is caudal to the trigeminal placode, and gives rise to 
epithelia and hair cells of the inner ear and the neurons of the vestibular and cochlear ganglia (Streit, 
2001). The first, second and third epibranchial placodes, located in the dorsal region of branchial 
clefts, give rise to the neurons of the geniculate, petrosal and nodose ganglia, respectively (D'Amico- 
Martel and Noden, 1983). The cranial sensory neurons of the trigeminal mesencephalic nucleus, the 
proximal (dorsomedial) parts of the trigeminal ganglion, and the entire jugular and superior 
glossopharyngeal ganglia are derived from the neural crest.
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Figure 1.2: Image adapted from (Streit, 2004)
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The illustration above shows the position of the cranial placodes in a 1.5- and 3.5-day chick embryo. 
At the 10- to 13-somite stage precursors for different placodes are segregated and occupy unique 
positions in the head ectoderm. At 3.5 days in development, all placodes can be recognized 
morphologically and some have begun to undergo differentiation.
Classically, most of the studies on the cellular interactions that influence the development of 
placodes and their derivatives have been carried out on amphibian and avian embryos using 
heterotopic and heterochronic grafting experiments and in vitro tissue recombination experiments. 
Placode induction begins in late gastrula stages, involving a series of inducers from different 
embryonic tissues including endoderm, mesoderm and the neural tube (Jacobson, 1963a; Jacobson, 
1963b; Jacobson, 1963c). Heterochronic grafting of ectoderm performed at very early stages before 
placodes have formed has shown that the graft adopts a fate that is appropriate to its new location, 
suggesting that commitment towards a particular placodal fate has not yet occurred. For example, 
heterotopic grafting in E l.5 chicken embryos of presumptive placodal ectoderm of the otic and third 
epibranchial placodes (which give rise to vestibular and nodose neurons, respectively) has 
demonstrated that the ectoderm is not determined to give rise to neurons of vestibular-type (short- 
neurotrophin-independent survival and slow axonal growth rate) or nodose-type (long-neurotrophin- 
independent survival and fast axonal growth rate) at this stage in development, suggesting that 
placodal cells become specified to particular neuronal fates between E l.5 and E2.5 in ovo (Vogel 
and Davies, 1993). However, by E2.5 the respective neuronal precursors in the otic and third 
epibranchial placodes have been specified to differentiate into vestibular-type and nodose-type 
neurons by this stage (Vogel and Davies, 1991). Accordingly, heterotopic grafting experiments 
carried out after overt placode formation have shown that most placodes are no longer able to change 
their fate when grafted to ectopic positions, so that ectodermal cells are already determined to 
undergo particular patterns of central and peripheral target innervation prior to overt neuronal 
differentiation (Stone 1924,1928, 1929).
More recent work has begun to elucidate key molecular aspects of placode development and 
neurogenesis. FGF, TGFp and Wnt signalling pathways have been implicated in the induction of a pre- 
placodal domain, a horse-shoe shaped region around the prospective anterior neural plate at the border 
of the neural plate and non-neuronal ectoderm that, is characterized by expression of the transcription 
factors Six, Eya and Dach (Streit, 2002; Streit, 2007) Specific markers, such as members of the Pax 
family of transcription factors, have been identified that are expressed by particular placodes from the 
earliest stages of their development (Dahl et al., 1997; Mansouri et al., 1996). For example, Pax6 is an 
early marker for the lens and olfactory placodes, Pax2 is an early marker for the otic and epibranchial
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placodes, and Pax3 is an early marker for the ophthalmic trigeminal placode (Favor et al., 1996; Hill et 
al., 1991; Hogan et al., 1986). Studying Pax gene expression in explant studies and heterotopic 
grafting experiments between the ophthalmic trigeminal placode and the third epibranchial placode 
has revealed that at the 3-to 4- somite stage, the ophthalmic trigeminal placode is competent to express 
epibranchial placode and neuronal markers (Pax2 and Phox2a) when grafted to the nodose region. This 
competence declines with time as the number of Pax3-expressing cells increases. Competence is 
mainly lost by stages 14-18 when many cells are already expressing Pax3. Moreover, Pax3 expression 
within presumptive ophthalmic trigeminal placodal ectoderm correlates at a single cell level both with 
neuronal specification and with commitment to a trigeminal neuron fate, and it is the Pax3-negative 
cells in presumptive ophthalmic trigeminal placodal ectoderm that can be induced to express the 
epibranchial placode marker Pax2 and form Phox2a-positive neurons in the nodose ganglion. These 
findings suggest that neurogenesis in the neurogenic placodes is not a two-step process in which 
neurons are induced and subsequently specified to a particular fate, but the different placodes are 
individualized by different cues. While formation of the otic and the epibranchial placodes both 
require FGF signalling (Sun et al., 2007), other factors may later determine their specific fates. . For 
example, Wnt, appears to be instructive for the otic placode and repressive for the epibranchial 
placode (Freter et al., 2008), and BMP signalling is additionally involved in otic placode induction 
(Kwon and Riley, 2009; Martin and Groves, 2006) neuronal differentiation and neuronal subtype 
identity seem to be coupled (Baker and Bronner-Fraser, 2000).
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4. Growth cones
Once sensory neuronal progenitor cells have migrated to their respective ganglia and differentiated 
into post-mitotic neurons they begin to extend axons towards their peripheral and central target 
fields . Since axonal outgrowth and path-finding is an essential mechanism in establishing a 
functional nervous system, I will discuss the morphology of growth cones, their movements and 
some aspects of the signalling involved in axonal path-finding.
4.1 Growth cone morphology and motility
The growing tip of axons and dendrites is a specialized structure called the growth cone. The 
existence of a growth cone was originally proposed by the Spanish histologist Santiago Ramon y 
Cajal. Cajal first described the growth cone based on histologically fixed cells as “a concentration of 
protoplasm of conical form endowed with amoeboid movements” (Cajal, S.R. 1890). The sensory, 
motor, integrative, and adaptive functions of growing axons and dendrites are all contained within 
this specialized structure. Growth cones have a central region bounded by veils of membrane called 
lamellipodia from which emerge fine, narrow, cylindrical extensions known as filopodia or 
microspikes that extend several microns beyond the edge of the growth cone to probe the 
environment. The membrane surrounding filopodia contains receptors and cell adhesion molecules 
that are important for axon growth and guidance. Filopodia contain actin filaments cross-linked into 
bundles by actin-binding proteins that are continuous with a dense actin meshwork in the 
lamellipodia. Actin filaments are helical polymers composed of F-actin microfilaments. F-actin 
microfilaments are in turn made up of actin monomers that, in the case of axons, are predominantly 
p-actin (Pak et al., 2008).
Actin monomers can spontaneously self-assemble into polarised, bi-helical filaments in vitro. This 
process requires ATP hydrolysis at the rapidly growing “barbed end” of filaments and the 
dissociation of ADP and inorganic phosphate at the slower growing “pointed end” of filaments. 
Assembled filaments are dynamic and constantly treadmilling, adding monomers to the barded end 
and removing them from the pointed end, even in a steady state. (Pak et al., 2008; Pollard and Borisy, 
2003). In order to contribute to growth cone motility, actin must be organised into-higher order 
networks of filaments, often called actin superstructures, that resemble either gels or bundles. In 
vitro, cell-free, studies have demonstrated that these superstructures are self-organizing, requiring a 
limited ensemble of actin binding proteins, but not extracellular signals or motor proteins (Cameron 
et al., 1999; Loisel et al., 1999). The generation of actin superstructures appears to occur in two steps. 
The first is de-novo actin filament assembly (nucleation), which in the motile cell is enhanced by a
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number of different proteins including ARP2/3, formins, spir proteins and cofilin(Andrianantoandro 
and Pollard, 2006; Mullins et al., 1998; Pruyne et al., 2002; Quinlan et al., 2005). These nucleating 
proteins are activated by association with activated signalling proteins such as the Rho GTPase, 
Cdc42, and Wiscott-Aldrich-syndrome proteins (WASPS) (Higgs and Pollard, 2000). The second 
step is the formation of higher-order structures and requires a multitude of actin binding proteins to 
both positively regulate actin bundle/gel assembly and to tether them to the plasma membrane. 
Several actin binding proteins also act to destabilise actin superstructures to allow for the 
remodelling in actin networks that is required for growth cone guidance (Pak et al., 2008).
In addition to actin filaments, the other major component of the growth cone cytoskeleton is 
microtubules, which are found in the central region of the growth cone and in the lamellipodia. 
Microtubules are long, hollow, non-branched cylindrical filaments composed of protofilament 
polymers of a- and p-tubulin heterodimers (Dent and Gertler, 2003). Tubulin heterodimers are 
intrinsically polar and associate head to tail in the protofilaments that lie parallel to the microtubule 
along the axis. The polymerization of tubulin heterodimers into microtubule protofilaments requires 
the binding and hydrolysis of GTP. The fast growing end of the microtubule that contains tubulin- 
bound GTP is known as the “plus” end, while the slow growing end, containing tubulin bound GDP, 
is called the “minus” end (Gordon-Weeks, 2004).
Growth cone motility is driven by a combination of dynamic actin filament assembly and 
disassembly and microtubule polymerization and depolymerization. Growth cones can extend 
rapidly, solely by virtue of microtubule polymersization, if actin assembly is inhibited. However, 
neuritic processes extend in a random, non-targeted fashion under these conditions, suggesting that 
actin filament assembly is essential for correct growth cone guidance (Bradke and Dotti, 1999; Pak et 
al., 2008). A number of key signalling cascades regulate microtubule and actin polymerization 
dynamics in the growth cone in response to attractive (e.g. chemoattractants, neurotrophins) or 
repellent (e.g. semaphorins, ephrins) guidance molecules. These cascades include MAP-Kinase, PI3- 
Kinase and GSK3 signalling pathways and their role in regulating growth cone motility will be 
discussed in detail in section 1.10, below.
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5. Axon guidance
Resolving the question of how growing axons accurately follow precise pathways during 
development to establish the correct synaptic connections to non-neuronal and neuronal targets 
tissues is an area of intense research. A large body of evidence has emerged suggesting that the 
growth cones of extending “pioneering” axons contain receptors for specific guidance molecules that 
are present in the extracellular environment. Once activated, guidance cue receptors initiate 
intracellular signalling cascades that modulate cytoskeletal dynamics within the growth cone to bring 
about growth cone extension, retraction, turning or collapse. Guidance cue molecules can be either 
contact-mediated or diffusible, and can either attract or repel axons. The list of guidance cues 
elucidated to date includes; netrins (Round and Stein, 2007), semaphorins (Kruger et al., 2005), slits 
(Dickson and Gilestro, 2006), ephrins (Egea and Klein, 2007), neurotransmitters (Spencer et al., 
2000), morphogens from the Wnt and TGFJ3 families (Charron and Tessier-Lavigne, 2005) 
neurotrophins, extracellular matrix molecules (Hari et al., 2004) and nitric oxide (Bicker, 2005). 
Since the roles of netrins, semaphorins, slits and ephrins in regulating axon guidance have been the 
most thoroughly characterized, I will briefly describe them below.
Netrins are bifunctional guidance cues that can either attract or repel growing axons depending on 
which netrin receptor is expressed within the growth cone of the axon. For example, Netrin 1 attracts 
axons that express the receptors DCC or neogenin, but repels axons that express the netrin receptors 
Unc5a, Unc5b, Unc5c or Unc5d. The cytoplasmic domains of netrin receptors do not contain any 
identifiable catalytic motifs, but bind, and become phosphorylated by, cytoplasmic tyrosine kinases 
like FAK, src and fyn following netrin engagment. Tyrosine phosphorylated netrin receptors recruit 
other cytoplasmic signalling proteins, resulting in the activation of PI3-Kinase, MAP-kinase, PLC- 
gamma and rac/Cdc42 signalling cascades, which in turn modulate cytoskeletal dynamics to bring 
about growth cone extension or turning (Round and Stein, 2007).
In most cases, semaphorins act to repel growth cones, resulting in growth cone turning or collapse. 
Semaphorins are either secreted or membrane associated glycoproteins that have been grouped into 
eight classes based on sequence and structural homology. Classes 3 to 7 are expressed in vertebrates, 
and individual semaphorins within each class are identified by a letter code. The most 
comprehensively characterized semaphorin is probably Sema3A (Kruger et al., 2005). Semaphorins 
derive their name from a conserved “Serna” domain that is approximately 400 amino acids in size. In 
addition to the Serna domain, all semaphorins contain a PSI domain that is shared with plexins and 
integrins. Additional domains may include immunoglobulin and thrombospondin domains. 
Vertebrate semaphorins in classes 4 to 7 are membrane-associated, whereas class 3 semaphorins are 
secreted proteins. The main group of semaphorin receptors are the plexins that are in turn divided
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into four groups, A to D. The plexins, which also contain “sema” and PSI domains, were first 
identified as cell adhesion molecules. Class 3 soluble semaphorins, like Sema3A, signal though 
plexins in group A and require neuropilins as essential plexin co-receptors. The intracellular domains 
of plexins have constitutively active RasGAP activity in the absence of semaphorin binding, and also 
contain motifs that bind Rho family GTPases such as Cdc42, Rac and RhoD (Kruger et al., 2005). 
Semaphorin binding leads to the phosphorylation of tyrosine residues in plexin intracellular domains 
by cytoplasmic kinases such as Fes and Fyn. In the case of Plexin A l, the binding of Sem3A and 
subsequent tyrosine phosphorylation by Fes leads to phosphorylation of Collapse Response Mediator 
Protein-2 (CRMP-2), probably via sequential activation of Cdc42 and GSK3, which in turn plays a 
role in mediating growth cone collapse. The role of CRMP-2 in mediating the effects of GSK3 
signalling pathways on neuronal process outgrowth are discussed further in section 1.10, below. 
Activated Plexin Al can also activate MAP-Kinase signalling pathways (Kruger et al., 2005).
Slit proteins have been shown to play a vital role in the guidance of commissural neuron axons. 
These neurons project axons that cross the midline to connect the two symmetric halves of 
invertebrate and vertebrate central nervous systems (Dickson and Gilestro, 2006). Mammals possess 
three slit genes (Slit-1, Slit-2 and Slit-3) that are all expressed in midline cells of the CNS. Studies of 
transgenic mice and Drosophila mutants, and in vitro assays of vertebrate neurons, have 
demonstrated that slits are repellent guidance cues for commissural axons. Slits exert their repellent 
effects by binding to Robo receptors that are expressed in the growth cones of commissural neurons. 
Mammalian genomes encode four Robo receptors, although only three (Robo-1, -2 and -3) are 
expressed in the CNS. Robo receptors consist of a large extracellular ligand-binding domain, 
comprising five immunoglobulin like domains and three fibronectin type repeats, a single 
transmembrane segment and a cytoplasmic domain that appears to be devoid of intrinsic catalytic 
activity and poorly conserved amongst Robo proteins (Dickson and Gilestro, 2006). Whilst the 
cytoplasmic domain has been shown to bind a number of SH2/SH3 domain adaptor proteins, the Abl 
tyrosine kinase and Rho GTPase-activating proteins, signal transduction from Robo receptors is 
relatively poorly understood at present.
Ephrins are a large family of membrane bound proteins that are divided into two subclasses, A and B. 
The A subclass (ephrinAl-ephrinA5) are tethered to the plasma membrane by a GPI linkage, whereas 
the B subclass (ephrinBl-ephrinB3) have a transmembrane domain and a cytoplasmic tail that 
appears to lack endogenous catalytic activity (Egea and Klein, 2007). Ephrins bind to Eph receptors 
that are transmembrane tyrosine kinases. Eph receptors are also divided into A- and B-subclasses 
with 9 and 5 members, respectively, in mammals. Eph-ephrin signalling can mediate either attraction
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or repulsion of growth cones and pre- and post-synaptic membranes. Eph-ephrin signalling can also 
be bi-directional (i.e both can act as ligand or receptor) and interactions between them can be both 
trans, between adjacent cells, or in cis, on the same cell. The regulation of Eph-ephrin signalling to 
bring about either the attraction or repulsion of cells/cell membranes is complex and appears to 
involve the formation of higher-order Eph-ephrin signalling clusters, cleavage of ephrin ectodomains 
from cell surfaces and the endocytosis of Eph-ephrin complexes (Egea and Klein, 2007). Eph-ephrin 
signalling has been shown to play an important role in directing retinotopic mapping of retinal axons 
to the midbrain tectum (Flanagan, 2006) and path-finding of limb motor axons (Helmbacher et al., 
2000).
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6. Axon growth rate
While there have been innumerable studies on the molecular cues that guide axons to their targets in 
the developing nervous system, relatively little attention has been given to the regulation of axonal 
growth rate during the stage of development when axons are growing to their targets. Rather, most 
studies on the regulation of axonal growth rate have been carried out on embryonic or postnatal 
neurons at stages of development after the neurons had already innervated their targets and were 
regenerating axons in culture, as opposed to initiating axon growth for the first time. One of the most 
detailed studies of de novo axonal growth rate, and the experimental system used for much of the 
work of this thesis, has been carried out on four populations of placode-derived cranial sensory 
neurons of the chicken embryo (Davies, 1989). The neurons of the vestibular, geniculate, petrosal 
and nodose ganglia are bom during the same period of development and start extending axons to their 
peripheral and central targets at approximately the same time, but have different distances to grow to 
reach their targets. Vestibular neurons have the closest targets, nodose neurons have the most distant 
targets, and geniculate and petrosal neurons have targets of intermediate distance. The rate at which 
the axons of these neurons grow to their targets in vivo is correlated with target distance: vestibular 
neurons have the slowest axon growth rates, and nodose neurons the fastest. Importantly, these 
distinctive differences in axonal growth rate appear to be an intrinsic property of the neurons. When 
they are cultured at very low density or as isolated single cells at the stage of development when their 
axons are normally growing to their targets, they extend axons at different rates: the axons of nodose 
neurons growing faster than those of petrosal neurons, which grow faster than those of geniculate 
neurons, which grow faster than those of vestibular neurons.
7. Neurotrophins and their receptors
In this section I will focus on the involvement of the neurotrophin family of neurotrophic factors in 
regulating neuronal survival and axonal growth. My studies have been carried out on early, 
neurotrophic factor-independent neurons as well as older axotomised, neurotrophic factor-dependent 
neurons. In the case of axotomised neurons, it is important to consider the regulatory effects of the 
neurotrophins on the intracellular signalling cascades involved in modulating axon growth when 
interpreting experimental data.
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7.1 Neurotrophic factors o f the neurotrophin family regulate neuronal survival
In 1934, Victor Hamburger discovered that removal of the limb bud in the chick embryo resulted in
reduced numbers of sensory and motomeurons in the spinal cord.
In 1939, Victor Hamburger demonstrated that transplantation of an extra limb bud caused increased 
numbers of sensory- and motomeurons in the spinal cord. In 1942, Rita Levi-Montalchini confirmed 
the loss of neurons after limb bud removal, and proposed that target- derived signals act on the 
innervating neurons to sustain their survival. In 1948, Elmer Buecker, a former student of Victor 
Hamburger, implanted tumour cells (Sarcoma 180) into a region of the hind limb to see if these cells 
would have that same effect on the innervating neuronal populations as transplanting an extra limb 
bud. Surprisingly, transplantion of these cells increased the size of limb innervating sensory ganglia, 
but motomeurons remained unaffected. By 1954, Rita Levi-Montalchini and Stanley Cohen used DRG 
explants in an in vitro assay to isolate and purify the factor in the sarcoma that acted on the sensory 
neurons, which turned out to be NGF.
During the development of the nervous system, excess neurons are generated, and those that are 
superfluous to requirement are removed during a phase of naturally occurring cell death shortly after 
neurons start innervating their targets (Oppenheim, 1991). This phase of apoptotic cell death is 
thought to remove neurons with inappropriate connections and to match the number of surviving 
neurons to the size and functional requirements of their target fields. During this phase of naturally 
occurring cell death, neurons compete for a limited supply of neurotrophic factors. According to the 
neurotrophic hypothesis, neurons that acquire neurotrophic support survive, whereas those that are 
unsuccessful in the competition for neurotrophic factors die by apoptosis. The neurotrophic 
hypothesis was substantiated by the discovery and classic experiments on the first neurotrophic 
factor, nerve growth factor (NGF), by Hamburger, Levi-Montalcini and Cohen (Hamburger and 
Levi-Montalcini, 1949; Levi-Montalcini, 1987). The original experiments that hinted at the existence 
of NGF were performed to determine whether implantation of various tumour tissues into mice might 
support the survival of sensory neurons. Mouse sarcoma tissue evoked extensive growth of sensory 
fibres into the tumour. In addition, dorsal root ganglia (DRG) near the site of the tumour were 
significantly larger then the corresponding ganglia on the opposite side of the spinal cord. Further 
studies showed that the effect of the sarcoma was caused by a diffusible factor. After purification this 
diffusible factor was named nerve growth factor. Additional experiments on NGF revealed that 
injecting antibodies against NGF into newborn mice or rats resulted in virtually the complete 
disappearance of sympathetic ganglia (Levi-Montalcini and Booker, 1960) The administration of 
anti-NGF antibodies at earlier stages of development also reduced the number of neurons in rodent 
DRG. These data together with recent demonstration that postganglionic sympathetic neurons and the
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majority of neural crest-derived sensory neurons are eliminated in mice lacking either NGF or its 
receptor tyrosine kinase TrkA clearly show that developing sympathetic and many sensory neurons 
require NGF for their survival (Yip et al., 1984).
NGF is the founder member of the neurotrophin family of structurally related proteins that comprises 
NGF, brain-derived neurotrophic factor (BDNF), neurotrophin (NT)-3 and NT-4/5 (now referred to 
as NT-4) in birds and mammals, together with two additional neurotrophins in fish, NT-6 and NT-7 
(Barde, 1990). BDNF has been shown to promote the in vitro survival of placode-derived trigeminal, 
nodose, geniculate, petrosal and vestibular neurons during embryonic development (Davies et al., 
1986; Lindsay et al., 1985a; Lindsay et al., 1985b) and the survival of the earliest differentiating 
neural crest-derived sensory neurons of the trigeminal ganglion and DRG. The neurons supported by 
these neurotrophic factors at early embryonic stages include many that will later become NGF 
dependent as they switch their neurotrophic factor requirements (Davies, 1997; Enokido et al., 1999; 
Farinas et al., 1996; Huang et al., 1999; Liebl et al., 1997; Pinon et al., 1996). Neurotrophins exert 
their effects by binding to and activating receptors that in turn initiate an array of intracellular signal 
transduction cascades (Hempstead, 2002; Miller and Kaplan, 2001). Neurotrophins signal through 
two classes of receptors. The first class of receptors are the Trk tyrosine kinases: TrkA, TrkB and 
TrkC. Trks bind neurotrophins with high affinity and specificity. TrkA is the cognate receptor for 
NGF, TrkB is the cognate receptor for BDNF and NT-4 and TrkC is the preferred receptor for NT-3. 
Under some circumstances NT-3 can also signal through TrkA and TrkB (Davies et al., 1995). The 
second class of neurotrophin receptor is p75, a member of the TNF receptor superfamily. p75 binds 
all neurotrophins with an equal affinity (Chao and Hempstead, 1995) (Figure 1.3).
TrkA
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Figure 13: Schematic diagram 
illustrating the receptor specificity 
of neurotrophin family members.
Studies on transgenic mice mice lacking neurotrophins or their receptors have confirmed the 
importance of the neurotrophins in promoting the survival of developing neurons of the peripheral
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nervous system. For example, BDNF-/- mice die perinatally and display defects in populations of 
sensory neurons that are dependent on BDNF for survival in culture (Emfors et al., 1994; Jones et al., 
1994). Trk B -/- mice also lose a substantial proportion of trigeminal, nodose and DRG neurons 
(Klein et al., 1993), while Trk C-/- mice have decreased numbers of myelinated axons emerging from 
the dorsal root of the spinal cord that correlates with the loss of a sub-population of DRG neurons 
(Klein, 1994). NT-3 deficient mice also display a significant loss of trigeminal and DRG neurons 
sensory neurons and sympathetic neurons (Farinas et al., 1996; Francis et al., 1999; Wilkinson et al., 
1996). Mice lacking NGF, or its receptor, TrkA, show a dramatic loss of peripheral sympathetic 
neurons and nociceptive and thermoceptive sensory neurons of the DRG (Crowley et al., 1994; 
Henderson et al., 1994; Smeyne et al., 1994).
Transgenic mice over-expressing neurotrophins have also provided evidence to support the 
neurotrophic hypothesis. For example, mice that over-express NGF in skin have increased numbers 
of sympathetic and sensory neurons of the peripheral nervous system (Albers et al., 1994). Over- 
expression of NT-3 in the skin results in significantly increased numbers of neurons in trigeminal, 
dorsal root and sympathetic ganglia (Albers et al., 1996). Interestingly, peripheral over-expression of 
BDNF in epithelial cells does not alter the number of neurons in trigeminal or dorsal root ganglia, 
although it does significantly increase the number of neurons in the nodose ganglion (LeMaster et al., 
1999).
Additional support for the neurotrophic factor hypothesis has been gained by studying the site, timing 
and level of expression of NGF. Initiation of NGF synthesis in the relevant peripheral target fields 
begins as invading axons start to enter the target field (Davies et al., 1987). Recent studies suggest 
that certain neurons may require neurotrophic support during the period their axons are growing to 
their targets in addition to requiring neurotrophic factors from their targets (Davies, 2003). Whilst 
many studies have demonstrated the importance of neurotrophins in regulating the survival of 
developing peripheral neurons, they are not alone in possessing this ability. Several other secreted 
proteins have also been shown to promote the survival of neurons of the PNS, both in vitro and in 
vivo. These include members of the glial cell-derived neurotrophic factor (GDNF) family (GDNF, 
neurturin, artemin and persephin), the neurotrophic cytokines (ciliary neurotrophic factor, CNTF; 
leukaemia inhibitory factor, LIF; oncostatin-M, OSM; cardiotrophin-1, CT-1 and interleukin-6, IL-6) 
and the related proteins hepatocyte growth factor (HGF) and macrophage-stimulating protein (MSP) 
(Airaksinen and Saarma, 2002; Forgie et al., 2003; Maina and Klein, 1999; Murphy et al., 1997). In 
addition to promoting the survival of developing PNS neurons, neurotrophins can also regulate 
certain aspects of target field innervation by developing PNS neurons (discussed in detail below) and
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regulate the phenotype and plasticity of adult sensory neurons (Bibel and Barde, 2000; Davies, 2000; 
Petruska and Mendell, 2004; Pezet et al., 2002).
7.2 Neurotrophic factor independence and the acquistion o f survival dependence 
Several populations of neurons survive in culture independently of neurotrophic factors during the 
earliest stages of their development, shortly after differentiating from their precursor cells when their 
axons are starting to grow to their targets. These include placode-derived cranial sensory neurons of 
the chick embryo (Vogel and Davies, 1991), embryonic mouse trigeminal ganglion (Buchman and 
Davies, 1993), paravertebral sympathetic neurons (Coughlin and Collins, 1985; Emsberger et al., 
1989), retinal ganglion cells (Rodriguez-Tebar et al., 1989) and motoneurons (Mettling et al., 1995). 
The duration of neurotrophin independence and the onset of neurotrophin-dependent survival have 
been most thoroughly investigated in populations of placode-derived cranial sensory neurons of the 
chick embryo and in the sensory neurons of the embryonic mouse trigeminal ganglion. These 
experimental systems will be discussed in turn.
The placode-derived sensory neurons of the embryonic chick vestibular, geniculate, petrosal and 
nodose ganglia do not initially require neurotrophic factors to support in vitro survival following their 
differentiation from progenitor cells, and remain neurotrophic factor independent throughout the 
period of development when their axons are growing to their targets. Because the distances that the 
axons of these different populations of neurons have to grow to their targets and the lengths of time 
taken to reach these targets differ, the duration of neurotrophic factor independence differs between 
these neurons. When cultured at low density, in the absence of neurotrophins at a time when their 
earliest axons would be extending to their targets in vivo, these neurons die at different rates: 
vestibular neurons die rapidly, geniculate and petrosal neurons die at intermediate rates, and nodose 
neurons die slowly. Thus, neurons that have more distant targets and that are innervated later in 
development appear to have a more protracted period of neurotrophin independence. The majority of 
the neurons in these ganglia become dependent on BDNF for survival when their axons reach their 
targets (Davies, 1989; Vogel and Davies, 1991). Accordingly, vestibular neurons, which are the first 
to innervate their targets, are the first to express TrkB and the first to become dependent on BDNF for 
survival, whereas nodose neurons, which are the last to innervate their targets, are the last to express 
TrkB and the last to become dependent on BDNF for survival (Vogel and Davies, 1991). Robinson et 
al. 1996). The duration of neurotrophin independence, together with differences in axonal growth 
rate (described above), appear to coordinate the onset of neurotrophin dependence with the arrival of 
axons in the vicinity of their targets (Davies, 1994). These intrinsic differences in axonal growth rate
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and duration of neurotrophin independence appeared to be specified in the placodal progenitor cells 
for vestibular and nodose neurons since neurons arising in otic vesicle cultures (presumptive 
vestibular neurons) have short neurites and die rapidly in the absence of neurotrophins, whereas 
neurons arising in third epibranchial placode cultures (presumptive nodose neurons) have long 
neurites and survive for several days and (Vogel and Davies, 1991). Heterotopic grafting experiments 
between the regions of presumptive placodal ectoderm that give rise to these neurons at E l. 5 revealed 
that the presumptive placodal ectoderm is not determined to give rise to neurons of the vestibular or 
nodose phenotype at this stage (Vogel and Davies, 1993). Explantation of presumptive placodal 
ectoderm at E l.5 also showed that this ectoderm is not specified to differentiate into neurons at this 
stage. Moreover, non-neurogenic ectoderm from the trunk can give rise to nodose-type neurons when 
transplanted heterotopically to the nodose region at this stage. These results suggest that signals 
acting in the vicinity of presumptive placodal ectoderm specify the growth and survival 
characteristics of the neurons that differentiate from these ectodermal cells (Vogel and Davies, 1993). 
In the developing mouse trigeminal ganglion, early bom trigeminal neurons (E9.5 to E ll) initially 
survive in culture without neurotrophic factor support, and subsequently become dependent on BDNF 
and/or NT-3 between 24 and 48 hours in culture. Cultured neurons begin to respond robustly to NGF 
at El 1.5, a time that corresponds to a significant increase in the differentiation of TrkA-positive 
neurons in the trigeminal ganglion and the arrival of the first TrkA-positive fibres in the peripheral 
target field epithelium where the highest levels of NGF are synthesized (Buchman and Davies, 1993; 
Davies and Lumsden, 1984; Enokido et al., 1999). The early response of developing trigeminal 
neurons to BDNF and NT-3 corresponds with both the onset of expression of the mRNAs encoding 
these neurotrophins in the mesenchyme that the neurons must grow through to reach peripheral target 
field epithelium and transient high level expression of the mRNA encoding full length, kinase 
competent TrkB receptors in the neurons themselves (Buchman and Davies, 1993; Ninkina et al., 
1996). The levels of NGF mRNA in target field epithelium and TrkA mRNA in neurons are both up- 
regulated dramatically as trigeminal neurons begin to acquire NGF dependence in vitro and innervate 
target field epithelium in vivo (Davies et al., 1987; Enokido et al., 1999; Wyatt and Davies, 1993). 
The developmental expression of the mRNA encoding the common neurotrophin receptor, p75, in the 
mouse trigeminal ganglion also mirrors the acquisition of NGF responsiveness (Wyatt et al., 1990). 
Although NGF production in target fields is temporally correlated with the onset of target field 
innervation by NGF-responsive neurons, this appears to occur independently of target- field/axon 
interactions. Supportive evidence comes from the observation that NGF mRNA expression occurs on 
schedule in chick embryo hindlimb buds deprived of innervation (Rohrer et al., 1988). The detailed 
analysis of neurotrophin responsiveness in developing mouse trigeminal neurons demonstrates that
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the expression of neurotrophic factors in the mesenchyme and epithelium of target fields and 
neurotrophin receptors by neurons are tightly temporally coordinated with the onset of target field 
innervation and the acquisition of neurotrophic factor dependence.
7.3 Neurotrophic factors regulate neurite growth
As the nervous system develops, functional connections are established between neurons and their 
targets. Whilst evidence suggests that initial neurite extension may be an intrinsic programme that 
does not require neurotrophic factor support, later stages of target field innervation require 
neurotrophic factors for successful completion. As part of my study was carried out on older 
axotomised neurons that depend on neurotrophic factor support for regenerative axonal growth and 
survival, I will give an overview of the evidence obtained from transgenic mouse studies that 
demonstrate the important role that neurotrophic factors play in regulating process outgrowth and 
establishing target field innervation. In addition, I will outline the intracellular signalling pathways 
that mediate axonal growth regulated by neurotrophic factors.
There are a number of mechanisms which regulate the length, branching, direction o f extending 
neurites and the formation of functional synapses once neurites reach their targets. Many different 
extracellular signals, including soluble factors such as growth factors, cell surface and extracellular 
matrix proteins influence these processes.
Members of the neurotrophin family have been shown to be crucial regulators of axonal growth. In 
vitro, neurotrophins promote a significant increase in the density of axons extending from explanted 
embryonic peripheral ganglia, although these observations can be attributed in part to increased 
neuronal survival within explants in the presence of neurotrophins (Deckwerth et al., 1996; Markus 
et al., 2002). Analysis of target field innervation in neurotrophin and neurotrophin receptor null mice 
is complicated by the death of neurotrophin-dependent neurons during the period of target field 
innervation. Thus reduced target field innervation may be due to a reduction in growth promoting 
neurotrophin signalling or a reduction in the number of neurons projecting axons to target fields as a 
result of cell death, or a combination of both. Even so, the analysis of such transgenic mice suggests 
that BDNF and NT-3 are required for successful target field innervation by vestibular and cochlear 
ganglion neurons and that NGF/trkA signalling is required for successful target field innervation by 
sympathetic neurons of the SCG and sensory neurons of the DRG (Fagan et al., 1996; Postigo et al., 
2002; Schimmang et al., 1995). In accordance with this, deletion of the common neurotrophin 
receptor, p75, results in significantly reduced axonal outgrowth from neural crest-derived sensory 
neurons at early embryonic ages before excessive neuronal death occurs due to p75 deletion (Bentley 
and Lee, 2000). More recent studies that have used transgenic mice to establish the roles of
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neurotrophins in regulating target field innervation have made use of the fact that developmental 
neuronal death does not occur in transgenic mice lacking the pro-apoptotic protein, Bax (White et al., 
1998). Double-transgenic mice lacking both Bax and neurotrophin or neurotrophin receptor 
expression are immune from neuronal death, thus allowing the effects of neurotrophic factor 
signalling deficits on target field innervation to be examined in isolation. Whilst both NGF and NT-3 
support the elongation and branching of processes from sympathetic neurons in vitro (Orike et al., 
2001), they appear to play distinct and complementary roles in regulating target field innervation in 
vivo. Bax/NGF double-null mutant mice have relatively normal axonal elongation of SCG neurons, 
but show defects in target-field terminal arborization. In contrast, Bax/NT-3 double-null mutant mice 
show decreased axonal extension long before the target field is reached (Glebova and Ginty, 2004; 
Kuruvilla et al., 2004). These data suggest that NT-3 is an intermediate factor, probably acting 
locally within the sympathetic ganglia and along the blood vessels sympathetic axons follow to reach 
their target organs, to promote initial axonal extension before neurons are exposed to NGF, whereas 
NGF is important for promoting terminal arborization and functional innervation of target fields. 
Interestingly, TrkA-positive nerve trunks and superficial terminal arbors of sensory neurons in the 
epidermis are absent in the hindlimbs of Bax -/- / NGF -/- double-transgenic mice, suggesting that 
NGF responsive DRG sensory neurons require NGF for both axonal extension and terminal 
arborization (Patel et al., 2000). An examination of Bax -/- / NT-3 -/- double-transgenic mice has also 
revealed that NT-3 is required for correct innervation of skeletal muscle by proprioceptive neurons 
and its mode of action involves both promoting axonal extension and target field terminal 
arborization (Patel et al., 2003). Analysis of Bax -/- / BDNF -/- double-transgenic mice has 
demonstrated that whilst cranial sensory neurons can navigate successfully to their various targets in 
the absence of BDNF, BDNF is required for afferents to arborize in the target fields and establish 
functional sensory connections (Hellard et al., 2004).
Several experiments designed in the late seventies showed that injection of NGF into cranial neurons 
caused excessive growth of sympathetic axons into the brain (Menesini Chen et al., 1978) Also, 
sensory neurons have been shown to turn towards a source of NGF in culture (Gundersen and Barrett, 
1979). Even though this was widely interpreted that neurotrophins would act as a guidance molecule 
for neurons to grow towards their targets, the finding that NGF is not expressed in the target field until 
the first neurons are innervating it, showed that target derived NGF could not play a role in long-range 
axonal guidance (Davies, 1987). However, co-culture experiments of trigeminal neurons and their 
target tissue, maxillary epithelium and mesenchyme, showed that trigeminal neurons grow towards 
these targets. Application of function blocking antibodies against NGF did not disturb this process, 
indicating that NGF is not the source which attracts trigeminal neurons towards their targets. Anti-NT-
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3 antibodies, and to a lesser extend anti-BDNF antibodies reduced neurite outgrowth and the 
application of both completely eliminated it (O'Connor and Tessier-Lavigne, 1999). In the ventral 
spinal cord, the expression of chemorepulsive signals act on DRG neurons to project towards the 
dorsolateral parts of the spinal cord. Netrin-1 has been shown to act as an early chemorepellent for 
DRG neurons and ectopically expressed netrin-1 in the dorsal and intermediate spinal cord prevents 
DRG neurons from being directed towards the dorsal spinal cord (Masuda et al., 2008). In the 
olfactory system, several guidance cues regulate axon guidance to innervate different layers within the 
olfactory epithelium. For example, axonal targeting within the dorso-ventral axis of the olfactory bulb 
is controlled by the graded expression of axon guidance cues and their receptors. The Slit receptor 
Robo2 is expressed in a high dorso-medial to low ventro-lateral gradient. Slit-1 expression in the 
ventral region of the olfactory epithelium prevents Robo-2 expressing axons to enter. Axonal targeting 
in the antero-posterior axis of the olfactory bulb is controlled through the differential expression of 
axon guidance molecules. Olfactory-receptors mediated signalling modulates the expression of 
molecules such as Npn-1 and Ephrin-A5 through a transcriptional mechanism. Olfactory sensory 
neurons containing high levels of cAMP express high levels of Npn-1 and low levels of Ephrin-A5 
and as a result innervate specific glomerumi in a posterior region of the olfactory bulb (Cho et al., 
2009).
7.4 Intracellular Signal Pathways Associated with Neuronal Survival and Growth: Trk- 
and p75NTR -mediated signalling pathways
The extracellular N-terminal domain of each Trk receptor consists of a cystein-rich cluster followed 
by three leucine- rich repeats, another cystein cluster and two immunoglobulin- like domains. Each 
receptor spans the membrane once and has a carboxy terminal cytoplasmic domain consisting of a 
tyrosine kinase domain surrounded by several tyrosine residues that serve as phosphorylation- 
dependent docking sites for cytoplasmic adaptors and enzymes. Truncated variants of TrkB and TrkC 
have been isolated that lack the cytoplasmic kinase domain and appear to sequester neurotrophins 
reducing the efficacy of signalling by full-length, kinase competent Trks (Reichardt, 2006; Zampieri 
and Chao, 2006). Upon binding neurotrophins, Trk receptors dimerize and specific tyrosine residues 
undergo phosphorylation in the Trk receptor cytoplasmic domain. Adaptor proteins, including She 
and FRS2 are recruited to these phosphorylated tyrosine residues, thereby coupling Trk receptors to 
three major intracellular signalling cascades which include the Ras-ERK (extracellular signal- 
regulated kinase) pathway, the PI3-Kinase (phosphatidylinositol-3-kinase)-Akt pathway and the 
phospholipase C (PLC)-y-protein kinase C (PKC) pathway (Chao et al., 2006; Reichardt, 2006; 
Zampieri and Chao, 2006). Activation of the Ras-ERK pathway promotes neuronal differentiation,
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including neurite growth, activation of PI3-Kinase promotes survival and growth of neurons, whereas 
activation of PLC-y results in the activation of Ca2+- and PKC-regulated pathways that affect 
synaptic plasticity.
NGF can be retrogradely transported from axon terminals by endocytosis of NGF-TrkA into 
signalling endosomes that are then transported back to neuronal cell bodies by microtubule driven 
mechanisms (Reichardt, 2006; Zweifel et al., 2005). Retrograde signalling is particularly important in 
relaying survival promoting signals back the cell body. Such signalling includes, increased activity of 
PI3-Kinase, which suppresses cell death by inhibiting the apoptotic activities of forkhead and Bel 2- 
associated death protein (BAD), and ERK5, which indirectly activates the transcription factor CREB 
(cAMP responsive element- binding protein).
Axonal growth, terminal arborization and synaptic plasticity are likely to be predominantly the result 
of local intracellular signalling events that occur near to the growth cone/terminal arbors. These 
signalling events, involving Ras-ERK, PI3-kinase and PLC-y activation, contribute to axonal 
outgrowth by regulating microtubule dynamics and actin stability (Gillespie, 2003; Reichardt, 2006). 
Retrograde transport of signalling endosomes to the cell soma is also likely to play a role in 
promoting axonal growth, since the transcription factors CREB and NFAT (nuclear factor of 
activated T-cells) have been shown to promote axonal growth (Graef et al., 2003; Lonze et al., 2002; 
Patel et al., 2003). The p75 NTR receptor is a member of the tumour necrosis factor superfamily with 
an extracellular domain that includes four cystein-rich motifs, a single transmembrane domain and a 
cytoplasmic domain that includes a “death” domain similar to those present in other members of this 
family (Liepinsh et al., 1997). p75 appears to modulate Trk receptor function in several ways. For 
example, p75 inhibits activation of Trk receptors by non-preferred neurotrophins both in vitro and in 
vivo (Bibel et al., 1999), and in vitro studies suggest that the presence of p75 NTR potentiates 
activation of TrkA by suboptimal concentrations of NGF (Davies et al., 1993). Before neurotrophins 
are secreted in their final form, they exist as proneurotrophins.
Proneurotrophins are precursor proteins of the neurotrophins which are about 240-260 amino acids 
long and are cleaved by various proteases to eventually become the much shorter, mature 
neurotrophins. It has been shown that proneurotrophins bind with high affinity to a complex of p75 
with sortilin (Nykjaer et al., 2004) and usually this binding of proneurotrophins to p75 and sortilin 
initiates apdptosis (Lu et al., 2005; Reichardt, 2006). In the presence of high concentrations of 
neurotrophins and the absence of appropriate Trk expression, the binding of neurotrophins to p75 
initiates a number of intracellular signalling pathways, many of which converge on Jun Kinase 
activation, that lead to apoptotic cell death (Lu et al., 2005) p75 also plays a direct role in 
modulating neuronal process outgrowth. In the absence of neurotrophin binding, the cytoplasmic
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domain of p75 binds and sequesters the small cytoplasmic GTPase, RhoGDI, preventing it from 
forming a complex with RhoA. Free cytoplasmic RhoA inhibits axonal growth. The engagement of 
p75 by neurotrophins releases p75 bound RhoGDI into the cytoplasm, thus allowing it to sequester 
free cytoplasmic RhoA and thereby promote axonal growth (Reichardt, 2006).
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Figurel.4:
Illustration detailing some of the intracellular signalling pathways activated after ligand-mediated Trk activation which 
results in gene expression, increased neuronal survival and neurite outgrowth. Image adapted (Pollack and Harper, 2002)
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8. The extracellular Ca2+- sensing receptor (CaSR) and the regulation of
2+extracellular ionised calcium concentration ([Ca ]0)
The CaSR has recently been shown to regulate axonal outgrowth and branching from cultured 
neonatal mouse sympathetic neurons and modulate innervation of their target fields in vivo 
(Vizard et al., 2008). In addition, CaSR mRNA is expressed in many parts of the rat brain and PNS 
(Ferry et al., 2000; Yano et al., 2004). This raises the possibility that the CaSR plays an important 
role in the developing and adult nervous system. To date, the role of the CaSR in regulating de novo 
axonal growth prior to the acquisition of neurotrophic factor responsiveness has not been examined. 
In my research, I have investigated whether the CaSR plays a role in regulating intrinsic axonal 
growth rates in neurotrophin independent chick placode-derived neurons from early developmental 
stages. In addition, I have examined whether the CaSR is involved in regulating axonal growth in 
later stage axotomised placode-derived neurons that are dependent on BDNF for survival. Below I 
will outline the role of the calcium receptor in maintaining homeostasis of ionised calcium 
concentrations in the body and then give an overview of its special role in the nervous system.
8.1 Regulation o f ionised calcium concentrations
Ca2+ is an allosteric cofactor in numerous enzymatic reactions (Brushia and Walsh, 1999; Cheung, 
1980; Quest, 1996; Sitaramayya, 2002; Stull et al., 1997). It serves as a charge-carrier and a second 
messenger in mediating secretion (Augustine, 2001), neural induction (Svoboda et al., 1997), blood 
clotting (Ganitkevich et al., 2002) and muscle contraction (Gordon et al., 2000). Additionally, Ca2+ is 
a critical component of the extracellular matrix of bone, cartilage, and teeth (Boskey, 1992). 
Maintaining appropriate concentrations of extracellular and intracellular Ca is vital to the survival 
of all organisms (Brown and MacLeod, 2001). Indeed, maintenance of postnatal extracellular ionised 
calcium concentration [Ca2+]0 within its narrow range (1.2-1.3mM) requires the coordinated and 
tightly regulated interactions of the calcium-regulating hormones; parathyroid hormone (PTH), 1,25- 
dihydroxyvitamin D3 (l,25(OH)2D3) and, to a lesser extent, calcitonin (CT), and their effector organs; 
the kidneys, bone and intestine. Small but physiologically relevant changes in [Ca2+]0 are sensed by 
the cells of the parathyroid gland which subsequently regulate the secretion of PTH into the systemic 
circulation; A steep inverse sigmoidal relationship exists between [Ca2+]c and PTH release, whereby 
slight decreases in systemic [Ca2+]0 promote the release of PTH into the systemic circulation, the 
targets of which then ensure normocalcaemia. It is now well established that the G-protein coupled, 
extracellular calcium-sensing receptor (CaSR) allows parathyroid cells to sense changes in [Ca2+]0 
and regulate the secretion of PTH, thereby allowing [Ca 2+]0 to act as a first messenger. Furthermore, 
the CaSR is expressed by thyroidal C-cells and its high [Ca2+]0-evoked activation promotes the
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secretion of calcitonin, an anti-hypercalcaemic hormone. In addition, the CaSR is also expressed in 
tissues that serve as targets for these hormones, where it regulates local processes that contribute to 
maintaining systemic [Ca2+]0 homeostasis. During development, elevated levels of [Ca2+]0 (1.69mM) 
are maintained in the foetus by the CaSR independently of maternal [Ca2+]0 (Brown and MacLeod, 
2001).
8.2 Structure o f the CaSR
The extracellular Ca sensing receptor is a class III, G-protein coupled, heptahelical receptor 
(GPCR). The human CaSR is 1078 amino acids residues long and has 3 predicted structural domains: 
a large hydrophilic N-terminal extracellular domain (ECD) of 612 residues which confers specificity 
to its low affinity physiological ligand, [Ca 2+]0; the seven a-helical transmembrane domain (TMD) 
of about 250 amino acids; and a hydrophilic C-terminal intracellular domain (ICD) 216 amino acids 
long, which couples to various G-proteins. The functional, cell surface form of the CaSR is a 
homodimer linked by disulphide bond within the ECD and a non-covalent, hydrophobic interaction 
between the transmembrane domains of each CaSR monomer (Bai, 2004).
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Figure 1.5: The predicted structure of the Calcium Sensing Receptor: Image adapted from (Bai, 2004)
8.3 Pharmacological Characterisation of the CaSR
While extracellular Ca is the primary physiological ligand of the CaSR in vivo, however, other 
ligands may activate the CaSR directly (class I calcimimetics) or potentiate the receptors sensitivity 
to other physiological agonists (class II calcimimetics). Class I calcimimetics, including [Ca 2+]0 
itself, are orthosteric CaSR agonists. These are organic or inorganic polycations that do not require 
the presence of [Ca 2+]0 to activate the CaSR. Class I calcimimetics include a number of di- and 
trivalent cations, polyamines, aminoglycosides and polybasic amino acids (Fig. 1.6) and are believed
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to act predominantly within the CaSR ECD (Chang and Shoback, 2004; Hu et al., 2005). Class II
2+calcimimetics are endogenous allosteric modulators which potentiate CaSR sensitivity to [Ca ]0, 
shifting the concentration-response curve to the left without altering the maximal response. The class 
II calcimimetics, therefore, require the presence of [Ca2+]0 for biological activity and are thought to 
act largely within the CaSR transmembrane domain, a mechanism distinct to that of the class I 
calcimimetics (Hammerland et al., 1999). The aromatic amino acids tyrosine, phenylalanine and 
tryptophan can act as positive allosteric modulators that activate the CaSR in the presence of at least 
ImM [Ca2+]0 in CaSR-transfected HEK-293 cells (Conigrave et al., 2000). In addition, the affinity of 
the CaSR for [Ca2+]0 and aminoglycoside antibiotics may also be modulated by ionic strength and 
alterations in extracellular pH (pHo), respectively (Quinn et al., 1998).
Due to the key role of the CaSR in the control of [Ca2+]0 and its suitability as a molecular target for 
the treatment of primary and secondary hyperparathyroidism, small organic compounds have been 
developed to manipulate the function of the CaSR. The so-called synthetic “calcimimetic” 
compounds, NPS R-467 and NPS R-568, act as positive allosteric modulators and increase the 
sensitivity of the CaSR to activation by [Ca 2+]0, and are, therefore, inactive in the absence of [Ca2+]0 
(Nemeth et al., 1998) In addition, the small molecules NPS-2143 and NPS-89636 are so-called 
‘calcilytic’ compounds which act as CaSR antagonists. Calcilytics were developed as compounds 
that could produce pulsatile changes in endogenous parathyroid hormone (PTH) which could be 
suitable as novel therapeutics for osteoporosis or osteopenia (Nemeth et al., 2001). However they, 
along with calcimimetic compounds, provide important research tools to distinguish between CaSR- 
and non CaSR-mediated effects of [Ca2+]0-
Class I Inorganic cations (e.g. La3+, Gd3+, Ca2+, Ba2+, Mg2+)
Polyamines (e.g. spermine, spermidine)
Aminoglycoside antibiotics (e.g. streptomycin, gentamycin, neomycin) 
Polybasic amino acids (e.g. polylysine, polyarginine)
Class II Aromatic L-amino acids (e.g. tyrosine, phenylalanine, tryptophan) 
Ionic strength 
pH
Synthetic calcimimetics (e.g. NPS R-467, NPS R-568)
Figure 1.6: List of class I and class II CaSR agonists
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8.4 CaSR Expression and Function in the Nervous System
In addition to its expression in tissues responsible for controlling [Ca2+]0, the CaSR is also widely 
expressed in both the developing and adult PNS and CNS. Indeed, within the adult rodent PNS the 
CaSR is expressed in neurons of DRG (Wang et al., 2003) trigeminal ganglion (Heyeraas et al., 
2008) and the superior cervical ganglion (SCG) (Vizard et al., 2008).Within the rat CNS, the CaSR is 
expressed in multiple sites including the olfactory bulb, piriform cortex, cerebral cortex, 
hippocampus, amygdala, basal ganglia, diencephalon thalamus, hypothalamus, zona incerta, 
mesencephalon and cerebellum (Yano et al., 2004). Until recently, however, a functional role for the 
CaSR in the nervous system has only been speculated. For example, it has been proposed that a 
general role for the CaSR at the post-synaptic membrane, the CaSR may sense activity-dependent 
changes in [Ca2+]0 in and around the synaptic cleft (Rusakov and Fine, 2003; Vassilev et al., 1997). 
Recent evidence has revealed a role for the CaSR in neuronal development. The CaSR has been 
shown to be expressed in the superior cervical ganglion (SCG), a population of sympathetic neurons 
which innervates targets in the head, including the iris. SCG neurons exposed to maximally 
activating concentrations of [Ca 2+]0 show an increase in axonal growth and branching in vitro. The 
growth- promoting effects of high [Ca 2+]0 are confined to a narrow developmental window between 
E18-P0, a stage of development when axons from these neurons are innervating and branching 
extensively in their target fields in vivo. Manipulating CaSR function using CaSR agonists or 
antagonists, or expressing a dominant negative CaSR during this stage of development also has 
marked effects on axonal growth in vitro. Furthermore, El 8 SCG CaSR-deficient neurons grow with 
smaller and less complex neurite arbors in vitro and the iris of CaSR-deficient animals has decreased 
sympathetic innervation density in vivo compared to wild-type and heterozygous littermates. 
Neurons of the SCG would be exposed to the elevated level of foetal [Ca 2+]0 (~1.7mM) during this 
period of development in utero, thereby providing a tonic signal for CaSR activation in vivo (Vizard 
et al., 2008). Furthermore, the over-expression of a dominant-negative CaSR in early postnatal 
hippocampal pyramidal neurons maintained in slice culture results in a decrease in the size and 
complexity of the dendritic arbors emerging from these neurons. In vivo, the activity of the CaSR 
may be affected by activity-dependent changes in [Ca 2+]0 during post-natal life to modulate 
hippocampal neuron dendritic arborization, thereby linking changes in neural activity with changes in 
dendritic architecture (Vizard et al., 2008).
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8.5 Signal Transduction Pathways Downstream of CaSR Activation 
Although the mechanism by which the CaSR regulates the growth of neural processes is yet to be 
elucidated, the downstream signalling effectors in many other cell types are known (Ward, 2004). 
Stimulated CaSR’s can activate phospholipases C, A2 and D. CaSR mediated activation of PLC 
appears to entail a direct, G- protein mediated process, probably involving Gq/n. Activation of PLC 
leads to the generation of inositol triphosphate (IP3) and diacylglycerol (DAG). The former mobilises 
intracellular calcium stores, whereas the latter leads to the activation of protein kinase C (PKC). 
Activation of phospholipase D by high extracellular calcium appears to involve activation of the 
receptor associated G-protein, G12/13 which then activates the small GTPase, Rho. Rho in turn 
stimulates phospholipase D, resulting in the production of the second messenger molecule, 
phosphatidic acid. Activation of the cytostolic form of PLA2 (CPLA2) by high extracellular calcium 
and other CaSR agonists might be indirect, utilizing CaSR-mediated, PLC-dependent stimulation of 
PKC. CPLA2 generates the second messenger arachidonic acid. CaSR ligands also decrease 
intracellular cAMP production by stimulating the CaSR associated G-protein, G*. In addition, CaSR 
activation in some cell types can lead to the phosphorylation and activation of numerous kinases that 
are central components of important signalling cascades. A summary of the intracellular signalling 
that arises from CaSR activation in non-neuronal cells is shown in figure 1.7.
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Figure 1.7: Image adapted from (Ward, 2004)
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9. PI3-Kinase, Glycogen Synthase Kinase 3 and MAP- Kinase signalling
Because of their central roles in transducing extracellular signals during neuronal development and 
their importance in the context of this study, this section will focus on a description of PI3-Kinase, 
Glycogen Synthase Kinase 3 and MAP-Kinase signalling in the context of their roles in regulating 
neuronal survival and process outgrowth.
Membrane phosphoinositides were recognized many years ago as precursors for second messengers 
in cell surface receptor-coupled signal transduction pathways. In the first pathway involving 
phosphoinositides to be elucidated, membrane phosphatidylinositol 4,5 diphosphate (PI(4,5)P2) is 
hydrolyzed to inositol (1,4,5) triphosphate (IP3) and diacylglycerol (DAG) by various isoforms of 
phospholipase C (Bootman et al., 1995; Nishizuka, 1992). Subsequently, IP3 releases calcium from 
intracellular stores (Bootman et al., 1995), whereas DAG activates protein kinases C. PI3-Kinase is a 
central player in a more recently characterised signalling pathway that revolves around dynamic 
changes in membrane phosphoinositide composition. PI3-Kinase catalyses the generation of 
phosphatidylinositol 3,4,5 triphosphate (PI(3,4,5)Ps) from (PI(4,5)P2) at the plasma membrane by 
phosphorylation of the D-3 position of the inositol ring. A number of proteins that are important in 
intracellular signalling pathways that promote cell differentiation, growth and survival translocate to 
the plasma membrane and are subsequently activated by binding directly to (PI(3,4,5)P3) via their 
pleckstrin homology (PH) domains (Cantley, 2002). In this study, I investigated the role of PI3- 
Kinase in modulating early, neurotrophic factor-independent axonal growth from placode-derived 
sensory neurons as well the regenerative growth that follows the axotomy of later neurotrophic factor 
dependent neurons. Below, I will give an overview over the structure of PI3-Kinase, its activation 
and its downstream targets as well as the involvement in growth and survival.
9.2 Structure o f PI3-Kinase
Numerous PI3-Kinases have been identified. From a consideration of sequence data, binding of 
adaptor proteins and phosphatidylinositol substrate specificity permitted a segregation of PI3Ks have 
been divided into three distinct families (Toker and Cantley, 1997; Zvelebil et al., 1996). Class I 
PI3-Kinases are heterodimers of approximately 200 kDa, composed of a 110-120 kDa catalytic 
subunit and a 50-100 kDa adaptor/regulatory subunit, that are capable of phosphorylating PI 4-P and 
PI(4,5)P2 in vitro. Adaptor subunits keep the catalytic subunit quiescent in non-stimulated cells. The 
preferred in vivo substrate for class I PI3-Kinases, seems to be PI(4,5)P2 (Hawkins et al., 1992; 
Stephens et al., 1991). Activation of class I PI3-Kinases is controlled by extracellular signalling via 
receptors with intrinsic protein tyrosine kinase activity, receptors coupled to src-like protein tyrosine
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kinases or G protein-linked receptors. Class I PI3-Kinases are the predominant generators of 
membrane (PI(3,4,5)P3) and are the focus of the research on PI3-Kinase in this thesis. Class II PI3- 
Kinases, with an in vitro substrate specificity restricted to PI and PI 4-P, are 170-210 kDa proteins 
with a characteristic C-terminal C2 homology domain. This class is subdivided into three class 2 
enzymes that are thought to act as monomeric enzymes. Class III PI3-Kinases are homologous to S. 
cerevisiae Vps34p (vascular protein sorting mutant,) and phosphorylate only Ptdlns (Hawkins et al., 
1992). The activity of Vps34p depends on a functional Vpsl5p protein Ser/Thr kinase, which 
recruits the phosphatidylinositol kinase to late Golgi compartments (De Camilli et al., 1996).
9.3 Signal Transduction Pathways involving Class I PI3-Kinases
Activation of PI3-Kinases by extracellular agonists is associated with their translocation to the 
plasma membrane where they get access to lipid substrates. Class I PI3-Kinases are subdivided into 
two groups depending on the adaptor proteins involved in regulating PI3-kinase catalytic subunit 
activity. PI3-kinases that utilise the p85 adaptor subunit are directed to phosphorylated tyrosine 
motifs on the intracellular domains of activated receptor tyrosine kinases or phosphorylated adaptor 
proteins associated these receptors (class IA). The GTP-binding protein, Ras, is activated by ligand- 
induced tyrosine phosphorylation of certain receptor tyrosine kinases via recruitment and 
phosphorylation of the adaptor proteins Grb2 and SOS to the receptor. Activated Ras can directly 
phosphorylate and activate PI3-Kinase (Rodriguez-Viciana et al., 1994). The Class IB PI3-Kinase, 
PI3-Kinase Q interacts with adaptor protein p i01 that in turn interacts with trimeric G proteins 
associated with G-protein-coupled receptors (Cantley, 2002).
One important PI3-Kinase downstream target is the protein serine/threonine (Ser/Thr) kinase 
Akt/PKB (formerly called RAC), which is activated through membrane localization (Andjelkovic et 
al., 1997) and Ser/Thr phosphorylation (Alessi et al., 1996; Andjelkovic et al., 1996). Both of these 
events are dependent on the generation of PI(3,4,5)P3 by PI3-Kinase. The PH domain of Akt/PKB 
promotes translocation to the plasma membrane by binding to PI(3,4,5)P3 (Klippel et al., 1997), and 
phosphorylation of Akt at Thr308 and Ser473 (Alessi et al., 1996) requires phosphoinositide- 
dependent kinases (PDKs), which are also activated by translocating to the plasma membrane and 
binding PI(3,4,5)P3. Interestingly, one phosphoinositide-dependent kinase, PDK1, has been recently 
shown to phosphorylate and activate protein kinases C (PKC) directly (Chou et al., 1998; Le Good et 
al., 1998). Integrin-linked kinase (ILK, interacting with the cytoplasmic domain of LI, L2, and L3 
integrin subunits (Hannigan et al., 1996) has been shown to be activated by PI(3,4,5)P3 and to 
phosphorylate Akt/PKB on Ser473. Moreover, catalytically inactive, dominant-negative ILK inhibits
36
endogenous phosphorylation of Akt/PKB on Ser473. ILK might thus qualify as the first member of 
the PDK2 family.
The actions of catalytically active Akt/PKB include phosphorylation and inactivation of GSK3 
(Cross et al., 1995) and the pro-apoptotic factor BAD (Borasio et al., 1993; Datta et al., 1997). 
Furthermore, PI3-Kinase activity leads to multiple phosphorylations of p70 S6-kinase, which is 
involved in G1 cell cycle transition (Chung et al., 1994)PI3-Kinase also mediates Jun amino-terminal 
kinase (JNK) activation through a Rac/PAX/MEKK/MKK4/JNK pathway.
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Figure 1.8: PI3 kinase signalling pathway. Signalling pathway adapted from: Expert reviews in molecular medicine 
(Stokoe, 2005)
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9.4 PI3-Kinase regulates neuronal survival
PI3-Kinase has been shown to be responsible for neurotrophin regulated cell survival in peripheral 
sympathetic and sensory neurons (Huang and Reichardt, 2001; Reichardt, 2006). However, one study 
has claimed that PI3-Kinase inhibition does not decrease NGF-mediated survival in rat sympathetic 
neurons (Borasio et al., 1993). Hie first neurotrophin-activated signalling protein shown to mediate 
the survival of neurons was the GTP-binding protein Ras. Inhibition of Ras decreases the survival of 
most populations of sympathetic neurons. In accordance with this, promoting Reis activity increases 
the survival of cultured neurons in the absence of neurotrophins (Nobes and Tolkovsky, 1995; Vogel 
et al., 1995). PI3-kinase appears to be a direct downstream target of Ras in the PC 12 rat 
sympathoadrenal cell line, PC12, and inhibition of Ras suppresses NGF-mediated PI3-Kinase activity 
in this cell line (Rodriguez-Viciana et al., 1994). Hie survival-promoting interaction between Ras 
and PI3-kinase was demonstrated with two approaches. Ras effector mutants that are selective for 
activating PI3-Kinase, but not those selective for activating MEK/MAPK or RalGDS (ras-related 
guanine- nucleotide dissociation stimulator), induced cell survival, while Ras-mediated survival was 
blocked by the PI3-Kinase inhibitor LY294002 (Rodriguez-Viciana et al., 1994).
Akt has been shown to be a target of survival-promoting, NGF-induced PI3-Kinase activity 
(Andjelkovic et al., 1998; Ashcroft et al., 1999). Akt not only mediates growth factor regulated 
survival, but also survival promoted by depolarisation- induced Ca influx through L-type calcium 
channels (Blair et al., 1999). Hie downstream targets of Akt that regulate survival include Bad, an 
inhibitor of the Bcl-2 anti apoptotic protein, pro- caspase 9, and Forkhead a transcription factor that 
induces apoptosis by increasing levels of the Fas ligand (FasL) (Nieuwkoop, 1985; Rosenquist, 
1981). Akt also promotes the activation of the transcription factor STAT3, leading to increased 
expression of antiapoptotic members of the Bcl-2 family, including Bcl-2 in pro-B lymphocyte lines 
and Bcl-xL in myeloid and fibroblast cell lines (Catlett-Falcone et al., 1999; Fukada et al., 1996; 
Kami et al., 1999)STAT3 activation by PI3-kinase/Akt appears to play an important role in the 
cytokine mediated survival of embryonic mouse nodose neurons (Alonzi et al., 2001).
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9.5 Glycogen synthase kinase 3 (GSK3)
GSK3 was initially characterised because of the key role it plays in insulin signalling. In the absence 
of insulin-insulin receptor interaction, GSK3 inhibits glycogen synthase activity by phosphorylating 
it. However, the binding of insulin to its receptor activates Akt (via PI3-kinase) which subsequently 
phosphorylates a serine residue in the amino terminus of GSK3, thereby causing its inactivation 
(Figure 1.8). This suppression of GSK3 activity allows the dephosphorylation of glycogen synthase 
which promotes glycogen synthesis (Parker et al., 1983).
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9.6 Structure of GSK3 and the regulation of its activity
The structure of GSK3 is similar to that of mitogen-activated protein kinase (MAPK) family 
members. GSK3 is phosphorylated at a tyrosine residue that is in an equivalent position to the 
phosphotyrosine residue in MAPKs (Hughes et al., 1993).
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GSK3 has two isoforms- GSKa and GSKp, as well as a splice variant of GSKp (Mukai et al., 2002). 
The two isoforms are encoded by different genes that share almost identical sequences in their kinase 
domains, but differ substantially at the N-terminal. Although GSK3 is considered to be a cytosolic 
protein, it can also be found in nuclei and mitochondria. Nuclear GSK3 regulates the activity of a 
number of transcription factors by phosphorylation, enabling it to influence the expression of many 
genes, and hence the efficacy of many signalling pathways (Jope and Johnson, 2004). The nuclear 
level of GSK3 is not static, but increases in response to intracellular cues. For example, nuclear 
levels of GSK3 fluctuate during the cell cycle, being highest at the S-phase which targets the 
phosphorylation of nuclear cyclin D (Manoukian and Woodgett, 2002).
Since GSK3 modulates the function and activity of a large number of substrate proteins with many 
diverse functions in the cytoplasm and nucleus, its activity must be tightly regulated within the cell. 
The activity of GSK3 is regulated by a number of mechanisms. The first of these is phosphorylation 
of GSK3. Phosphorylation of the serine 9 residue of GSK3P or serine 21 residue of GSK3a by Akt 
and a number of other kinases results in significant inhibition of GSK3 activity. Other signalling 
pathways that can lead to GSK3 inactivation by serine phosphorylation include the MAPK cascade, 
cyclic AMP (cAMP) dependent protein kinase A and other PI(3,4,5)P3 dependent pathways not 
involving Akt (Armstrong et al., 2001; Fang et al., 2000; Hughes et al., 1993; Stambolic and 
Woodgett, 1994). In contrast to serine phosphorylation, tyrosine phosphorylation of residue 216 of 
GSKp or residue 279 of GSK3a by a group of at present poorly defined kinases promotes GSK3 
activity. (Jope and Johnson, 2004). A second parameter that regulates GSK3 activity is the 
phosphorylation state of its substrates, since many substrates need “priming” for phosphorylation by 
GSK3 by prior phosphorylation events. Other factors regulating GSK3 activity are cellular 
localization and interaction with GSK3 binding proteins (Jope and Johnson, 2004). Figure 1.11 
illustrates three of the main signalling pathways involving GSK3. These pathways will be briefly 
explained in the following section. In addition, figure 1.11 illustrates how GSK3 can regulate 
microtubule dynamics and growth cone motility. This aspect of GSK3 function will be discussed
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below in section 1.10.
9.7 Signalling pathways involving GSK3
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Figure 1.11: Hedgehog, Wnt and G-protein signalling Adapted (Jope and Johnson, 2004)
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WNT signalling pathway:
In the absence of WNT ligands, cytoplasmic GSK3 is bound to a protein complex containing the 
scaffold protein, axin, CK1 (casein kinase 1), APC (Adenomatous polyposis coli protein) and (3- 
catenin. CK1 phosphorylates p-catenin in order to prime it for phosphorylation by GSK3. If p- 
Catenin becomes phosphorylated by GSK3 it is targeted for degradation via the proteasome pathway, 
while Axin is stabilized by this phosphorylation. The binding of WNTs to one of their many 
receptors (eg. frizzled, LRP5/6 or ryk) releases GSK3 from the Axin/CK1 /APC/p-catenin complex, 
thereby inactivating it and preventing P-catenin phosphorylation. Subsequently, p-catenin 
accumulates and gets translocated to the nucleus where it binds to and transactivates TCF/LEF 
family transcription factors leading to increased transcription of Wnt signalling pathway target genes 
(Manoukian and Woodgett, 2002).
Hedgehog Signalling:
GSK3 plays an important role in the signal transduction pathway initiated by the binding of 
hedgehog to its receptor, patched (Ptc). In the absence of hedgehog, Ptc inhibits the activity of the 
smoothened receptor (Smo). This enables a tripartite protein complex to form on microtubules that 
consists of the zinc finger transcription factor cubitus interruptus (Ci), costal2 (Cos) and fused (Fus). 
When Ci is held in this microtubule bound complex it is subject to multi-site phosphorylation by 
protein kinase A (PKA), CK1 and GSK3, resulting in its proteolysis to Ci75 which, unlike Ci, is a 
transcriptional repressor. Stimulation of Ptc by Hedgehog activates Smo, resulting in the dissociation 
of the microtuble bound Cos/Fus/Ci complex, decreased phosphorylation of Ci and hence decreased 
proteolysis to Ci75. Released Ci translocates to the nucleus to function as a transcriptional activator 
(Jope and Johnson, 2004).
Signalling pathway via cyclic AMP second messenger:
In the presence of appropriate G-proteins, ligand engagement of G-Protein coupled receptors 
(GPCR’s) can result in the stimulation of adenylyl cyclase (AC) activity and increased cAMP 
production. Increased cAMP production in turn leads to increased protein kinase A activity. The 
PKA anchoring protein 220 binds both PKA and GSK3 keeping them in close proximity, thereby 
allowing activated PKA to serine phosphorylate and inhibit GSK3 in a localised manner (Jope and 
Johnson, 2004).
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9.8 Role o f GSK3 in cell survival
As discussed above, phosphorylation and inactivation of GSK3 is a downstream event in PI3-kinase 
mediated survival signalling. In accordance with this, over-expression of GSK3 induces apoptosis 
in PC 12 cells, whereas expression of a dominant-negative, kinase inactive isoform of GSK3 into the 
same cells prevents cell death induced by inhibiting PI3-kinase (Pap and Cooper, 1998). Similarly, 
over-expression of GSK3 in the human neuroblastoma cell line SH-SY5Y, potentiates staurosporine 
and heat-shock induced apoptosis and ectopic expression of dominant-negative GSK3 protects cells 
from apoptosis in a cell line model of Huntington’s disease. In addition, lithium, which is an inhibitor 
of GSK3, provides protection from apoptosis in both of these cell line based apoptosis models (Bijur 
et al., 2000; Carmichael et al., 2002). Nuclear levels of GSK3 increase rapidly during apoptosis 
(Bijur and Jope, 2001). One target of nuclear GSK3 is the transcription factor, p53. The direct 
binding of GSK3 to p53 activates GSK3 and activated GSK3 subsequently promotes the 
transcriptional and apoptotic activities of p53 (Watcharasit et al., 2002). Nuclear GSK3 is also 
capable of inhibiting the activity of survival-promoting transcription factors, such as heat-shock 
factor 1 (Li et al., 2002).GSK3p knockout mice develop normally until mid-gestation, but die around 
embryonic day 14 due to massive tumour necrosis factor-a (TNFa) induced hepatocyte apoptosis 
(Hoeflich et al., 2000; Schotte et al., 2001). This finding demonstrates the isoform specific functions 
of GSK3, since GSK3a is unable to compensate for the loss of GSK3p.
9.9 MAP-Kinase signalling
Mitogen activated protein kinases (MAP kinases) are a group of related proteins that are crucially 
involved in a wide range of signalling pathways that play important roles in proliferation, 
differentiation, regulation of gene expression, survival/apoptosis and responses to stress. In general, 
MAP kinase signalling pathways consist of a signalling cascade involving four distinct steps. The 
initial step is plasma membrane receptor mediated activation of MAP kinase kinase kinases 
(MAPKKK’s or MP3K’s) via a number of proteins including Ras, PKC and PKA. In the second step, 
MAP3K’s phosphorylate and activate MAP kinase kinases (MAPKK’s or MAP2K’s), which in turn 
phosphorylate and activate MAP kinases (MAPK’s) by dual phosphorylation of threonine and 
tyrosine residues in the motif T-X-Y. In the fourth step of the cascade, MAP kinases can either 
phosphorylate non-kinase proteins, such as transcription factors, or activate further kinases that are 
often referred to as MAP kinase-activating protein kinases (MAPKAP kinases or MK’s) (Qi and 
Elion, 2005).
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The classical MAP kinase pathway, and the first to be fully elucidated, involves the MAP kinases 
ERK1 and ERK2. This pathway can be initiated in a number of ways including; ligands binding to 
cytokine and growth factor associated receptor tyrosine kinases, G-protein-coupled receptor 
activation, integrin activation by extracellular matrix components and certain cell stressors. The 
MAP3K’s in the classical pathway are A-Raf, B-Raf and c-Raf-1 and these activate the MAP2K’s, 
MEK1 and MEK2. ERK1 and ERK2 phosphorylate and modulate the activity of numerous proteins 
including the transcription factors STAT3, Ets, CREB, CBP, NFkB and Myc and the cytoplasmic 
isoform of phospholipase A2 (Qi and Elion 2005 J Cell Science; Yoon and Seger 2006 Growth 
factors). Kinase targets of ERK1 and ERK2 include the ribosomal S6 kinases, rsk 1 and rsk 2 (Howe 
et al., 1992), and MAPKAP kinase-2, a protein that phosphorylates glycogen synthase kinase 3 at 
Ser-7 (Stokoe et al., 1992)
Four other MAPK families have been identified and characterised, in addition to the ERK1/ ERK2 
family. These are; the Jun N-terminal kinases (JNK1, JNK2 and JNK3), p38 MAP kinases (p38a, 
p38p and p38y), ERK3 and ERK4, ERK5 (Qi and Elion, 2005). Each of these four MAPK families 
utilise different MAP3K’s, MAP2K’s and downstream substrates. JNK’s play important roles in 
neuronal development and apoptosis, whereas p38’s are key regulators of cell migration, 
proliferation and differentiation, particularly in the immune system. In the nervous system, p38’s 
appear to be implicated in regulating the myelination of axons, in both the PNS and CNS, and in the 
aetiology of neuropathic pain (Ji and Suter, 2007). The roles of ERK3/4 and ERK5 are less well 
characterised than ERK1/2, JNK and p38 MAP kinases. Each of the five MAPK familes, and the 
corresponding upstream and downstream kinases of their signalling modules, are associated with 
numerous intracellular scaffolding proteins. These scaffolding proteins appear to act both to 
segregate different modules and to modulate their activity by binding phosphatases and cytoskeletal 
proteins. Recent research has identified a large family of dual specificity phosphatases that 
dephosphorylate threonine and tyrosine residues of MAP kinases, thereby regulating their kinase 
activity. Evidence is accumulating to suggest that many of these phosphatases are cell type and 
MAP-kinase type specific (Jeffrey et al., 2007). In addition, several single specificity threonine or 
tyrosine phosphatases also modulate MAP kinase function (Qi and Elion, 2005).
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9.10 ERK1/ERK2 activation is involved in neurotrophin-promoted neurite growth bur 
not in neurotrophin mediated-neuronal survival in vitro
Most studies investigating the role of ERK1/2 in neurotrophin mediated survival have used either 
PC 12 cells or sympathetic neurons and have focused on NGF. Although NGF induces a strong 
activation of ERK1/2 in sympathetic neurons and PC 12 cells, inhibition of MEK1, the principle 
upstream activator of ERK1/2, has minimal effects on NGF dependent neuronal survival (Creedon et 
al., 1996; Virdee and Tolkovsky, 1996). In accordance with this, adenovirus mediated expression of 
dominant-negative isoforms of several kinases within the ERK signalling casacade does not reduce 
the survival of NGF stimulated PC 12 cells or embryonic mouse sensory neurons in serum free 
culture (Klesse et al., 1999). Interestingly, inhibition of MEK1 or the expression of dominant- 
negative ERK dramatically reduces the ability of NGF to promote neurite outgrowth from PC 12 cells 
and sympathetic neurons, strongly suggesting that the ERK1/2 MAP kinase pathway mediates NGF- 
induced process outgrowth (Creedon et al., 1996; Klesse et al., 1999; Virdee and Tolkovsky, 1996).
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Figure 1.12: MAP Kinase signalling pathway. Signalling pathway adapted from: kinase.uhnres.utoronto.ca/signallingmap.html
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10. The roles o f GSK3p, PI-3 Kinase and MAP-Kinase signalling in 
regulating neuronal process outgrowth
GSK3p has been found on the leading edge of the growth cone where it is maintained in its inactive 
form (Eickholt et al., 2002). Experimental inactivation of GSK3(3 in cerebellar granule cells results 
in growth cone expansion, axonal spreading and increased branching of neuritic processes (Lucas et 
al., 1998), whereas semaphorin 3A and lysophosphatic acid, both of which activate GSK3P, cause 
growth cone collapse and neurite retraction (Sayas et al., 2002). These observations raise the 
possibility that inactivation and activation of GSK3p promote growth cone extension and collapse, 
respectively, implicating GSK3p in the regulation of neuronal process outgrowth and synaptic 
remodelling.
Several mechanisms have been proposed to account for the inhibitory effects of activated GSK3P on 
growth cone extension. The protein APC, which as described above forms a complex with p-catenin, 
CK1, axin and GSK3p as part of the Wnt signalling pathway, is also associated with microtubules. 
The positioning of functional APC at the plus-end of microtubules is essential for maintaining the 
appropriate direction of microtubule assembly and hence growth cone extension. Activated GSK3P 
appears to phosphorylate APC and disrupt its function in both astrocytes and neurons. Indeed it has 
been shown that inactivation of GSK3p locally within growth cones by Cdc42-Par6-aPKC mediated 
serine phosphorylation increases the association of APC with the plus-ends of microtubules and is 
necessary for normal astrocyte motility (Etienne-Manneville and Hall, 2003; Jimbo et al., 2002). 
Similarly, local NGF-induced activation of PI3-Kinase at the distal tips of embryonic DRG axons 
has been shown to lead to local inactivation of GSK3p in growth cones (via the PI3-kinase substrate 
ILK) which in turn increases the association of APC with the tips of microtubules, leading to growth 
cone extension (Zhou et al., 2004). A similar mechanism appears to be involved in regulating axon 
specification and elongation in hippocampal neurons (Jiang et al., 2005). APC is not the only 
substrate of activated GSK3p that plays a role in regulating microtubule assembly and hence axonal 
extension. For example, activated GSK3 has been shown to phosphorylate Collapsin Response 
Mediator Protein-2 (CRMP-2) thereby reducing its ability to bind to tubulin dimers and promote 
microtubule polymerization (Yoshimura et al., 2005). CRMP-2 appears to play an important role in 
determining neuronal polarity by promoting the elongation of one dendrite to become an axon. In 
accordance with this, over-expression of CRMP-2 in cultures of embryonic rat hippocampal neurons 
results in the formation of multiple axons. Non-phosphorylated, CRMP-2 is predominantly localised 
in the tips of axonal growth cones in cultured hippocampal neurons, together with serine 
phosporylated, inactive, GSK3p. In the same neurons, activation of the PI3-kinase/Akt pathway by 
either NT-3 or BDNF promotes the serine phosphorylation and inactivation of GSK3p which in turn
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leads to reduced CRMP-2 phosphorylation and enhanced axonal extension (figure 1.12). In addition 
to APC and CRMP-2, GSK3p has been shown to phosphorylate the microtubule-associated proteins 
tau and MAP IB (Lucas et al., 1998; Sperber et al., 1995; Trivedi et al., 2005). In contrast to its 
effects on other microtubule associated proteins, GSK3p activates MAP IB by phosphorylation, 
thereby promoting its ability to destabilise microtubules, increase the rate of axon elongation and 
reduce the size of growth cones (Owen and Gordon-Weeks, 2003; Trivedi et al., 2005).
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GSK3P can also regulate axonal outgrowth from neurons by a mechanism that does not 
involve phosphorylation of microtubule associated proteins. It has recently been shown that 
transcription factors of the nuclear factor of activated T-cells (NFATc) family play a role in 
regulating axonal outgrowth during vertebrate development. NFATc family members are 
activated by the cytoplasmic phosphatase, calcineurin, leading to their nuclear import and the 
transcription of several genes that promote axonal extension. GSK3p is one of several kinases 
that can inactivate NFATc family transcription factors, thereby inhibiting axonal extension 
(Nguyen and Di Giovanni, 2008). GSK3P can also phosphorylate the cyclic AMP response 
element binding protein (CREB) transcription factor, thereby inhibiting its DNA binding 
activity (Grimes and Jope, 2001). As discussed below, CREB appears to play an important 
role in neurotrophin mediated axon extension.
In addition to influencing microtubule polymerisation via modulation of Akt, ILK, Cdc42 and 
GSK3 activity, PI3-kinase can also promote neuronal process outgrowth by modulating actin 
dynamics (figure 1.13) Indeed, PI3-Kinase has been shown to be activated at the leading edge
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of axonal growth cones where it co-localises with polymerizing actin filaments (Shi et al., 
2003; Zhou et al., 2004). A series of studies in non-neuronal cells has provided clues as to 
how activated PI3-Kinase in the growth cone may regulate actin dynamics in extending 
axons. In non-neuronal cells, PI3-Kinase regulates actin filament assembly mainly via the 
activation of Rac and Cdc42 (Hall and Nobes, 2000; Raftopoulou and Hall, 2004). Over­
expression of constitutively active Rac in cultured 3T3 cells enhances membrane ruffling, 
lamellipodia protrusion and cell motility (Nobes and Hall, 1995). More recent studies suggest 
that activated Rac facilitates lamellipodia protrusion via activation of the WAVE protein 
complex and subsequent activation of Arp2/3. Activated Arp2/3 promotes actin 
polymerization. (Smith and Li, 2004). NGF induced activation of PI3-kinase and subsequent 
activation of Rac 1 is required for NGF induced neurite outgrowth from PC 12 cells (Aoki et 
al., 2005; Nusser et al., 2002). The over-expression of constitutively active Rac in rat 
hippocampal neurons promotes neurite/axon elongation, whereas over-expression of 
dominant-negative isoforms of Rac in the same neurons inhibits neurite outgrowth 
(Schwambom and Puschel, 2004). Interestingly, the modulation of actin polymerisation by 
Rac can also negatively influence axonal outgrowth in drosophila neurons by a second 
pathway not involving WAVE and Arp2/3 complexes. In this pathway, Rac induces the 
activation of the p21-activated kinase (PAK) which in turn phosphorylates and activates LIM 
domain-containing kinases (LIMK) leading to the phosphorylation of the actin 
depolymerisation factor, cofilin. Thus in Drosophila neurons at least, Rac can modulate actin 
polymerisation dynamics by activating two pathways that have opposing effects on axon 
extension. (Ng and Luo, 2004).
48
<s>
PAK
Par6/aPKC
. - - ;
\ C mDia /  1  /
<^filopodia^>
APC CRMP-
microtubules
J r PAK
/  [ WASP ^GSK-3f3^1 WAVE
i
LIMK
\ / 
C^jamellipodi^)
Figure 1.14 Local PI3-kinase signalling activates signalling pathways that modulate both microtubule and 
actin polymerization to regulate growth cone extension (Zhou and Snider, 2006)
In non-neuronal cells, Cdc42 appears to modulate actin rearrangements that are involved in 
filopodia formation. It achieves this either by sequential activation of WASP family proteins 
and the Arp2/3 complex, or by direct activation of the actin binding protein, mDia (Higgs and 
Pollard, 2000). Activated Cdc42, like Rac, can also activate the PAK, LIMK, cofilin pathway 
(Govek et al, 2005). PI3-Kinase mediated activation of Cdc42 has been shown to be an 
important event in the process of NGF-induced neurite outgrowth from PC 12 cells (Aoki et 
al., 2005). Cdc42 also appears to play a role in regulating neurite outgrowth from cultured 
neurons. For example, over-expression of active Cdc42 in chick spinal cord neurons promotes 
filopodia formation and neurite/axon elongation (Brown et al., 2000) and BDNF induced 
activation of Cdc42 in filopodia of Xenopus spinal cord neurons is associated with filopodia 
extension (Robles et al., 2005).
Long-range axon extension requires elevated gene transcription, to provide the raw materials 
for axon assembly, not just local signalling events in the vicinity of the growth cone. MAP- 
kinase signalling appears to play a major role in regulating the activity of transcription factors
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that direct the transcription of genes associated with axon extension in response to 
neurotrophic factor stimulation. One well characterised transcription factor whose activity is 
regulated by neurotrophic factors is the cyclic AMP response element binding protein 
(CREB) (Lonze and Ginty, 2002). The binding of neurotrophic factors to their receptors has 
been shown to lead to the phosphorylation of CREB on serine residue 133, the subsequent 
recruitment of CREB co-activators, such as CBP, and the initiation of CREB mediated 
transcription. An in-vitro comparison of the extent of NGF-induced neurite outgrowth from 
sympathetic neurons dissected from wild type and CREB/Bax double-null mutant mouse 
embryos has demonstrated the crucial role that CREB plays in mediating neurotrophin 
stimulated process outgrowth (Lonze et al., 2002). Experimental evidence suggests that 
CREB phosphorylation in response to neurotrophins is primarily mediated by ERK pathway 
induced activation of rskl and rsk2 (De Cesare et al., 1999; Xing et al., 1996). In addition to 
CREB activation, ERK-mediated signalling also promotes the formation of functional NFATc 
transcription factor complexes, thereby promoting the transcription of several genes that play 
a role in directing axon extension (Nguyen and Di Giovanni, 2008).
Although microtubule associated protein 2 (MAP-2) and tau were two of the first substrates of 
MAP-kinases to be identified (Ray and Sturgill, 1987) relatively little is known about the role 
of MAP-kinase signalling in the local modulation of microtubule / actin polymerisation 
dynamics and hence growth cone extension. An elegant study using compartmentalised 
chambers and exogenous expression of wild type and mutated trkB isoforms in cultured rat 
SCG neurons has demonstrated that localised axonal ERK signalling is required to induce 
local axon assembly in response to BDNF (Atwal et al., 2000). A more recent study has 
shown that the phosphorylation and activation of the microtubule associated protein, MAP IB, 
by GSK3 is positively regulated by ERK activity during neurotrophin-induced axon growth, 
creating a possible link between ERK signalling and axonal microtubule dynamics (Goold 
and Gordon-Weeks, 2005). ERK signalling has also been implicated in regulating actin 
filament dynamics, since pharmacological inhibition of ERK in growing axons results in 
growth cone collapse associated with rapid actin depolymerization (Atwal et al., 2003). There 
is increasing evidence that some mRNAs encoding actin related cytoskeletal proteins are 
translated in the local vicinity of extending growth cones. Examples include p-actin, cofilin 
and GAP43 mRNAs (Bassell et al., 1998; Smith et al., 2004; Willis et al., 2005). 
Interestingly, ERK signalling can regulate local protein translation in axonal growth cones in 
response to extracellular cues that either promote growth cone extension or collapse 
(Campbell and Holt, 2003; Wu et al., 2005).
50
11. Aims and Objectives
The aim of my research was to ascertain whether the CaSR plays any role in the development of 
sensory neurons, and if so, to determine the intracellular molecular mechanisms that mediate the 
effects of the CaSR on these neurons. The specific objectives at the outset were as follows:
(i). To determine if activation of the CaSR by physiological levels of [Ca 2+]0 affects either the 
survival of or growth of axons from embryonic sensory neurons at the stage when their axons are 
growing to their targets in vivo and the neurons are not dependent on neurotrophic factors for 
survival.
(ii). If the CaSR did affect early de novo axonal growth, to investigate if it plays any role in 
governing intrinsic differences in growth rate related to target distance.
(iii). To determine if activation of the CaSR by physiological levels of [Ca 2+]0 affects either the 
survival of or the regeneration of axons from embryonic sensory neurons in culture at stages in 
development after their axons have reached their targets in vivo and the neurons have become 
dependent on neurotrophic factors for survival.
(iv). To investigate the intracellular signalling pathways that mediate the effects of the CaSR 
in developing sensory neurons, with a particular focus on several key signalling pathways that 
have been implicated in regulating axonal growth and/or neuronal survival, namely, MAP- 
Kinase, PI3-Kinase and GSK3 signalling.
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Chapter 2 
Material and Methods
2.1 Introduction
Because the peripheral and central axons of different cranial sensory ganglia have markedly 
different distances to grow to reach their targets during development, cultures of cranial 
sensory neurons at the stage when their axons would reach their targets in vivo have been 
useful for studying differences in de novo axonal growth rate and the onset of neurotrophic 
factor dependence in relation to differences in the timing of the target field innervation. 
Naturally occurring cell death occurs in cranial sensory ganglia during target-innervating 
stages where each population of cranial sensory neurons become dependent on a particular 
neurotrophic factor or combination of factors. Studying these neurons at this stage of 
development has been useful for analysing the function and co-operation of neurotrophic 
factors.
The research described in this thesis uses a variety of in vitro and in vivo protocols to analyse 
neuronal survival and process outgrowth. The in vitro protocols developed in this lab are well 
established, widely used and serve as a powerful tool for investigating the mechanisms of 
neuronal survival and neurite outgrowth.
2.1.1 Making Tungsten Needles
Tungsten needles were used to complete dissections and to remove adherent connective tissue 
from the dissected neuronal tissue. To make tungsten needles, two 3-5 cm pieces of 0.5 mm 
diameter tungsten wire (Goodfellow, Cambridge) were cut and at the end 1cm of each bent by 
an angle between 60°-90°. This end was immersed in 1M KOH and a 3-12V AC current was 
passed through the wire and a second electrode immersed in the solution. The tungsten is 
etched away, forming a taper from the bend to the tip of the needle. The needles were then 
held in chuck- grip platinum wire holders and sterilised using either a Bunsen flame or 70 % 
ethanol.
2.1.2 Preparation o f culture substratum
Neurons were grown on a laminin/ polyomithine substratum. Dishes were prepared by 
transferring either 1ml Poly-DL-omithine (Sigma) / borate solution to 35mm tissue culture 
dishes (Greiner), or 250 pi to each well of a 4- well- dish (Greiner), and left overnight at room 
temperature. The poly- ornithine solution was aspirated the following morning and the dishes 
were washed twice with sterile distilled water before being allowed to air dry in the laminar 
flow hood. Two or three hours prior to the use, 100 pi of a 20 mg.ml’1 solution of laminin 
(Sigma) in Hank’s Balance Salt Solution (HBSS, Gibco, Invitrogen) was transferred to the
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centre of each dish and subsequently spread over the dish surface. The dishes were then 
placed in a tissue culture incubator for 2-3 hrs. The dishes were then removed from the 
incubator and washed twice with sterile distilled water, taking care not to let the dishes to dry 
out, and then 1 ml of medium added immediately after washing.
2.1.3 Preparation o f culture medium
Ham’s modified F-14 (JRH Biosciences) was obtained in powdered form where a 10X 
concentrate would be made, including the antibiotics penicillin G (Sigma) and streptomycin 
sulphate (Sigma, final concentrations in IX F-14: 179 pM and 68.8 fiM, respectively) and 
stored at 25ml aliquots at -20 °C. To make F-14, 500 mg sodium hydrogen carbonate (BDH) 
was dissolved in 250 ml tissue culture- grade distilled water (Gibco, Invitrogen), 25 ml of this 
was replaced with the 10X F-14 concentrate. The lx  F-14 solution was then supplemented 
with 2.5 ml 200 mM glutamine (Gibco, Invitrogen, 2 mM final) and 25 ml of 10% HIHS.
2.2 Dissection techniques
2.2.1 Dissection o f early cranial sensory ganglia
All dissections and subsequent preparations of neuronal cultures were carried out in a laminar 
flow hood using standard sterile technique. Fertile chicken eggs were incubated in a forced- 
draft, humidified incubator at 38 °C for the required time. To remove the embryos from the 
eggs, the egg was held with he blunt end uppermost where the air space is located. This end 
was disinfected with 70 % ethanol and allowed to dry. The shell was cracked in a line around 
the air space with scissors. This portion of the shell was removed and the embryo was 
carefully removed together with the adherent membranes with a pair of curved forceps. The 
embryo was washed in a petri dish containing L-15 medium and all membranes were removed 
with a pair of watchmaker’s forceps. The embryos where then transferred into a 60mm Petri 
dish containing L-15 medium. Here the embryos were then carefully staged according to 
criteria set out by Hamburger-Hamilton (see Fig. 2.1).
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Figure 2.1: Staging diagrams
Tungsten needles were used to make the transverse cuts to isolate the part of the developing 
head that contains the trigeminal, geniculate, vestibular and nodose ganglia. The head was 
bisected along the sagittal plane. This was done by inserting the tungsten needle into the 
cavity of the developing fourth ventricle. The tissue was orientated so that the dorsal aspect 
lay next to the bottom of the petri dish. Then it was cut through the roof of the fourth 
ventricle. The tissue then was orientated so that the ventral aspect was facing the bottom of 
the petri dish. Tungsten needles were used to remove the hindbrain from the medial aspect of 
each half of the bisected tissue. With the tissue lying on its side, the ganglia could be 
observed.
The ganglia were dissected from the surrounding tissue by bringing two tungsten needles 
down on either side of each ganglion and remove any adherent connective tissue with these 
needles. Ganglia were collected into a separate dish, transferred there using a siliconized 
Pasteur pipette.
2.2.2 Isolation of nodose ganglia in mid- embryonic development 
The embryos were extracted from the eggs by using a pair of curved forceps placed beneath 
the neck. The embryos were decapitated close to the base of the skull. Skin was removed 
from the front of the neck and the upper thorax by using a pair of watchmaker’s forceps and 
the great vessels emerging from the heart where exposed by separating the overlying muscular 
and skeletal tissues at the upper part of the thorax. One blade of the watchmaker’s forceps 
was inserted deep to the root of the great vessel. The great vessels were grasped and their 
attachment to the heart was severed by using a pair of watchmaker’s forceps. The great 
vessels were and the attached tissues lying in front of the neck pulled out gently away from 
the underlying vertebral column, by using a second pair of forceps to loosen the tissue so that 
they peal away from the vertebral column without tearing. Tissue containing the nodose 
ganglia was harvested in a fresh 60mm Petri dish containing L-15 medium. Tissue was 
subdissected using tungsten needles. Nodose ganglia can easily be recognized by their
16+ 17 17+ 18 20 21
for chicken embryos. Adapted from the Hamburger- Hamilton staging diagrams.
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glistering white appearance, spindle shape and attached vagus nerve. Vagus nerve was 
removed and ganglia cleaned of adherent tissue.
Stage 24Stage 22
Nodose
ganglion
Figure2.2: Location of the nodose Ganglion in early development. Scalebar = 1mm
TMN
ganglia are located in the neck and can be
obtained after removing the heart
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2.2.3 Dissociated neuronal cultures
Dissociated cultures of chick nodose ganglion neurons were set up from embryos from stages 
18- 33. Ganglia were resuspended in 950 pi HBSS (Gibco, Invitrogen) and 50pl 1% Trypsin 
(Worthington) was added and mixed. The trypsin-HBSS mixture was incubated at 37°C for 
about 10 minutes. The trypsin-HBSS mixture was then aspirated and the ganglia were 
washed twice with 1ml F-12 (Gibco, Invitrogen) with 10 % heat inactivated horse serum 
(HIHS), to inactivate any residual trypsin. The F-12/ 10% HIHS was then aspirated and 
replaced with a suitable volume of F-14. A single cell suspension was made by trituration 
using a siliconised pipette (Fisher Scientific), the end of which had been polished to a fine 
bore using a Bunsen burner. The tissue was taken up slowly into the pipette and expelled with 
firm pressure, avoiding over- tituration and the introduction of bubbles. Trituration was 
monitored by pipetting lOpl of the cell suspension onto a lid of a 35 mm dish and examined 
under a phase contrast Nikon Diaphot inverted microscope. Trituration was complete when 
only connective tissue fragments were present in the cell suspension and single neurons, with 
fairly long processes, were visible under the microscope.
2.2.4 Seeding neurons
Neurons were seeded in laminin-coated 35 mm dishes at a density of either 100-150 neurons 
per 12 mm grid in the centre of the dishes to study neurite growth or 200-250 neurons per 12 
mm2 grid to study neuronal survival. Neuronal cultures were set up in triplicate.
2.2.5 Addition o f Neurotrophins and pharmacological inhibitors
Three hours after plating, neurons were exposed to different pharmacological inhibitors or 
neurotrophic factors. Compounds added are as following:
2.2.6 Agonists, Antagonists, Caspase- and pharmacological inhibitors 
Caspases are cysteine-dependent, aspartate-dependent proteases that exist as latent precursors, 
and when activated by limited proteolysis, initiate a cell death program by cleaving key 
components of the cell infrastructure and activate additional apoptotic mechanisms. Caspase 
activation can occur by either the receptor mediated (Fas ligand/ TNF a- mediated, for 
example) apoptotic pathway, leading to the activation of pro- caspase 8, or the mitochondrial 
apoptotic pathway, resulting in the association of Bcl-2 family members with the 
mitochondria, release of cytochrome c and activation of pro- caspase 9. The broad spectrum
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caspase inhibitor III (Boc-D-FMK, Calbiochem), used in this study, acts by binding 
irreversibly to the caspase active site, directed by a peptide recognition sequence bound to a 
functional group (fluromethylketone, FMK). In experiments performed in the presence of 
caspase inhibitors, 8 pi were added into 2 ml of culture medium.
Bio: (2’Z, 3’E)-6-Bromoindirubin-3’-oxime
GSK3 inhibitor/ Calbiochem: Bio is a cell- permeable, selective and reversible ATP- 
competitive inhibitor of GSK3 a/p. After applying the inhibitor GSK3 a/p is not able to 
phosphorylate its substrates. In experiments done in the presence of bio, we used a final 
concentration of 100 nM of the inhibitor as we found this an adequate concentration in our 
dose- response experiments.
Ly 294002: 2-(4-Moipholinyl)-8-phenyl-4H-l-benzopyran-4-one 
PI3 kinase inhibitor/Calbiochem: LY294002 is a cell permeable, potent and specific 
phosphatidylinositol 3-kinase inhibitor that acts on the ATP- binding site of the enzyme, on 
the catalytic subunit of DNA- activated protein kinase. In our experiments we used a 
concentration of 50 pi in each dish.
U 0126: 1,4-Diamino-2,3 -dicyano-1,4-bis(2-minophenylthio)butadiene 
Mek inhibitor/Calbiochem The U0126 compound is a potent and specific inhibitor of MEK1 
and MEK2. The inhibition is non-competitive with respect to MEK substrates, ATP and Erk. 
We used a concentration of 10 pM in each dish for our experiments.
U 0124: 1,4^Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene 
U0124 is used as negative control to the MEK inhibitor U0126 and provided by Calbiochem. 
This compound does not inhibit MEK even at concentrations of 100 pM.We used a 
concentration of 10 pM in each dish for our experiments.
PD98059: 2 -Amino-3-methoxyflavone
The PD98059 compound is a Mek inhibitor, provided by Invitrogen. A selective and cell- 
permeable inhibitor of MAP kinase kinase (MEK) that acts by inhibiting the activation of 
MAP kinase and subsequent phosphorylation of MAP kinase substrates. PD98059 does not
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block NGF-dependent activation of PI 3-kinase. We used a final concentration of 10 pM for 
our experiments.
Calhex 231
Calhex 231 is a potent CaSR agonist (calcilytic) that activates the receptor at nM levels. The 
compount was provided by TRC
Calindol Hydrochloride
This compound is a specific CaSR antagonist (calcimimetic) that inactivates the receptor at 
nM levels. Calindol Hydrochloride was provided by TRC.
BDNF: Brain derived neurotrophic factor
In experiments where neurons would go apoptosis in the absence of BDNF, we added a final 
concentration of lOng/ml of BDNF into each dish. BDNF is provided by R&D Systems.
2.1.7 Expression constructs
The pi 10a of PI3K expression constructs were gifts from Dr. Julian Downward (Cancer 
Research UK, London, United Kingdom). The pi 10 subunit was constructed as described 
(Volinia et al., 1994), in brief, DNA fragments, encoding the carboxy terminus of bovine 
pi 10a with an extension corresponding to the famesylation-palmitylation signal from H-Ras, 
were amplified by PCR with the sense primer
5,CACACACTCCATCAGTGGCTCAAAGACAAGAAC3' and the antisense primer 
5,CGCGGATCCTCAAGAGAGCACACACTTACAGTTCAAAGCATGCTGC3\ The PCR 
products were digested with Clal and BamHl, ligated into the pi 10 sequence, and subcloned 
into the mammalian expression vector pSG5 (Stratagene) to generate pi 10-CAAX. The 
construct was confirmed by DNA sequencing (Volinia et al., 1994).
The p85 Mutant of PI3-Kinase was a generous gift from Cathrine Mounier, Departement des 
Sciences Biologiques, Centre de recherche BioMed, Universite du Quebec, Montreal, Canada. 
Previous work has shown that the p85 deletion mutant lacking the pi 10 binding site works as 
a dominant negative regulator for wild-type p85 in competing for upstream docking proteins 
(Dhand, R. EMBO J. 1994). The mutant p85(A478-513) was constructed as described (Dhand 
et al., 1994). Briefly, the 478-513 coding region, corresponding to the pi 10 binding domain, 
was deleted from the wild-type p85 using PCR. Two PCR fragments (PI and P2) were
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generated. PI encompassed nucleotides 1-1431 and had a Bglil site introduced at the 5'-end.
P2 encompassed nucleotides 1542-2172 and had 30 bases complementary to the 3-end of PI 
product introduced at the 5-end. After purification, the two PCR fragments were mixed, 
denaturated, and reannealed. Using primers at each end, the mutated p85 was then reamplified 
by PCR and subcloned into pShuttle-CMV vector digested by Bglll and EcoKV. The pShuttle- 
CMV-Ap85 plasmid was then mixed with pAdEasy-1 vector to prepare recombinant 
adenovirus as described previously (He et al., 1998). Chick CaSR was cloned by Thomas 
Vizard using PCR from chicken brain Poly A(+) RNA (Clontech) using a LongRange 2 step 
RT-PCR kit (Qiagen) and the forward primer 5f-ACA GAG GGA CAA ATA CCA GCA 
CTG-3' and reverse primer 5'-CTG GAG GTA AAG CTA CAT CTG CTG-3'. The 4kb PCR 
product was then ligated into pGEM-T Easy (Promega) and the correct sequence confirmed 
by restriction analysis and nucleotide sequencing before cloning into pcDNA3.1. The R185Q 
dominant negative mutation was introduced to the second and third positions of codon 185 of 
the chicken CaSR sequence using a QuikChange Multi Site-Directed Mutagenesis kit 
(Stratagene) and the mutagenic primers 5-GTT CAA GTC CTT CCT CCA CAC AAT CCC 
CAA TGA CG-3' and 5'-AGT TCA AGT CCT TCC TCC AAA CAA TCC CCA ATG AC-3' 
(Vizard, T.N. personal communication)
The HA-GSK3p R96E construct was a gift from Trevor Dale. Mutant GSK-3 constructs were 
generated using site-directed mutagenesis according to the manufacturer’s instructions 
(QuikChange; Stratagene).
Surface scanning mutagenesis was performed on HA-tagged GSK-3 cDNAs within the 
pcDNA3.1_ expression vector. The R96E mutation, a exchange of Arginine into Glutamic 
acid is directed to the basic pocket in the gsk3 catalytic cleft. Two other residues make up this 
pocket, R180 and K205. This mutation removes the catalytic activity and therefore reduces 
the activity of GSK3.
2.1.8 Quantification o f neuronal survival
To determine neuronal survival, a standard graticule for examining each culture dish was 
made from the base of a 900mm plastic Petri dish, where a scalpel blade was used to inscribe 
a 12 x 12 mm grid consisting of 2 mm squares. Cells were counted 3-4 hours after plating by 
mounting the graticule on an inverted phase- contrast Nikon Diaphot microscope. Each dish 
was then placed over the graticule and the number of neurons present in the 12 mm2 grid was
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then counted. Neurons which had not been attached to the substratum were ignored. The 
number of phase- bright neurons in all dishes was counted after 24 hrs intervals until 
necessary. The number of 24 hrs or 48 hrs was then expressed as a percentage of the initial 
cell count. For each survival experiment, the mean percentage survival from three dishes per 
condition was determined.
2.1.9 Measuring total neurite length
Neurons were fluorescently labelled using calcein- acetoxymethyl ester (AM) fluorogenic 
esterase substrate (Molecular Probes, Invitrogen). 4pl of Calcein-AM (lmg.ml -1 in DMSO) 
was added to 2 ml of cell culture medium and incubated for 10-30 mins. The dye is retained 
in cells that have intact membranes but does not label dead cells. For every condition studied, 
40 to 70 neurons were digitally captured using either a Zeiss laser scanning microscope LSM 
510 or Zeiss Axiovert 200 inverted fluorescent microscope using Simple PCI software. Total 
neurite length was measured using Zeiss examiner software. Neurons were traced over using a 
1 pixel line that automatically measured neurite length.
2.1.10 Transfection o f neurons by electroporation
Electroporations were carried out using the Microporator MP100 (Digital Bio). 
Electroporation, or electropermeabilization, is a significant increase in the electrical 
conductivity and permeability of the cell plasma membrane caused by an externally applied 
electrical field. Pores are formed when the voltage across a plasma membrane exceeds its 
dielectric strength. If the strength of the applied electrical field and/or duration of exposure to 
it are properly chosen, the pores formed by the electrical pulse reseal after a short period of 
time, during which extracellular compounds have a chance to enter into the cell.
Ganglia were trypsinised, washed twice with F-12/10% horse serum and washed a further two 
times with PBS. The ganglia were then pelleted by centrifugation for 2 min at 2000 x g, the 
PBS was then aspirated and replaced with Resuspension Buffer (12 pi per transfection). The 
ganglia were then mechanically dissociated by passing through a sterile pipette tip several 
times. For each transfection, 12 pi of cell suspension was then transferred to 0.5ml microfuge 
tubes containing lpg target plasmid and 0.5 pg pYFP. The cell-DNA mixture was then 
drawn into a MicroPorator Pipette, making sure not to introduce air bubbles. The 
MicroPorator Pipette was then transferred to the pipette station were it was inserted into the 
Microporation tube, containing 3ml Electrolytic Buffer E. Each transfection was carried out 
using the following settings:
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Voltage 1400 V
Pulse Width 10 ms
Pulse Number 3
After transfection, the cells were immediately transferred to F-14 medium and plated in 4- 
well dishes. The number of neurons transfected compared to non-transfected cells was 
between 30 and 40 % in all experiments.
2.1.11 Quantification o f neuronal survival and neurite outgrowth in transfected 
cultures
YFP- labelled neurons were counted 24 hrs after plating using a Zeiss Axiovert 200 inverted 
microscope and again at 48 hrs. the number of neurons surviving at 48hrs was then expressed 
as a percentage of the initial number of neurons counted at 24 hrs
Fluorescent images of the neurons counted were taken after 24Hrs in culture using a Zeiss 
Axiovert 200 invered fluorescent microscope and neurite ougrowth quantified according to 
methods described above.
2.1.12 Immunocolocalisation o f the CaSR in Dissociated Neurons
Neurons were grown in 4-well 35 mm dishes (Greiner) and fixed after 24 hrs using ice-cold 
methanol. Cells were then washed twice with PBS before blocking with 5 % bovine serum 
albumin (BSA), 0.02 % Triton-XlOO in phosphate buffered saline (PBS, Sigma) for 1 hour. 
The primary antibody, the anti- CaSR polyclonal antibody (Imgenex), was added in 1% BSA, 
0.02 % Triton-X in PBS, together with a monoclonal p-III tubulin antibody (R&D Systems, 
used at 1:1000) as a neuronal marker and incubated overnight at 4 °C. The cells were then 
washed three times with PBS before applying the secondary antibodies, Alexa 488- 
conjugated anti- rabbit IgG (Molecular Probes) and Alexa 594-conjugated anti-mouse IgG 
(Molecular Probes) diluted 1:500 in 1 % BSA, 0.02 % Triton-X in PBS for 90 mins at room 
temperature, protected form light. The secondary antibodies were removed and the cells 
washed a further three times with PBS. Immunofluorescence as visualised using a Zeiss laser 
scanning microscope LSM 510 and images were acquired and processed using LSM 510 
software.
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2.1.13 Western Blotting
The Biorad system was used for running polyacrylamide gels in size of 72 x 83 x 75 mm . 
After pouring the separating gel with an acrylamide concentration of 10 %, the acrylamide 
solution was covered with isopropanol to ensure a level surface and to avoid an inhibitory 
effect of 0 2. After the gel was polymerized, the isopropanol was removed and the stacking gel 
solution was added. Combs of 10 wells were used with a breadth of 7.5mm. Before running 
the gel, samples were boiled shortly for 3 minutes to destroy any remaining secondary or 
tertiary structure in the samples which could bind to the SDS. 10 pi of Rainbow marker (Bio- 
Rad) was loaded as reference. After transferring into the electrophoresis chamber with 
electrophoresis buffer, gels were run first at a voltage of 80 V (EPS, Amersham) and then, 
when the samples reached the separating gel, the voltage was increased to 150V.
2.1.14 Transferring to nitrocellulose membrane
Proteins separated during gel electrophoresis were transferred to Hybond™-P PVDF 
membrane (Amersham) by assembling a blot sandwich under transfer buffer which 
comprised; sponge, gel-sized Whatman paper, gel, PVDF membrane (activated by a prior 
rinse in methanol), gel-sized Whatman paper, sponge. The sandwich was sealed in a within a 
blotting cassette, transferred to the electrophoresis chamber and immersed in transfer buffer. 
Transfer was carried out in the electrophoresis chamber at 80V for 1 hour with ice to keep it 
cool. Successful transfer of proteins was determined by the transfer of molecular weight 
markers to the nitrocellulose membrane and by immersion of the membrane in Ponceau S 
(0.2 % in 3 % TCA, Serva) for 3-5mins. The membrane was then rinsed with water until the 
proteins were visible.
2.1.15 Immuno-detection
Ponceau stained membranes were again rinsed with water and then blocked by incubating 
with 10 ml PBS-0.1 % Tween (PBS-T) containing 5% dried milk for 1 hour, to prevent non­
specific binding of the antibodies. After blocking, the membrane was incubated with the 
primary antibody (dilutions listed in Table 2.4) overnight at 4 °C. The following day the 
membrane was washed 3 x 1 0  min with PBS-T. After washing, the membrane was incubated 
with a horseradish peroxidase (HRP)-conjugated secondary antibody diluted in PBS-T 
containing 5% dried milk (specific dilutions in Table 2.4) for 1 hour. The antibody/PBS-T-
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milk solution was removed and the membrane was washed for a further three times with PBS- 
T. ECL Plus detection system (Amersham) was used to detect immobilised proteins 
conjugated to HRP-labelled antibodies. HRP and peroxide catalyse the oxidation of a PS-3 
Acridan substrate, generating thousands of acridinium ester intermediates per minute. These 
intermediates react with peroxide under alkaline conditions providing high intensity 
chemiluminescence which can be detected by autoradiography film. Briefly, 50 pi ECL plus 
solution B is added to 2 ml solution A, mixed, pipetted onto the membrane and incubated for 
5min at room temperature. The excess detection reagent was poured off and the membrane 
transferred to an ECL Hyperfilm cassette. Hyperfilm ECL (Amersham) was placed over the 
membrane and exposed for 1 min before developing using a Xograph developing machine.
2.1.16 Stripping
To re-probe the PVDF membrane with another antibody, the membrane was stripped to 
remove both primary and secondary antibodies, this was carried out by incubating membranes 
in stripping buffer (see Appendix) for 15 min at 55 °C with a further 10 min rocking at room 
temperature. Membranes were then washed with 3 x lOmin PBS-T to remove remaining 
traces of stripping solution. The membrane was blocked again by incubating with PBS-T 
containing 5 % milk for 60 minutes and then incubated with the next primary antibody as 
described above.
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2.1.17 Antibodies and Proteins
Dilution of antibodies:
Antibody Source and Company Dilution
Anti-phospho Akt Polyclonal Antibody
specific to pS473 
(Acris), Rabbit
1:1000
Anti-phospho GSK3 Rabbit polyclonal p- 
GSK3 alpha and 
beta (abeam)
1:1000
Anti-Akt Rabbit polyclonal to 
pan-Akt 
(abeam)
1:1000
Anti-GSK3 Rabbit polyclonal GSK3 
(alpha and beta) 
(abeam)
1:1000
Anti Rabbit Promega 1:2000
Anti Mouse Promega 1:2000
Figure 2.4: Dilutions of antibodies
All Antibodies were diluted in 1 % BSA + 0.02 % Azide
2.1.18 Quantitative PCR
2.1.19 RNA Isolation
10-12 ganglia from chicken embryos at early developmental stages were collected for each 
RNA isolation, pelleted and stored at -80 °C until required. Total RNA from the unprocessed
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ganglia was extracted using RNeasy ® Kit (Qiagen) according to the manufacturer’s protocol 
and stored in RNAse- free dH20 at -70 °C until required.
2.1.20 cDNA Synthesis using STRATASCRIPT® RT
cDNA synthesis reactions were assembled on ice and contained; 4 pi 1 OX StrataScript ® 
buffer, 2pl pd(N)6 Random Hexamers (0.005U.pl-1; Amersham Biosciences), 2 pi 
deoxynucleoside triphosphate (dNTP) mixture (100 mM), 0.38pl StataScript® Reverse 
Transcriptase (50U.pl'1), 3 pi RNA and Rnase free dlUO to 40 pi and were incubated at 42°C 
for 90minutes. The subsequent cDNA was then stored at -20 °C for long periods or 4 °C if to 
be used immediately.
2.1.21 Quantitative PCR using Stratagene MX3000P
In real-time PCR using SYBR green binding to amplified cDNA, we are simply measuring 
the fluorescence increase as the dye binds to the increasing amount of DNA in the reaction 
tube. We hope that this increase in fluorescence is coming from the DNA that we wish to 
measure but some of the signal could come from DNA other than that which we are trying to 
amplify. The way to make sure that the correct fragments were amplified is checking the 
products’ melting curve.
Each real-time PCR reaction was prepared using 2.5 pL of cDNA, 2.5 pL of Brilliant QPCR 
core buffer (Stratagene), 1.5 pL of 3 mM MgCh (Stratagene), 0.5pL of primers, 0.4 pL of 
(1/500) reference dye (Stratagene), 0.25 pL (1/4000) Sybr Green® (Invitrogen), 1 pL of 20 
mM dNTP’s (Stratagene), 15.8pL of distilled water and 0.33 pL of Hot Taq® enzyme 
(Stratagene).
The following table shows the primer set for each gene and the respective annealing 
temperature.
Gene Sense Locus Sequence Annealing Melting
Temperature temperature 
Ck_CaSR F XM_416491 5'- ACA ATA CCC ATAGAC TC -3' Ta: 48.3°C Tm: 87.2°C 
R 5 - ATT ACA GCA ACA CTT -3'
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2.1.22 Standard curve
The most accurate quantitative result from real time PCR is to compare the experimental 
sample with the reference gene. The reference gene is to be used as a loading control (or 
internal standard) and should have various features, such as: having the same copy number in 
all cells; be expressed in all cells, and have a medium copy number, to permit more accurate 
comparison. The reference gene we used was glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). The standard curve for the real time PCR was prepared with Stage 28 whole - 
embryo cDNA synthesized using the same method of the samples. This standard curve was 
prepared by serially diluting Stage 28 whole -embryo cDNA from 1 to 1/64 using the cDNA 
blank mixture (cDNA synthesis reaction mixture without template RNA) 2.5 pi of each 
dilution and a no template control (NTC- cDNA blank mix only) was transferred to 0.2ml 
optical PCR tubes (Stratagene) containing the PCR reaction mixture. Following amplification 
of the standard dilutions, a standard curve was generated by plotting the log of the initial 
template copy number against the ct value for each dilution. The ct value (threshold cycle) is 
the first cycle at which the PCR instrument can distinguish amplification- generated 
fluorescence from background signal. The Ct values of the unknown samples were then 
compared with the standard curve and the initial quantities determined.
2.1.23 Statistical Analyses
The sample number (n) shown for each experiment describes either the total number of 
neurons sampled (for neurite growth experiments) or the total number of separate cultures 
carried out (for neuronal growth and survival experiments). Where data is shown from more 
than one experiment, the number of separate cultures is indicated. Data are presented as 
means ± SEM, and statistical significance was determined by the unpaired T-test or, if there 
were more than two sets of data compared, then one-way analysis of variance (ANOVA) with 
Tukey post hoc test was used. The significance was accepted for P< 0.05.
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Chapter 3
Regulation of de novo axonal growth from cranial 
sensory neurons by the extracellular calcium- 
sensing receptor (CaSR)
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3.1 Introduction
The great majority of studies of the molecular mechanisms that control axonal growth rate 
have been undertaken either on neuronal cell lines or on axotomised neurons that regenerate 
axons in culture. Virtually nothing is known about the molecular control of axonal growth 
rate at the developmentally significant stage when neurons are initiating and extending axons 
to their targets. There are two main reasons for this. First, because of the very small size of 
neuronal populations at the relevant stage of embryonic development, it is technically 
challenging to harvest neurons for in vitro studies of de novo axonal growth. Second, the very 
limited numbers of neurons that can be harvested from embryos at the appropriate early stages 
of development imposes severe restrictions of the biochemical studies that can be undertaken 
to investigate the molecular mechanisms regulating axonal growth rate.
Despite these technical difficulties, de novo axonal growth exhibits several features that 
distinguish it from axon regeneration, and thus make it an intriguing, important and especially 
relevant topic for study in the field of developmental neuroscience. First, neuronal survival 
and axon extension are independent of neurotrophic factors for many populations of neurons 
at this early stage of their development (Davies and Lumsden, 1984; Davies, 1987; Vogel and 
Davies, 1991). In contrast, neurons that have already innervated their targets and regenerate 
axons in culture, not only depend on particular neurotrophic factors for survival, but also 
extend axons in response to these factors (Deckwerth et al., 1996; Markus et al., 2002). 
Second, neurons extending axons in culture at the stage of development when their axons are 
normally growing to their targets in vivo replicate key features of their appropriate in vivo 
morphology. For example, sensory neurons cultured at this early stage of development 
exhibit the characteristic bipolar morphology, with two unbranched axons growing from 
opposite poles of the cell body, as observed in vivo (Davies, 1989). In marked contrast, 
neurotrophin-dependent sensory neurons that have already innervated their targets regenerate 
an abnormal morphology in culture. Typically, these regenerating neurotrophin-dependent 
sensory neurons are multipolar, with excessively branched axons (Scott and Davies, 1993). 
Third, and most intriguingly, certain populations of neurons exhibit distinctive rates of axonal 
growth both in vivo and in vitro at the stage when their axons are growing to their targets that 
are lost when they are cultured during the later stage of neurotrophin dependence (Davies, 
1989).
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The most striking and thoroughly characterized example of distinctive differences in de novo 
axonal growth rates is provided by four populations of placode-derived cranial sensory 
neurons of the chicken embryo. The neurons of the vestibular, geniculate, petrosal and 
nodose ganglia are bom during the same period of development and start extending axons to 
their peripheral and central targets at approximately the same time, but have different 
distances to grow to reach their targets. Vestibular neurons have the closest targets, nodose 
neurons have the most distant targets, and geniculate and petrosal neurons have targets of 
intermediate distance. The rate at which the axons of these neurons grow to their targets in 
vivo is correlated with target distance: vestibular neurons have the slowest axon growth rates, 
and nodose neurons the fastest. Importantly, these distinctive differences in axonal growth 
rate appear to be intrinsic property of the neurons. When they are cultured at very low density 
or as isolated single cells at the stage of development when their axons are normally growing 
to their targets, they extend axons at different rates: the axons of nodose neurons growing 
faster than those of petrosal neurons, which grow faster than those of geniculate neurons, 
which grow faster than those of vestibular neurons. At this stage of development, the neurons 
survive independently of neurotrophins and axonal growth rate is unaffected by BDNF, the 
neurotrophin that the majority of the neurons in each ganglion become dependent on when 
their axons reach their targets (Davies, 1989). In addition to axonal growth rate, the duration 
of neurotrophin independence and the expression of TrkB in these early neurons is also 
correlated with target distance. Vestibular neurons are the first to express TrkB and the first 
to become dependent on BDNF for survival, whereas nodose neurons are last (Robinson et al., 
1996; Vogel and Davies, 1991). The duration of neurotrophin independence, together with 
intrinsic differences in axonal growth rate, appear to coordinate the onset of neurotrophin 
dependence with the arrival of axons in the vicinity of their targets (Davies, 1994).
The aim of the research reported in this chapter was to identify a molecular mechanism that 
plays a role in effecting differences in axonal growth rate at the stage of development when 
axons are growing to their targets. For this work, I focused on the populations of placode- 
derived cranial sensory neurons that have the greatest differences in axonal growth rate, 
namely, those of the vestibular and nodose ganglia of Hamilton-Hamburger Stage 20 chicken 
embryos, the stage when many of their axons are growing to their peripheral and central 
targets in vivo. Because neurotrophins play no role in regulating axonal growth from these 
neurons at this early stage of development, I focused on alternative possible mechanisms of 
axon growth regulation. One recently identified regulator of axonal growth in the developing
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nervous system is the CaSR. This is expressed at relatively high levels in embryonic mouse 
superior cervical ganglia (SCG) just before birth, a stage in development when the axons of 
these neurons are innervating and branching extensively in their distal targets (Vizard et al., 
2008). Manipulating CaSR function in these neurons by varying [Ca2+]0, by using CaSR 
agonists and antagonists or by expressing a dominant-negative CaSR markedly affects neurite 
growth in vitro during a narrow developmental window during the immediate perinatal period 
when CaSR expression is highest. SCG neurons lacking the CaSR have smaller neurite arbors 
in vitro, and sympathetic innervation density is reduced in CaSR-deficient mice in vivo. 
These findings suggest that under the hypercalcaemic conditions of the embryo, the activated 
CaSR in SCG neurons promotes, by an intracellular mechanism yet to be elucidated, axonal 
growth and branching that is physiologically relevant for the establishment of normal 
sympathetic innervation density in vivo (Vizard et al., 2008).
In this chapter I report that CaSR is expressed in placode-derived cranial sensory neurons of 
the chicken embryo, with higher levels of CaSR mRNA in nodose compared with vestibular 
neurons, and that manipulating CaSR function in nodose, but not vestibular neurons, affects 
axonal growth rate. These findings provide the first evidence for a mechanism involved in 
regulating intrinsic differences in early axonal growth rate.
3.2 Results
3.2.1 CaSR mRNA and protein is expressed in early placode-derived cranial sensory 
neurons
I began investigating the potential involvement of the CaSR in regulating axonal 
growth from early placode-derived neurons by using RT-QPCR to determine if CaSR mRNA 
is expressed in vestibular and nodose ganglia at the stage of development when axons are 
growing to their targets and ascertain the relative levels of expression in these ganglia. Total 
RNA was extracted from pooled nodose and vestibular ganglia harvested from stage 20 
chicken embryos, and after reverse transcription, primers based on the published chicken 
CaSR sequence were used to amplify CaSR cDNA. To compare the relative levels of CaSR 
mRNA in these ganglia and correct for differences in ganglion size, I also used real-time PCR 
to measure the level of mRNA encoding the ubiquitous, constitutively expressed, 
housekeeping protein glyceraldehyde phosphate dehydrogenase (GAPDH). CaSR mRNA 
was detected in both nodose and vestibular ganglia, with significantly higher levels in the 
nodose ganglion (approximately 3-fold higher in the nodose ganglion compared to the 
vestibular ganglion) (Fig. 3.1). While the great majority of cells in these early ganglia are
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neurons and neuroblasts, I nonetheless carried out immunocytochemistry using a specific 
affinity-purified anti-CaSR polyclonal antibody to identify which cells express the CaSR in 
dissociated cultures established from stage 20 nodose and vestibular ganglia. In double­
labelled preparations, in which neurons were positively identified with anti-P-III tubulin 
antibodies, the CaSR antibody stained the cell bodies, entire axons and growth cones of all 
nodose (Fig. 3.2) and all vestibular neurons (Fig. 3.3). None of the very few non-neuronal 
cells were immunoreactive for CaSR, and staining was not evident with the secondary 
antibody alone when the primary antibody was omitted (data not shown).
4^*3.2.2 Varying [Ca ]Q over the CaSR sensitivity range influences the extent of axonal 
growth from stage 20 nodose neurons but not vestibular neurons
To begin investigating the potential role of the CaSR in regulating axonal growth from 
early nodose and vestibular neurons, I cultured these neurons at low density in medium 
containing several different concentrations of extracellular Ca , spanning the CaSR response 
range. The sensitivity of CaSR to changes in [Ca2+]c varies within the range of 0.5 to 3 mM 
according to cell type and the signalling events or physiological responses being quantified. 
The EC50 or IC 50 ranges between -1 mM and -1.7 mM (Ferry et al., 2000; Nemeth et al., 
1998). In the case of El 8 mouse SCG neurons, comparison of the extent of neurite growth 
from wild type and CaSR-deficient neurons has demonstrated that 0.7mM [Ca2+]0 has a 
minimal effect on CaSR-promoted neurite growth, and detailed dose response analysis has 
demonstrated that 2.3 mM [Ca2+]0 exerts the maximal effect on CaSR-promoted neurite 
growth (Vizard et al., 2008). For this reason, these same concentrations were used in the 
experiments described here together with two intermediate concentrations, 1.1 mM and 1.3 
mM, the latter being the standard [Ca2+]0 in media generally used to culture embryonic 
neurons.
Nodose and vestibular neurons were plated at low density in laminin-coated tissue 
culture dishes containing medium with different levels of [Ca ]0. The number of neurons 
within a standard grid in the centre of each dish was counted three hours after plating, and 
again after 24 hours in order to estimate the number of neurons surviving under each 
experimental condition. The neurons were stained with the fluorescent vital dye calcein-AM 
at 24 hours, and photomicrographs of randomly selected neurons were taken for quantification 
of neurite length. Because the great majority of stage 20 nodose neurons survive 
independently of neurotrophins for 24 hours following plating, these neurons were grown 
without neurotrophins. Cell counts confirmed that the majority of nodose neurons had
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survived without neurotrophins for 24 hours, as expected, and revealed no significant 
differences in survival over the [Ca2+]0 range studied (Fig. 3.4 A). Measurements of total 
axon length revealed a dose-dependent increase with [Ca2+]0, with a highly significant, two­
fold difference between 0.7 mM and 1.1 mM, and smaller increases in axonal length between 
the higher concentrations (Fig. 3.4 B). These findings show that varying [Ca2+]0 over the 
CaSR sensitivity range influences the magnitude of axonal growth from embryonic nodose 
ganglion neurons at the stage when these axons are normally growing to their targets.
Because a significant proportion of stage 20 vestibular neurons start becoming 
dependent on BDNF for survival within 24 hours after plating, all cultures received the 
irreversible caspase inhibitor Boc-D-FMK to prevent excessive loss of neurons during this 
period. A caspase inhibitor, rather than BDNF, was used to sustain the survival of those 
neurons that acquire BDNF dependence during the 24 hour culture period because the aim of 
these experiments was to investigate neurotrophin-independent axon growth. Neuron counts 
revealed that over 80% of the neurons survived in these cultures for 24 hours and there was no 
significant difference in survival between cultures containing 0.7 mM and 2.3 mM [Ca2+]0 
(Fig. 3.5 A). In marked contrast to nodose neurons, the shorter axons of vestibular neurons 
were not stimulated to grow by 2.3 mM [Ca2+]0 at stage 20 in development (Fig 3.5 B). This 
suggests that the CaSR does not regulate de novo axonal growth from vestibular neurons at 
this early stage in their development. However, because a caspase inhibitor was used in the 
vestibular neuron experiments, the nodose neuron experiments were repeated under identical 
conditions with the same caspase inhibitor to control for any unexpected effect of this reagent 
that could account for the different responses o f the two kinds of neurons to changes in 
[Ca2+]0* In these experiments, nodose neurons were grown in parallel in 0.7 mM and 2.3 mM 
[Ca2+]„ in presence and in the absence of Boc-D-FMK. Quantification of neuronal survival 
and axonal length after 24 hours revealed almost identical results in the presence and absence 
of Boc-D-FMK. There was no significant difference in survival under all experimental 
conditions, and there were highly significant, ~3-fold differences in axonal length between the 
0.7 mM and 2.3 mM [Ca2+]0 conditions in both the presence and in the absence of 
Boc-D-FMK (Fig. 3.6). Taken together, the above results show that changes in [Ca2+]0 over 
the response range of the CaSR affect neurotrophin-independent axon growth from nodose 
neurons but not vestibular neurons of stage 20 chicken embryos.
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3.23 The CaSR agonist Gd enhances axonal growth from stage 20 nodose neurons 
incubated with 0.7 mM [Ca ]0, but does not affect the growth of vestibular neurons
The above findings implicate the CaSR in mediating the effects of [Ca2+]0 on 
neurotrophin-independent axonal growth from cultured stage 20 nodose neurons. To provide 
further support for the involvement of the CaSR, I carried out experiments with a potent
*5 i
CaSR agonist, the trivalent ion of the rare-earth metal, gadolinium. Gd , which activates the 
CaSR in the absence of Ca2+ (Hofer and Brown, 2003).
Nodose and vestibular neurons were cultured for 24 hours in medium containing 0.7 
mM [Ca2+]0 alone or 0.7 mM [Ca2+]0 with Gd3+ at a concentration of 1 pM. Neuron counts 
revealed that Gd3+ did not affect the survival of either nodose neurons or vestibular neurons
^  I
(Fig 3.7 A). Whereas Gd had no significant effect on axon growth from vestibular neurons, 
it caused a three-fold increase in the length of nodose neuron axons (Fig. 3.7 B). In further 
dose response studies, Gd3+ at concentrations down to 0.1 pM enhanced axon growth from 
nodose neurons incubated with 0.7 mM [Ca2+]0 to a similar extent to that observed in medium 
containing 2.3 mM [Ca2+]0 without affecting survival (Fig.3.8) These results provide further 
support for a role for the CaSR in promoting axon growth from nodose neurons but not 
vestibular neurons at a stage in development when the axons of these neurons are growing to 
their targets in vivo.
3.2.4 The CaSR agonist, Calhex, and the CaSR antagonist, Calindol, modulate axonal 
growth from stage 20 nodose neurons.
The specific CaSR agonist, Calhex, and CaSR antagonist, Calindol, have recently 
become commercially available. I therefore decided to confirm the involvement of the CaSR 
in regulating de novo axon growth by using them in experiments with stage 20 nodose 
neurons. Nodpse neurons were cultured with 0.7 mM [Ca2+]0 with and without 10 nM of 
Calhex. Whilst Calhex did not alter the survival of stage 20 nodose neurons, it greatly
increased the length of their axons (Fig. 3.9). In further experiments, stage 20 nodose neurons
• 2+were cultured with and without 10 nM Calindol in medium containing 2.3 mM Ca , a 
calcium concentration that activates the CaSR to promote axon elongation. Calindol did not 
affect the survival of stage 20 nodose neurons cultured with 2.3 mM [Ca2+]0 (Fig. 3.10 A). 
However, Calindol was able to significantly reduce axonal length under the same culture 
conditions (Fig. 3.10 B, p< 0.0001, ANOVA with Fisher’s ad hoc). These findings provide 
further evidence that the CaSR plays a role in promoting de novo axon growth
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3.2.5 Inhibiting Gj proteins with Pertussis toxin prevents Gd^-induced axonal growth 
stage 20 nodose neurons Gd ^
To obtain further, though indirect, support for the involvement of the CaSR in 
enhancing de novo axonal growth in from stage 20 nodose neurons, I examined the effects of 
pharmacologically inhibiting G proteins with Pertussis toxin (PTX). PTX catalyzes the ADP- 
ribosylation of the a subunits of the heterotrimeric G proteins Gi, G0, and Gt which prevents 
these G proteins from interacting with G protein-coupled receptors like the CaSR on the cell 
membrane (Katada and Ui, 1982). Nodose neurons were cultured for 24 hours at low density 
in medium containing 0.7 mM [Ca2+]0 with and without lpM Gd3+ alone or with lpM Gd3+ 
plus 1 mg/ml PTX. Neuron counts revealed that PTX did not affect the survival of nodose 
neurons (Fig. 3.11 A), but completely inhibited the ability of Gd to enhance axon growth 
(Fig. 3.11 B). This finding is consistent with the involvement of CaSR in regulating de novo 
axon growth rate from early nodose neurons.
3.2.6 Effects of over-expressing wild type and dominant-negative CaSRs on axonal 
growth from stage 20 nodose neurons
To provide an additional test of the role of the CaSR in promoting early axonal 
growth, I transfected stage 20 nodose and vestibular neurons with pcDNA3.1 expression 
plasmids containing the cDNAs encoding either the wild-type chicken CaSR or a mutated 
chicken CaSR with an arginine-to-glutamine substitution (R185Q) that exerts a dominant- 
negative effect on CaSR function (Vizard T.N. personal correspondence) Expression plasmids 
were electroporated into freshly dissociated stage 20 nodose and vestibular neurons, using the
^ I
high-efficiency microporator, and neurons were cultured in media containing 2.3 mM Ca . 
To control for the transfection procedure, control cultures were transfected with an empty 
pcDNA3.1 vector. A yellow fluorescent protein (YFP) expression plasmid was included in all 
transfection procedures to identify the transfected neurons. The YFP expression plasmid was 
assumed to be taken up and expressed by the same neurons as the CaSR expression plasmids 
because co-transfection experiments with mixtures of two expression plasmids encoding 
different coloured fluorescent proteins demonstrated that both fluorescent proteins are 
invariably expressed in the same neurons (data not shown). The typical transfection 
efficiency of early chicken sensory neurons with the microporator ranged from 30% to 40% 
(data not shown). Fluorescent neurons were counted 24 hrs after plating and after 48 hrs in 
culture, allowing the percentage neuronal survival of fluorescent neurons at 48 hrs compared
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to 24 hrs to be determined. Fluorescent images for analysis of axonal growth were captured 
24 hr after transfection.
The axons of nodose neurons transfected with the wild type CaSR expression plasmid 
and cultured in medium containing 2.3 mM [Ca2+]0 for 24 hours after transfection were 
significantly longer than those of control plasmid transfected neurons (Fig. 3.12 B). Nodose 
neurons transfected with the dominant-negative CaSR expression plasmid and cultured under 
the same conditions had significantly shorter axons than control plasmid transfected neurons 
(Fig. 3.12 B). Estimates of neuronal survival showed no significant differences between all 
three experimental groups (Fig. 3.12 A). These results not only provide additional support for 
a role for the CaSR in promoting axonal growth from early nodose neurons, but suggest that 
the level of endogenous CaSR expression is limiting for the response of the neurons to 
maximally activating levels of [Ca2+]0- It should be pointed out that transfected nodose 
neurons extend axons more slowly than non-transfected neurons. This is not a peculiar 
feature of nodose neurons, but is a consistent finding in transfection studies of many other 
kinds of sensory and autonomic neurons cultured from embryonic and postnatal mice (Vizard 
et al., 2008). In contrast to nodose neurons, axonal growth from vestibular neurons was 
unaffected by over-expression of the wild type CaSR. Transfection of vestibular neurons with 
the dominant-negative CaSR were not carried out because any potential effect on axon growth 
would be difficult to ascertain since the length of axons was already very short in control- 
transfected vestibular neurons. There were no significant differences in axon length between 
control and wild type CaSR transfected neurons after 24 hours incubation in medium 
containing 2.3 mM [Ca2+]0 (Fig. 3.12 B) and no significant differences in neuronal survival 
(Fig. 3.12 A). These results demonstrate that over-expression of the CaSR is not in itself 
sufficient to confer increased axon growth in response to maximally activating levels of 
[Ca2+]0* This raises the possibility that mere expression of sufficient levels of the CaSR in 
early neurotrophin-independent nodose neurons is not the only difference between nodose and 
vestibular neurons that facilitates rapid axon growth from the former.
3.2.7 The role of the CaSR in regulating axon growth from older, BDNF-dependent 
nodose and vestibular neurons
Previous work has shown that the CaSR plays a role in promoting axonal growth and 
branching from late fetal mouse sympathetic neurons during a developmental window when 
the axons of these neurons are innervating their targets and are dependent on target-derived
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NGF for survival. To investigate if the CaSR plays any role in regulating regenerative axon 
growth from nodose and vestibular neurons at later developmental stages when these neurons 
are innervating their targets and are dependent on BDNF for survival, I assayed the levels of 
CaSR mRNA expression and investigated the effects of manipulating CaSR function between 
stages 25 and 30.
3.2.8 Developmental changes in CaSR mRNA expression in nodose and vestibular 
ganglia
The level of CaSR mRNA relative to GAPDH mRNA was measured by RT-QPCR in 
total RNA extracted from nodose and vestibular ganglia harvested from stage 20, stage 25 and 
stage 30 chicken embryos as outlined in section 3.2.1. Figure 3.13 shows that the levels of 
CaSR mRNA expressed in nodose ganglia were similar at stages 20 and 25, but there was a 
marked, almost 4-fold, increase in expression between stages 25 and 30. In contrast, the levels 
of CaSR mRNA expressed in vestibular ganglia were not significantly different between the 
three stages studied. Nodose ganglia expressed significantly higher levels of CaSR mRNA 
compared to vestibular ganglia at all stages analysed. Since the CaSR is clearly expressed at 
functional levels in stage 20 nodose ganglia, these findings suggest that functional levels of 
the CaSR protein are also expressed in nodose neurons after they reach their targets and 
become dependent on BDNF for survival, thus raising the possibility that the CaSR may 
modulate the extent of BDNF-promoted, regenerative axon outgrowth at stages 25 and 30. 
This hypothesis was tested in section 3.2.9, below. In contrast, although vestibular neurons 
express CaSR mRNA throughout the earliest period of BDNF dependency, the levels 
expressed at stages 25 and 30 are of a similar order of magnitude as those expressed at stage 
20.
3.2.9 Extracellular calcium modulates the extent of BDNF-promoted axonal growth in 
older, BDNF-responsive nodose neurons
To investigate the potential role of the CaSR in modulating BDNF-promoted axonal 
growth, I cultured stage 27 and stage 30 nodose neurons at low density in the presence and 
absence of BDNF in medium containing either 0.7 mM or 2.3 mM [Ca2+]0- The number of 
neurons within a standard grid in the centre of each dish was counted three hours after plating, 
and again after 24 hours in order to estimate the number of neurons surviving under each 
experimental condition. Neurons were stained with the fluorescent vital dye calcein-AM at 24 
hours, and photomicrographs of randomly selected neurons were taken for quantification of
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neurite length. Although nodose neurons start to express TrkB, from stage 25 in development 
(Robinson et al., 1996), the survival of stage 27 nodose neurons was not significantly greater 
in the presence of BDNF in media containing either 0.7mM or 2.3mM [Ca2+]0 after 24 hours 
in culture (Fig. 3.14 A). However, BDNF greatly increased the extent of axonal outgrowth 
from stage 27 nodose neurons after this time in culture in media containing 0.7 mM and 2.3 
mM [Ca2+]0 (Fig. 3.14 B). In the absence of BDNF, the extent of axonal outgrowth was not 
significantly different between cultures containing 2.3 mM [Ca2+]0 and 0.7 mM [Ca 2+]0. In 
contrast, in the presence of BDNF, the extent of axonal outgrowth was significantly greater in 
cultures containing 2.3 mM [Ca2+]0 compared to 0.7 mM [Ca2+]0. In cultures established 
from stage 30 embryos, BDNF significantly enhanced neuronal survival in media containing 
0.7 mM and 2.3 mM [Ca2+]0, and there was no significant difference in survival between 
cultures containing 0.7 mM and 2.3 mM [Ca2+]0 in the presence and absence of BDNF (Fig. 
3.15 A). Since stage 30 nodose neurons require BDNF for maximal survival in culture, image 
analysis of axonal outgrowth was only performed on neurons cultured with BDNF. Increasing 
[Ca2+]0 to 2.3mM enhanced BDNF-promoted axonal outgrowth from stage 30 nodose 
neurons by 2.5-fold compared to 0.7mM [Ca 2+]0 (Fig. 3.15 B).
3.2.10 CaSR agonists enhance axonal growth from stage 30 nodose neurons incubated 
with 0.7 mM [C a 2+]o, whereas the CaSR antagonist, Calindol, inhibits axonal growth in
2.3 mM [Ca2+]0
To obtain further support for a role for the CaSR in modulating axon growth in BDNF- 
dependent stage 30 nodose neurons, I cultured these neurons for 24 hours in medium 
containing BDNF and 0.7 mM Ca2+ with and without either 10 nM Calhex or 1 pM Gd3+. 
Neuron counts revealed that neither Calhex nor Gd3+ significantly affected neuronal survival 
(Figs 3.16 A and 3.18 A, respectively). However, Calhex promoted a 3.5-fold increase in 
axon length after 24 hours in culture (Fig. 3.16 B) and Gd3+ increased axon length by 5-fold 
over the same period (Fig. 3.18 B). Significantly, the axon growth-promoting effect of Gd3+ 
was completely prevented by treatment with 1 mg/ml of the Gi protein inhibitor, PTX (Fig. 
3.18 B). In further experiments, stage 30 nodose neurons were cultured with and without 10 
nM Calindol in medium containing BDNF and 2.3 mM Ca , a calcium concentration that 
activates the CaSR to promote axon elongation. Calindol did not affect the survival of stage 
30 nodose neurons cultured with BDNF in 2.3 mM [Ca2+]0 (Fig. 3.17 A). However, Calindol 
was able to significantly reduce axonal length under the same culture conditions (Fig. 3.17 B,
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p< 0.0001, ANOVA with Fisher’s ad hoc). These results provide further support for an 
involvement of the CaSR in enhancing BDNF-promoted axon growth from nodose neurons 
that have begun to innervate their targets in vivo.
3.2.11 Extracellular calcium modulates the extent of BDNF-promoted axonal growth in 
older, BDNF-responsive vestibular neurons
Neither increased [Ca2+]0 nor Gd 3+ promoted de novo axonal outgrowth from cultured 
stage 20 vestibular neurons. Whilst this may reflect the low level of CaSR mRNA expressed 
by vestibular neurons, the inability o f exogenously expressed wild type CaSR protein to 
enhance de novo, BDNF-independent axon growth from stage 20 vestibular neurons in media 
containing a high calcium concentration suggests that crucial signalling pathways that 
transduce CaSR activation into increased axonal growth are absent at this stage. To ascertain 
whether activation of the CaSR could influence later, BDNF-dependent, regenerative axon 
outgrowth from vestibular neurons, I cultured stage 25 vestibular neurons for 24 hrs in 
medium containing 10 ng/ml BDNF and calcium ion concentrations ranging from 0.7 mM to
2.3 mM. Figure 3.19 A shows that although increasing [Ca2+]0 in increments from 0.7 mM to
2.3 mM appears to promote slightly increased survival of stage 25 vestibular neurons cultured 
with BDNF, the increases in survival are not statistically significant. In contrast, 1.3 mM and
2.3 mM [Ca2+]0 increase the mean total axon length of stage 25 vestibular neurons cultured 
with BDNF to the extent of BDNF-promoted axon outgrowth from stage 25 vestibular 
neurons by around 60% compared with neurons cultured with 0.7 mM [Ca2+]0. These 
increases are highly statistically significant (p< 0.001) (Fig. 3.19).
To further investigate the role of the CaSR in modulating BDNF-promoted axonal 
outgrowth from stage 25 vestibular neurons, I used electroporation to co-transfect pcDNA3.1 
based expression constructs encoding YFP and the wild type CaSR into vestibular neurons at 
this developmental stage and cultured them in medium containing 2.3mM calcium and 10 
ng/ml BDNF. Control neurons were co-transfected with empty pcDNA3.1 together with 
pcDNA3.1 encoding YFP. Whilst over-expression of the wild type CaSR did not alter 
neuronal survival compared to control-transfected neurons, it increased the extent of axon 
outgrowth by 2.5-fold compared to control cultures (Fig 3.20 A and B). Together, the data in 
Figures 3.19 and 3.20 demonstrate that by stage 25, vestibular neurons express the signal 
transduction machinery that links CaSR activation to axon growth and that CaSR activation 
can enhance BDNF-promoted axon growth.
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Figure 3.1: Expression levels of CaSR mRNA in stage 20 nodose and vestibular ganglia
The graph shows the levels o f  CaSR m RNA relative to Gapdh mRNA expressed in stage 20  
nodose and vestibular ganglia.
Stage 20 nodose neurons expressed a level o f  CaSR mRNA relative to Gapdh mRNA that is 
approximately 3-fold higher than that expressed by stage 20 vestibular neurons. The difference in 
relative CaSR mRNA expression between the two ganglia is staisitically significant (P= 0.024  
ANOVA with Fisher's ad hoc), n =  3 separate dissections for both ganglia.
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Figure 3.2: The CaSR is expressed in stage 20 nodose neurons.
Stage 20 nodose neurons were cultured in the absence o f  neurotrophins for 24 hours before being 
fixed and double-labelled with antibodies against the CaSR and (3-III Tubulin.
A-C are representative confocal microscope images showing double-labelling o f  the same field with 
an antibody against (3-III Tubulin combined with an FITC conjugated secondary antibody (A) and an 
antibody against the CaSR combined with a rhodamine conjugated secondary antibody (B). The 
merged image (C) demonstrates that the CasR was expressed in the cell soma and processes o f  all 
stage 20 nodose neurons.
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Figure 3.3: The CaSR is expressed in stage 20 vestibular neurons.
Stage 20 vestibular neurons were cultured in the absence o f  neurotrophins for 24 hours before being 
fixed and double-labelled with antibodies against the CaSR and (3-III Tubulin.
A-C are representative confocal microscope images showing double-labelling o f  the same field with 
an antibody against p-III Tubulin combined with an FITC conjugated secondary antibody (A) and an 
antibody against the CaSR combined with a rhodamine conjugated secondary antibody (B). The 
merged image (C) demonstrates that the CasR was expressed in the cell soma and processes o f  all 
stage 20 vestibular neurons.
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Figure 3.4: The effects of modulating [Ca2+]0 on the survival of and extent of axon outgrowth from 
cultured stage 20 nodose neurons.
Stage 20 nodose neurons were cultured without BDNF for 24 hours in media containing either 0.7mM, l.lm M , 
1.3mM or 2.3mM Ca2+. Neurons were counted 3 hrs after plating and after 24 hrs in culture, allowing 
percentage neuronal survival at 24 hrs to be determined. Fluorescent images o f  surviving neurons were also 
captured after 24hrs in culture. These im ages were analysed to calculate the extent o f  axon outgrowth in each 
culture condition.
A: Percentage neuronal survival at 24 hours. Altering [Ca2+]0 in a range between 0.7mM and 2.3mM did 
not affect the survival o f  cultured stage 20  nodose neurons. Data are the mean +/- SEM from three separate 
cultures each containing triplicate dishes for each condition.
B: Increasing [Ca 2+]0 from 0.7m M  to 2.3m M  significantly increased axon outgrowth in a dose dependent 
manner. n= 150 neurons per condition from 3 different experiments. Data are presented as the mean ±
SEM. ***denotes a p value o f  less than 0.0001 after statistical comparisons with control (ANOVA with 
Fisher's ad hoc).
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Figure 3.5: The effects of modulating |Ca2+]0 on the survival of and extent of axon outgrowth from 
cultured stage 20 vestibular neurons.
Stage 20 vestibular neurons were cultured in media containing either 0.7mM or 2.3mM Ca2+ for 24 hours. 
Because cultures did not contain BD N F, they were supplemented with the pan caspase inhibitor Boc-D-FM K to 
sustain neuronal survival. Neurons were counted 3 hrs after plating and after 24 hrs in culture, allowing 
percentage neuronal survival at 24 hrs to be determined. Fluorescent images o f  surviving neurons were also 
captured after 24hrs in culture. These im ages were analysed to calculate the extent o f  axon outgrowth in each 
culture condition.
A: Percentage neuronal survival at 24 hours. There was no significant difference in survival between stage 20 
vestibular neurons cultured in media containing either 0.7mM  or 2.3mM  Ca2+ Data are the mean +/- SEM 
from three separate cultures each containing triplicate dishes for each condition.
B: Mean total axon length o f  neurons. There was no significant difference in the extent o f  axon outgrowth 
between stage 20 vestibular neurons cultured in media containing either 0.7mM  or 2.3 mM Ca2+. n= 150 
neurons per condition from 3 different experiments. Data are presented as the mean ±  SEM.
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Figure 3.6: The effects of modulating[Ca2+]0 on survival of and axon outgrowth from stage 2o r*odose 
neurons in the presence and absence of caspase inhibitor.
Stage 20 nodose neurons were cultured for 24 hours without BDNF. H alf o f the cultures contained media 
without caspase inhibitors and either 0.7m M  Ca2+ or 2.3m M  Ca2+. The other h a lf o f the cultures Confined  
media supplemented with the pan caspase inhibitor Boc-D-FM K and either 0.7mM C32+ or 2.3mM  £ a2+. 
Neurons were counted 3 hrs after plating and after 24 hrs in culture, allowing percentage neuronal survival at 24  
hrs to be determined. Fluorescent im ages o f  surviving neurons were also captured aftef 24hrs in cmtvjre. These 
images were analysed to calculate the extent o f  axon outgrowth in each culture condition.
A: Percentage neuronal survival at 24  hours. In accordance with figure 3-4, there was no significant difference 
in survival between stage 20 nodose neurons cultured in media containing either 0-7mM C a 2+ 0f  2.3mM  
Ca2+ in the absence o f  caspase inhibitors. In addition, the caspase inhibitor B oc-D-FMK  did not affect the 
survival o f  stage 20  nodose in media containing either concentration o f  Ca2+. Data nre the mean ^  SEM 
from three separate cultures each containing triplicate dishes for each condition.
B: Mean total axon length o f  neurons. 2.3m M  [Ca2+]0 increased axonal growth to the s ame extent, compared 
to 0.7mM [Ca2+]0, in both the presence and absence o f  the caspase inhibitor Boc-D-FMK. n= 150 neurons 
per condition from 3 different experiments. Data are presented as the mean ±  SEM. *** denotes a P value o f  
less than 0.0001 after statistical comparisons with cultures containing 0.7mM  Ca2+ (ANO VA With Fisher's 
ad hoc).
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Figure 3.7:The effects of Gd3+ on the survival of and the extent of axon outgrowth from stage 20 nodose and 
vestibular neurons cultured in media containing a low calcium concentration.
Stage 20 nodose and vestibular neurons were cultured for 24 hrs, without BDNF, in media containing 0.7mM  Ca2+. 
Vestibular neuron cultures were supplemented with the caspase inhibitor Boc-D-FM K to prevent apoptosis in the 
absence o f  BDNF or without with lp M  Gd3+. Neurons were counted 3 hrs after plating and after 24 hrs in culture, 
allowing percentage neuronal survival at 24 hrs to be determined. Fluorescent images o f  surviving neurons were also 
captured after 24hrs in culture. These images were analysed to calculate the extent o f  axon outgrowth in each culture 
condition.
A: Percentage neuronal survival at 24  hours. lpM  Gd3+ did not modulate the survival o f  stage 20 nodose neurons in 
media containing a low  concentration o f  Ca2+. Similarly, lpM  Gd3+ did not modulate the survival o f  stage 20 
vestibular neurons cultured in media containing a low  concentration o f  Ca2+ together with caspase inhibitors. Data 
are the mean +/- SEM from three separate cultures containing triplicate dishes for each condition.
B: Mean total axon length o f  neurons. The addition o f  lpM  Gd3+ to cultures o f  stage 20 nodose neurons containing 
media with a low  concentration o f  calcium significantly increased the extent o f  axon outgrowth. In contrast, lpM  
Gd3+ did not increase axon outgrowth from stage 20 vestibular neurons cultured in media containing a low  
concentration o f  calcium together with caspase inhibitors, n = 150 neurons per condition from 3 different 
experiments. Data are presented as the mean ±  SEM. *** denotes a p value o f  less than 0.0001 after statistical 
comparisons with control (A N O V A  with Fisher's ad hoc). 84
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Figure 3.8: The effects o f  G d3* on the survival o f  and the extent o f  axon outgrowth from  stage 20 
nodose neurons cu ltured  in m edia contain ing a low  calcium  concentration.
Stage 20 nodose neurons were cultured for 24 hours, in the absence o f  neurotrophins, in media containing 
0.7mM Ca2+. With the exception o f  control cultures, cultures were supplemented with a range o f  O.lpM  
to lOpM o f  Gd3+. Neurons were counted 3 hrs after plating and after 24 hrs in culture, allowing percentage 
neuronal survival at 24 hrs to be determined. Fluorescent images o f  surviving neurons were also captured 
after 24hrs in culture, so that the extent o f  axon outgrowth could be determined in each culture condition. 
A: Percentage neuronal survival at 24 hours. There were no significant differences in survival between  
cultures containing 0.7m M  Ca2+ alone and 0.7mM  Ca2+ supplemented with either O.lpM, lpM  or 
lOpM Gd3+. Data are the mean +/- SEM  from three separate cultures each containing triplicate dishes 
for each condition.
B: Mean total axon length o f  neurons. 0. lpM , lpM  and lOpM o f  Gd 3+ significantly increased axonal 
growth compared to 0.7m M  Ca2+ alone. n= 150 neurons per condition from 3 different experiments. 
Data are presented as the mean ±  SEM. *** denotes a p value o f  less than 0.0001 after statistical 
comparisons with control (A N O V A  with Fisher's ad hoc).
85
a>
cz>
n°
120
100
80
60
40
20
0
0.7m M
[Ca2+]0
0.7mM
[Ca2+]0
Calhex
B
s
=L
% 1000 C<d
<L>
0.7m M 0.7mM
Calhex
Figure 3.9: The effects o f  the C aSR  agonist, C alhex on the survival o f  and the extent o f  axon  
outgrowth from  stage 20 nodose neurons cultured in m edia containing 0.7m M  [Ca2+]0 
Stage 20 nodose neurons were cultured for 24 hours, in the absence o f  neurotrophins, in media containing 
0.7mM Ca2+. With the exception o f  control cultures, cultures were supplemented with lOnM o f  Calhex. 
Neurons were counted 3 hrs after plating and after 24 hrs in culture, allowing percentage neuronal survival 
at 24 hrs to be determined. Fluorescent im ages o f  surviving neurons were also captured after 24hrs in 
culture, so that the extent o f  axon outgrowth could be determined in each culture condition.
A: Percentage neuronal survival at 24 hours. There was no significant differences in survival between 
cultures containing 0.7m M  Ca2+ alone and 0.7mM  Ca2+ supplemented with Calhex. Data are the mean 
+/- SEM from three separate cultures each containing triplicate dishes for each condition.
B: Mean total axon length o f  neurons. Calhex significantly increased axonal growth compared to 0.7mM  
Ca2+ alone. n= 150 neurons per condition from 3 different experiments.
Data are presented as the mean ±  SEM. *** denotes a p value o f  less than 0.0001 after statistical 
comparisons with control (A N O V A  with Fisher's ad hoc).
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Figure 3.10: T he effects o f  the C aSR  antagon ist, C alindol on the survival o f  and the extent o f  axon  
outgrowth from  stage 20 nodose neurons cultured in m edia containing 2.3m M  [Ca2+]0 
Stage 20 nodose neurons were cultured for 24 hours, in the absence o f  neurotrophins, in media containing 
2.3mM Ca2+. With the exception o f  control cultures, cultures were supplemented with lOnM o f  Calindol. 
Neurons were counted 3 hrs after plating and after 24 hrs in culture, allowing percentage neuronal survival at 24  
hrs to be determined. Fluorescent im ages o f  surviving neurons were also captured after 24hrs in culture, so that 
the extent o f  axon outgrowth could be determined in each culture condition.
A: Percentage neuronal survival at 24 hours. There was no significant difference in survival between  
cultures containing 2.3m M  Ca2+ alone and 2.3m M  Ca2+ supplemented with Calindol. Data are the mean 
+/- SEM from three separate cultures each containing triplicate dishes for each condition.
B: Mean total axon length o f  neurons. Calindol significantly decreased axonal growth compared to 2.3mM Ca2+ 
alone. n= 150 neurons per condition from 3 different experiments.
Data are presented as the mean ±  SEM. *** denotes a p value o f  less than 0.0001 after statistical 
comparisons with control (A N O V A  with Fisher's ad hoc).
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Figure 3.11: T he effects o f  PT X  on the survival o f  and extent o f  axonal outgrowth from stage 20  
nodose neurons cu ltured  in m edia containing 0.7m M  [Ca2+]0 plus lp M  Gd3* .
Stage 20 nodose neurons were cultured for 24 hours, in the absence o f  neurotrophins, in media containing 
0.7mM Ca2+. With the exception o f  control cultures, cultures were supplemented with lpM  o f  Gd3+ alone 
or lpM  o f  Gd3+ together with 1 mg/ml PTX. Neurons were counted 3 hrs after plating and after 24 hrs in 
culture, allowing percentage neuronal survival at 24 hrs to be determined. Fluorescent images o f  surviving 
neurons were also captured after 24hrs in culture, so that the extent o f  axon growth could be determined in 
each culture condition.
A: Percentage neuronal survival at 24 hours. There were no significant differences in neuronal survival 
between control cultures and cultures containing either lpM  G d 3+ alone or lpM  o f  Gd3+ plus 
1 mg/ml PTX. Data are the mean +/- SEM from three separate cultures each containing triplicate 
dishes for each condition.
B: Mean total axon length o f  neurons. lpM  o f  Gd3+significantly increasd axonal growth compared to 
control cultures. The Gd3+ induced increase in axon length was dramatically reduced in the presence o f  
1 mg/ml PTX.
n= 150 neurons per condition from 3 different experiments. Data are presented as the mean ±  SEM. 
*** denotes a p value o f  less than 0.0001 after statistical comparisons with Gd3+ alone (ANOVA with 
Fisher's ad hoc). 88
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F ig u re  3.12: T ra n s fe c tio n  o f  cD N A  exp ressio n  c o n s tru c ts  encoding  e ith e r  w ild type o r  dom in an t-n eg a tiv e  
C aSR s in to  s tag e  20  n odose  a n d  v e s tib u la r  n eu ro n s  c u ltu red  in m edium  con ta in ing  2 .3m M  [C a2+]0 
Stage 20 nodose and  vestibular w ere cu ltured  in the absence (nodose neurons) or presence o f  BD N F (vestibular 
neurons), in m edium  contain ing 2 .3m M C a2+. N eurons w ere co-transfected, by electroporation, w ith pY FP together 
w ith either the em pty expression vector pcD N A 3.1 (control), pcDNA3.1 containing the cD N A  encoding the w ild type 
CaSR (CaSR W T), o r pcD N A 3.1 contain ing the cD N A  encoding a dom inant-negative isoform  o f  the CaSR (CaSR 
DN). Fluorescent neurons w ere counted 24 hrs after plating and after 48 hrs in culture, allowing the percentage 
neuronal survival o f  fluorescent neurons at 48  hrs com pared to  24 hrs to  be determ ined. F luorescent im ages for 
subsequent analysis o f  p rocess grow th w ere captured after a 24 hr culture period.
A: Percentage neuronal survival after 48  hrs. O ver-expression o f  either the w ild type or dom inant-negative CaSR in 
stage 20 nodose or vestibular neurons did no t m odulate their survival in m edia containing 2.3m M  Ca2+.
B: M ean total axon length o f  neurons. In m edia containing 2.3m M  C a 2+, over-expression o f  the dom inant-negative 
CaSR decreased axon outgrow th from  stage 20 nodose neurons com pared to control tranfected neurons. In 
contrast, over-expression o f  the w ild type C aSR  significantly increased axon grow th com pared to  control 
transfected neurons. O ver-expression o f  either the dom inant-negative or w ild type C aSR  did not effect axon 
outgrowth from  stage 20 vestibular neurons com pared to  controls, n  = 90 neurons per condition from  3 different 
experim ents). D ata  p resen ted  are the m ean ±  SEM . *** denotes p  <  0.0001 and * denotes p <  0.01 after statistical 
com parisons w ith controls (A N O V A  w ith F isher's  ad hoc).
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Figure 3.13: The relative levels o f CaSR mRNA expressed in stage 20, 25 and 30 nodose and 
vestibular ganglia.
RT-QPCR was used to assay the levels of CaSR mRNA expressed in stage 20, 25 and 30 nodose and 
vestibular ganglia. CaSR mRNA levels are normalised to the expression of the mRNA for the 
housekeeping protein Gapdh. CaSR mRNA was expressed at similar low levels in vestibular ganglia 
at stage 20, 25 and 30. CaSR mRNA was expressed at significantly higher levels in nodose ganglia 
compared to vestibular ganglia at all three developmental stages studied. The levels of CaSR mRNA 
expression increased more than three-fold in nodose ganglia between stage 25 and stage 30. n = 3 
separate dissections for both ganglia at each developmental stage. * denotes a p value of less than 
0.05 and ** denotes a p value of less than 0.01 after statistical comparisons between the levels of 
CaSR mRNA expressed within nodose and vestibular ganglia at each developmental stage (students 
paired t-test).
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Figure 3.14:T he effects o f  m odulating (Ca2+J0 on the survival o f  and extent o f  axon outgrowth from  stage 27  
nodose neurons cu ltured  eith er w ith  or w ithout BDNF.
Stage 27 nodose neurons were cultured for 24 hours, either in the presence or absence o f  10 ng/ml BDNF, in media 
containing either 0.7m M  Ca2+ or 2.3m M  Ca2+. Neurons were counted 3 hrs after plating and after 24 hrs in culture, 
allowing percentage neuronal survival at 24 hrs to be determined. Fluorescent images o f  surviving neurons were 
also captured after 24hrs in culture. These images were analysed to calculate the extent o f  axon outgrowth in each 
culture condition.
A: Percentage neuronal survival at 24 hours. There were no significant differences in neuronal survival between 
cultures containing either 0.7m M  [Ca2+]0 or 2.3mM  [Ca2+]0 either with or without BDNF. Data are the mean 
+/- SEM from three separate cultures each containing triplicate dishes for each condition.
B: Mean total axon length o f  neurons. Although BDNF did not significantly promote the survival o f  stage 27 
nodose neurons, it greatly increased the extent o f  axon outgrowth from them. In the absence o f  BDNF,
2.3mM [Ca 2+]0 did not significantly promote axon outgrowth compared to 0.7mM  [Ca2+] 0. However, in 
BDNF supplemented cultures 2.3mM  [Ca2+] 0 significantly increased axon outgrowth compared to 0.7mM  
[Ca 2+ ]0. n= 150 neurons per condition from 3 different experiments. Data are presented as the mean ±  SEM.
** denotes a p value o f  less than 0.001 after statistical comparison with BDNF supplemented cultures in media 
containing 0.7 mM Ca2+ (A N O V A  with Fisher's ad hoc). 91
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Figure 3.15: T he effects o f  m odulating [Ca2+]0 on the survival o f  and extent o f  axon outgrowth from  
stage 30 nodose neurons cu ltured  in m edia containing BDNF.
Stage 30 nodose neurons were cultured for 24 hours, with or without 10 ng/ml BDNF, in media containing 
either 0.7mM Ca2+ or 2.3m M  Ca2+. Neurons were counted 3 hrs after plating and after 24 hrs in culture, 
allowing percentage neuronal survival at 24 hrs to be determined. Fluorescent images o f  surviving neurons 
were also captured after 24hrs in culture. These images were analysed to calculate the extent o f  axon 
outgrowth in each culture condition.
A: Percentage neuronal survival at 24 hours. Although BDNF promoted increased survival o f  cultured stage 
30 nodose neurons, there were no significant differences in survival between cultures containing either 
0.7mM [Ca2+]0 or 2.3m M  [Ca2+]0 either with or without BDNF. Data are the mean +/- SEM from three 
separate cultures each containing triplicate dishes for each condition.
B: Mean total axon length o f  neurons cultured with BDNF. 2.3mM [Ca2+]0 significantly increased axonal 
growth compared to 0.7m M  [Ca2+ ]0 in the presence o f  BDNF. n= 150 neurons per condition from 3 
different experiments. Data are presented as the mean ± SEM. *** denotes a p value o f  less than 0.0001 
after statistical comparison with neurons cultured in media containing 0.7 mM Ca2+ (AN O V A  with 
Fisher's ad hoc).
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Figure 3.16: T he effects o f  theC aSR  agonist, Calhex on the survival o f and the extent o f  axon outgrowth  
from stage 30  nodose neurons cultured in m edia containing 0.7m M  [Ca2+]0
Stage 30 nodose neurons were cultured for 24 hours, in the absence o f  neurotrophins, in media containing 
0.7mM Ca2+. With the exception o f  control cultures, cultures were supplemented with lOnM o f  Calhex. 
Neurons were counted 3 hrs after plating and after 24 hrs in culture, allowing percentage neuronal survival at 
24 hrs to be determined. Fluorescent im ages o f  surviving neurons were also captured after 24hrs in culture, so 
that the extent o f  axon outgrowth could be determined in each culture condition.
A: Percentage neuronal survival at 24 hours. There was no significant difference in survival between 
cultures containing 0.7mM  Ca2+ alone and 0.7mM Ca2+ supplemented with Calhex. Data are the mean 
+/- SEM from three separate cultures each containing triplicate dishes 
for each condition.
B: Mean total axon length o f  neurons. Calhex significantly increased axonal length compared to 0.7mM Ca2+ 
alone. n= 150 neurons per condition from 3 different experiments.
Data are presented as the mean ±  SEM. *** denotes a p value o f  less than 0.0001 after statistical 
comparison with 0.7m M  Ca2+ alone (AN O V A  with Fisher's ad hoc).
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Figure 3.17: T he effects o f  the C aSR  antagonist, C alindol on the survival o f  and the extent o f  axon
outgrowth from  stage 30  nodose neurons cultured in m edia containing 2 3 m M  [Ca2+]0
Stage 30 nodose neurons were cultured for 24 hours, in the absence o f  neurotrophins, in media containing
2.3mM Ca2+. With the exception o f  control cultures, cultures were supplemented with lOnM o f  Calindol. Neurons
were counted 3 hrs after plating and after 24 hrs in culture, allowing percentage neuronal survival at 24 hrs to be
determined. Fluorescent im ages o f  surviving neurons were also captured after 24hrs in culture, so that
the extent o f  axon outgrowth could be determined in each culture condition.
A: Percentage neuronal survival at 24  hours. There was no significant difference in survival between cultures 
containing 2.3m M  Ca2+ alone or 2.3m M  Ca2+ supplemented with Calindol. Data are the mean +/- SEM 
from three separate cultures each containing triplicate dishes for each condition.
B: Mean total axon length o f  neurons. Calindol significantly increased axonal growth compared to 2.3mM  Ca2+ 
alone. n= 150 neurons per condition from 3 different experiments.
Data are presented as the mean ±  SEM. *** denotes a p value o f  less than 0.0001 after statistical comparison 
with 2.3 mM Ca2+ alone (A N O V A  with Fisher's ad hoc).
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Figure 3.18: T he effects o f  PT X  on the survival o f  and extent o f  axon outgrowth from stage 30  
nodose neurons cu ltured  G d3* and m edium  containing BD N F and 0.7m M  [Ca2+]0 .
Stage 30 nodose neurons were cultured for 24 hours in media containing lOng/ml BDNF. With the 
exception o f  control cultures, cultures were supplemented with either lpM  o f  Gd3+ alone or lpM  o f  Gd3+ 
together with 1 m g/m l PTX. Neurons were counted 3 hrs after plating and after 24 hrs in culture, allowing  
percentage neuronal survival at 24 hrs to be determined. Fluorescent images o f  surviving neurons were 
also captured after 24hrs in culture, so that the extent o f  axon outgrowth could be determined in each 
culture condition.
A: Percentage neuronal survival at 24 hours. There were no significant differences in survival between  
control cultures and cultures supplemented with either lpM  Gd3+ alone or lpM  o f  Gd3+ together with 
1 mg/ml PTX. Data are the mean + /- SEM from three separate cultures each containing triplicate 
dishes for each condition.
B: Mean total axon length o f  neurons. lpM  o f  Gd3+ significantly increased axonal growth compared to 
control cultures and this increase can be prevented by 1 mg/ml PTX. n= 150 neurons per condition from 
3 seperate experiments. Data are presented as the mean ±  SEM. *** denotes a p value o f  less than 
0.0001 after statistical comparisons with control and **** denotes a p value o f  less than 0.0001 after 
statistical comparison with Gd3+ (A N O V A  with Fisher's ad hoc).
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Fig 3.19: The effect o f  m odulating [Ca2+]0 on the survival o f  and extent o f  axon outgrowth from  stage 25  
vesibular neurons cu ltured  in m edium  containing BDNF.
Stage 25 vestibular neurons were cultured for 24 hours, in the presence o f  10 ng/ml BDNF, in media containing 
either 0.7mM, 1. ImM, 1.3mM or 2.3m M  Ca2+. Neurons were counted 3 hrs after plating and after 24 hrs in 
culture, allowing percentage neuronal survival at 24 hrs to be determined. Fluorescent images o f  surviving 
neurons were also captured after 24hrs in culture. These images were analysed to calculate the extent o f  axon 
outgrowth in each culture condition.
A: Percentage neuronal survival at 24 hours. There were no significant differences in survival between 
BDNF supplemented cultures containing either 0.7mM , l.lm M , 1.3mM or 2.3mM Ca2+. Data are the 
mean +/- SEM from three separate cultures each containing triplicate dishes for each condition.
B: Mean total axon length o f  neurons. 1.3mM and 2.3mM  [Ca 2+]0 significantly increased axon outgrowth 
from stage 25 cultured vestibular neurons compared to 0.7mM [Ca 2+ ]0. However, l.lm M  [Ca 2+ ]0 
did not promote axon outgrowth compared to neurons cultured in media containing 0.7mM Ca2+. n =
150 neurons per condition from 3 different experiments. Data are presented as the mean ±  SEM. ** 
denotes a p value o f  less than 0.001 after statistical comparisons with neurons cultured in media 
containing 0.7 mM Ca2+ (A N O V A  with Fisher's ad hoc).
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Figure 3.20: Transfection of a cDNA expression construct encoding the wild type CaSR into stage 26 
vestibular neurons cultured in media containing 2.3 mM [Ca2+]0.
Stage 26 vestibular were cultured in medium containing 2.3mM Ca 2+ plus 10 ng/ml BDNF. Electroporation 
was used to co-transfect neurons with pYFP together with either the empty expression vector pcDNA3.1  
(control) or p cD N A 3.1 containing the cD N A  encoding the wild type CaSR (CaSR WT). Neurons were 
counted 24 hrs after plating and after 48 hrs in culture, allowing percentage neuronal survival at 48 hrs to be 
determined. Fluorescent im ages for subsequent analysis o f  process outgrowth were captured after a 24 hr 
after transfection.
A: Percentage neuronal survival after 48 hrs. Overexpression o f  the wild type CaSR in stage 26 vestibular 
neurons did not effect their survival compared to control transfect neurons.
B: Mean total axon length o f  neurons. Overexpression o f  the wild type CaSR in stage 26 vestibular 
neurons significantly increased the extent o f  axon outgrowth compared to control transfected neurons, 
n = 90 neurons per condition from 3 different experiments.
Data presented are the mean ±  SEM. *** denotes p <  0.0001 after statistical comparison with control 
(ANOVA with Fisher's ad hoc).
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3.3 Discussion
It has recently been reported that the CaSR plays a crucial, physiologically relevant, 
role in promoting axonal growth and branching from mouse sympathetic neurons during a 
window of development in the immediate perinatal period when the axons of these neurons 
are ramifying extensively in their targets under the influence of target-derived NGF. Neonatal 
mice lacking CaSR have reduced sympathetic innervation density, but normal numbers of 
sympathetic neurons (Vizard et al., 2008). The research presented in this chapter not only 
extends the role of the CaSR in regulating axonal growth to developing sensory neurons of 
chick embryos at a stage in development when they are responsive to target-derived BDNF 
but also to the earliest stages of neuronal development when sensory axons are growing to 
their targets before the neurons have become dependent on neurotrophins for survival. As 
with developing sympathetic neurons, the CaSR affects axonal growth from embryonic 
sensory neurons but has no effect on their survival.
One of the most interesting aspects of my data is that they suggest a mechanism that 
may account for the marked intrinsic differences in axon growth rates displayed by different 
populations of neurotrophic factor-independent cranial sensory neurons at the stage in 
development when their axons are growing to their targets (Davies, 1989). Among 
populations of placode-derived cranial sensory neurons in the chick embryo, nodose neurons, 
which have the most distant targets, extend axons towards their targets at the fastest rate, 
whereas vestibular neurons, which have the closest targets, have the slowest growing axons. 
At stage 20, when many nodose and vestibular axons are growing to their targets in vivo, 
nodose ganglia express 3-fold higher levels of CaSR mRNA relative to GAPDH mRNA than 
vestibular ganglia. Whilst, immunocytochemistry demonstrates that stage 20 nodose and 
vestibular neurons both express CaSR protein, the non-quantitative nature of this techniques 
precludes a comparison o f relative levels of CaSR protein expressed by both types of neurons. 
Also, the small number of neurons present in chick stage 20 cranial sensory ganglia makes a 
semi-quantative assessment of relative CaSR levels between the two ganglia by Western 
Blotting technically very challenging. For these reasons, it has been difficult to ascertain if the 
highly significant differences in the relative levels of CaSR mRNA between nodose and 
vestibular ganglia are translated into significant differences in the levels of CaSR proteins in 
nodose and vestibular neurons. Both elevated [Ca2+]0 and the potent CaSR agonists Gd3+ and 
Calhex greatly increase the mean length of axons growing from stage 20 nodose neurons after 
24 hrs in cultures. I have demonstrated that the increase in axon length induced by elevated 
[Ca2+]0 can be inhibited by the CaSR antagonist, Calindol, and that Gd3+ -promoted axon
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growth can be inhibited by the G-protein inhibitor, PTX, strongly suggesting that the CaSR 
receptor mediates the axon growth promoting effects of these molecules. In accordance with 
this, over-expression of a dominant-negative CaSR protein in stage 20 nodose neurons 
cultured for 24 hours in media containing 2.3mM calcium significantly reduces the mean 
length of axons compared to control transfected neurons. In marked contrast to nodose 
neurons, neither increased [Ca2+]0 nor Gd3+ enhance de novo axonal growth from cultured 
stage 20 vestibular neurons. Whilst the lack of effect of these molecules may reflect a lower 
level of CaSR expression by vestibular neurons, the ability of exogenously expressed wild 
type CaSR protein to promote BDNF-independent axon growth from stage 20 nodose 
neurons, but not stage 20 vestibular neurons, in media containing a high (2.3 mM) [Ca ]0 
suggests that crucial signalling pathways that transduce CaSR activation into increased axon 
growth are absent in vestibular neurons at this stage of development.
The level o f [Ca2+]0 in developing vertebrate embryos is 1.69 mM (Brown and 
MacLeod, 2001), a level that is high enough to significantly activate the chick CaSR and 
enhance axon growth from stage 20 nodose neurons as shown in figure 3.4. It is therefore 
tempting to speculate that the faster in vivo growth of nodose neurons compared to vestibular 
neurons (Davies, 1989). is due to CaSR activation and signalling in the former. Verification of 
this hypothesis will require further experimental studies, particularly in ovo. For example, I 
will use whole mount staining with neurafilament antibodies to determine whether in ovo 
application of Calindol specifically reduces the growth rate of axons emerging from newly 
differentiated nodose neurons, but not vestibular neurons. Similarly, I will use in ovo 
electroporation to transfect a dominant-negative CaSR expression plasmid containing a 
neuron specific promotor into very early chicken embryos to see if the dominant-negative 
CaSR specifically reduces the growth rate of nodose neurons in ovo.
Interestingly, the ability of CaSR activation to promote BDNF-independent axonal 
growth from newly differentiated nodose neurons appears to be short lived, since elevated 
[Ca2+]0 does not increase axon extension from stage 27 nodose neurons cultured without 
BDNF. Whilst the survival of cultured stage 27 nodose neurons is not dependent on BDNF, I 
have shown that BDNF greatly increases the length of axons projecting from nodose neurons 
at this age, an effect that is enhanced by elevated [Ca2+]0 and therefore presumably CaSR 
activation. This finding, together with the fact that the levels of CaSR mRNA expressed by 
stage 27 nodose neurons is higher than that expressed by stage 20 nodose neurons, suggests 
that developmental changes in the repertoire of growth-related signalling pathways may be
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responsible for the loss in the ability of the CaSR to promote BDNF-independent axon 
outgrowth at stage 27. This possibility will be explored in Chapter 4, below.
I have shown that either elevated [Ca2+]0, 1 pM Gd3+ or 10 nM Calhex are capable of 
enhancing BDNF-promoted axon outgrowth from stage 30 nodose neurons. The fact that 
Gd3+-enhanced axon growth can be inhibited by PTX and elevated [Ca2+]0 -promoted axon 
growth can be inhibited by Calindol strongly suggests that the CaSR mediates the growth 
promoting effects of these molecules. CaSR activation by elevated [Ca2+]0 increases the extent 
of BDNF-promoted axon outgrowth by some 2.5-fold at stage 30 compared to 20% at stage 
27. It is tempting to speculate that the greater efficacy of CaSR activation in enhancing 
BDNF-promoted axonal outgrowth at stage 30 compared to stage 27 is linked to the higher 
expression of CaSR mRNA at stage 30. This hypothesis needs to be tested by comparing the 
extent of BDNF-promoted axon outgrowth from stage 27 and stage 30 nodose neurons that 
have been transfected with the wild type CaSR cDNA expression construct and cultured in 
media containing either high [Ca 2+]0 ,lpM  Gd3+ or lOnM Calhex.
The data presented in this chapter clearly demonstrates that CaSR activation does not 
enhance the rate of de novo, BDNF-independent axon outgrowth from newly differentiated 
stage 20 vestibular neurons. However, 1.3 mM and 2.3mM [Ca2+]0 increases the length of
axons projecting from stage 25 vestibular neurons cultured with BDNF by some 60%
2+
compared to vestibular neurons cultured with BDNF in media containing 0.7mM Ca . If 
CaSR mRNA expression reflects CaSR protein expression, the relatively small effect that 
CaSR activation has on axon outgrowth from stage 25 vestibular neurons may be due to the 
low level of CaSR expressed by vestibular neurons at this stage. In accordance with this, over­
expression of the wild type CaSR in stage 25 vestibular neurons increases the extent of 
BDNF-promoted axon outgrowth by 2.5-fold.
Although the data presented in this chapter suggest that activation of the CaSR can 
enhance BDNF-promoted axon outgrowth from nodose neurons, and to a lesser extent 
vestibular neurons, more detailed experimental work is required to confirm this interpretation 
of the data. In particular, the physiological relevance of my in vitro data also needs to be 
tested by both in ovo electroporation of an expression construct encoding the dominant- 
negative chick CaSR under the control of a neuron-specific promotor and in ovo application 
of the specific CaSR antagonist, Calindol.
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Summary
I have shown that CaSR activation can promote de novo axon growth from newly
2+differentiated nodose neurons, but not vestibular neurons. Since the level of [Ca ]0 in the 
developing chick is high enough to significantly activate the CaSR, my data suggests that 
selective CaSR activation in nodose neurons may at least partly account for the differences in 
the intrinsic rates of de novo, neurotrophic factor-independent, axonal growth between nodose 
and vestibular neurons. This hypothesis needs to be tested and validated by further in vitro 
and in ovo experimental studies
Later in development, CaSR activation enhances BDNF-promoted, regenerative 
axonal growth from cultured nodose neurons, and to a lesser extent vestibular neurons. Once 
again, the physiological relevevance of this finding needs to be investigated further with 
additional in vitro and in ovo experimental studies.
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Chapter 4
Developmental switch in the signal transduction 
pathways required for axonal growth
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4.1 Introduction
The data presented in Chapter 3 clearly demonstrates that activation of the CaSR by 
either elevated [Ca2+]0 or lpM Gd3+ enhances BDNF-independent, de novo axon growth from 
cultured stage 20 and 23 nodose neurons. CaSR activation also enhances BDNF-promoted 
axon growth from later stage nodose neurons. As outlined in Chapter 1, several studies have 
identified the intracellular signalling proteins GSK3, PI3-Kinase and ERK1/2 as key players 
in modulating neurotrophic factor-promoted axon growth. For example, GSK3 regulates the 
binding of several proteins to microtubules, thereby enhancing microtubule polymerization 
(Etienne-Manneville and Hall, 2003; Jimbo et al., 2002; Yoshimura et al., 2005). In addition 
to influencing microtubule polymerization dynamics by regulating GSK3 activity (Yoshimura 
et al., 2005), PI3-kinase also promotes neuronal process extension by modulating actin 
polymerization dynamics (Aoki et al., 2005; Nusser et al., 2002). The binding of 
neurotrophins to their receptor tyrosine kinases initiates a series of signalling events that leads 
to the activation of ERK1/2 that can in turn promote the phosphorylation and activation of the 
transcription factors CREB and NFATc. Activated CREB and NFATc lead to increased 
transcription of several genes that promote axon extension (De Cesare et al., 1999; Lonze and 
Ginty, 2002; Nguyen and Di Giovanni, 2008). Whilst the signal transduction pathways that 
regulate neurotrophic factor-promoted, regenerative axon growth have been well 
characterised, no information exists on the signal transduction pathways that modulate de 
novo axon growth, in part because, until now, no extracellular signals have been identified 
that are capable of regulating the rate of de novo axon growth.
Activation o f the CaSR initiates a number of intracellular signal transduction pathways 
downstream of initial G-protein coupling, the nature of which depends on both cell type and 
the physiological outcome of CaSR activation (Ward, 2004). One signalling pathway that is 
activated by CaSR agonists is the ERK1/2 MAP-kinase pathway. ERK activation by CaSR 
agonists has been demonstrated in numerous cell types, including fibroblasts, osteoclasts, 
parathyroid cells and kidney proximal tubule cells. In many cases PD98059, an inhibitor of 
MEK1/2, the upstream activators of ERK1/2 in the classical MAP-Kinase pathway, has been 
shown to prevent ERK 1/2 activation by CaSR agonists (Ward, 2004). The PI3-kinase 
inhibitors wortmannin and LY2942004 prevent CaSR agonist-induced activation of ERK in 
the HEK cell line, primate ovarian surface epithelial cells (OSE cells) and human parathyroid 
cells, suggesting that CaSR activation can also lead to activation of PI3-kinase upstream of 
ERK activation. In addition, treatment of human OSE cells with CaSR agonists has been
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shown to activate PI3-kinase, leading to phosphorylation of its downstream target, Akt. PI3- 
kinase mediated phosphorylation and activation of Akt and ILK in neurons has been shown to 
result in the phosphorylation of GSK3 which modulates its activity (Jiang et al., 2005; 
Yoshimura et al., 2005; Zhou et al., 2004). Since CaSR activation can result in PI3-kinase and 
Akt activation (Ward, 2004)it is also possible that activation of the CaSR may also be able 
modulate the activity of GSK3 in certain cell types.
The aim o f the research presented in this chapter was to begin to characterise the 
intracellular signalling pathways that transduce activation of the CaSR into enhanced 
neurotrophin-independent axon growth from early nodose neurons and BDNF-dependent 
axon elongation from these neurons at later stages of development. Because of their 
involvement in mediating neurotrophic factor-promoted axon growth in several kinds of 
neurons and because they have been shown to be downstream targets of the activated CaSR in 
certain cell types, I decided to examine the potential roles of PI3-Kinase, ERK and GSK3 in 
transducing CaSR activation into enhanced axon growth. The role of PI3-kinase was 
investigated primarily by determining the effects of the specific pharmacological PI3-Kinase 
inhibitor LY294002 on axon growth. Similarly, the specific GSK3 inhibitor, Bio ((2’Z,3’E)-6- 
Bromoindirubin-3’oxime (Sato et al., 2004), was used to examine the role of GSK3 signalling 
in axon growth. Because no effective selective ERK1/2 inhibitors are currently available, the 
role of ERK in transducing activation of the CaSR into enhanced axon growth was 
investigated by inhibiting the function of MEK1/2, the upstream kinases in the ERK1/2 MAP- 
Kinase signalling cascade, by PD98059.
My findings suggest that PI3-kinase signalling plays a pivotal role in transducing 
CaSR-enhanced, neurotrophin-independent axon growth from early nodose neurons and that 
GSK3 signalling plays a major role in transducing the growth-enhancing effects of CaSR 
activation on BDNF-promoted axonal growth from older BDNF-dependent nodose neurons.
4.2 Results
4.2.1 Effects of PI3-kinase, GSK3 and MEK1/2 inhibitors on CaSR-promoted BDNF- 
independent axon growth from stage 20 nodose neurons
To begin to investigate the signalling pathways that transduce activation of the CaSR 
into enhanced neurotrophic factor-independent axon growth, I cultured stage 20 nodose 
neurons at low density on laminin-coated tissue culture dishes, in BDNF-free medium 
containing 0.7 mM Ca2+and lpM of the potent CaSR agonist Gd3+ in the presence and
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absence of pharmacological inhibitors of PI3-kinase, GSK3 and MEK1/2. Measurement of 
axon lengths 24 hours after plating confirmed the experimental results presented in Chapter 3
_ j  j  ^ ^
that lpM Gd substantially increased axon growth from early nodose neurons incubated in 
medium containing 0.7 mM Ca2+ (Fig. 4.1 A). This Gd3+-enhanced axon growth was 
significantly decreased by all three inhibitors (p< 0.0001 in all cases, ANOVA with Fisher’s 
ad hoc), with the greatest decrease being brought about by the PI3-kinase inhibitor 
LY294002, where the axons were 70% shorter (Fig. 4.1C). the MEK1/2 inhibitor PD98059 
caused a 50% reduction in axon length (Fig. 1C), and the GSK3 inhibitor Bio caused a 30% 
reduction in axon length (Figs. 4 .IB and C). Neurons counts carried out 24 hours after plating 
revealed there were no significant differences in survival under all experimental conditions at 
this time (Fig. 4.2). These results suggest that PI3-kinase signalling plays a major role in 
CaSR-enhanced, neurotrophin-independent axon growth from stage 20 nodose neurons, with 
lesser roles played by MEK1/2-ERK1/2 signalling and GSK3 signalling. These results also 
demonstrate that neither PI3-kinase, GSK3 nor MEK1/2 are required for neurotrophin- 
independent survival at this early stage of development.
I carried out additional experiments to ascertain whether inhibition of PI3-kinase, 
GSK3 and MEK1/2 had any effect on the low level of axonal growth from stage 20 nodose
^  i
neurons grown in BDNF-free medium containing 0.7 mM Ca without the CaSR agonist 
Gd3+. Measurement of axon lengths 24 hours after plating revealed no significant differences 
in axon lengths between control cultures (no pharmacological inhibitors) and cultures 
containing either LY294002, PD98059 or Bio (Fig. 4.3B), and no significant differences in 
survival under these different experimental conditions (Fig. 4.3A). While these results 
suggest that neither PI3-kinase, GSK3 nor MEK1/2 signalling are required for the very 
limited axonal growth that occurs at minimal levels of CaSR activation, this conclusion is 
subject to the caveat that is more difficult to clearly observe an effect on axon growth when 
the axons are so short. However, these results further confirm that activated PI3-kinase, 
GSK3 and MEK1/2 are not required for neurotrophin-independent survival.
4.2.2 Effects of expressing PI3-kinase mutant proteins on CaSR-promoted, BDNF- 
independent axon growth from stage 20 nodose neurons
Because of the clear and pronounced effects of the PI3-kinase inhibitor LY294002 on 
early CaSR-promoted, neurotrophin independent axon growth, I carried out experiments to 
confirm the role o f PI3-kinase by an alternative approach. I co-transfected stage 20 nodose 
neurons with a YFP expression plasmid together with a plasmid expressing either a
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constitutively active PI3-Kinase or a dominant-negative PI3-Kinase. Control cultures were co­
transfected with the YFP plasmid and an empty pcDNA3.1 expression plasmid. The neurons 
were incubated in medium containing 1.3mM Ca2+, a [Ca2+]0 that leads to significant 
activation of the chick CaSR and enhanced axon growth (Fig. 3.4 B). YFP expressing co­
transfected neurons were counted after 24 hours and 48 hours in culture, and the percentage 
survival of YFP expressing neurons at 48 hours was calculated relative to the number of YFP- 
positive neurons counted at 24 hours. This protocol for assessing the survival of co­
transfected neurons was adopted because YTP is not robustly expressed in transfected cultures 
until 24 hrs. YFP expressing neurons were imaged 24 hours after plating for measurements of 
axonal length.
Expression of constitutively active PI3-Kinase did not significantly alter the survival 
of stage 20 nodose neurons compared to control transfected cultures (Fig. 4.4A) but 
significantly increased mean total axon length by approximately 30% (Fig. 4.4B, p< 0.01, 
ANOVA with Fisher’s ad hoc). Surprisingly, expression of dominant-negative PI3-Kinase 
significantly enhanced the survival of stage 20 nodose neurons by 25% compared to control 
transfected cultures (p< 0.001, ANOVA with Fisher’s ad hoc). However, in accordance with 
the data obtained with LY294002, expression of dominant negative PI3-kinase reduced mean 
total axon length compared to control transfected cultures by approximately 60% (Fig. 4.4B), 
a reduction that was highly statistically significant (p< 0.0001, ANOVA with Fisher’s ad 
hoc). Although the length of transfected neurons is less than non-transfected neurons, as 
noted in Chapter 3, these data nonetheless support the conclusion of the pharmacological 
inhibitor experiments that PI3-Kinase plays an important role in transducing the effects of 
activated CaSR into enhanced neurotrophin-independent axon growth from early nodose 
neurons, but is not required for neurotrophin-independent neuronal survival.
As in the pharmacological inhibitor experiments reported above, I carried out 
additional experiments to ascertain if expression of mutant PI3-kinase proteins affects axonal
2"Fgrowth from stage 20 nodose neurons grown in BDNF-free medium containing 0.7 mM Ca . 
Measurement of axon lengths 24 hours after plating revealed no significant differences in 
survival or axon lengths between control-transfected neurons and neurons transfected with 
plasmids expressing either constitutively active PI3-Kinase or a dominant-negative PI3- 
Kinase (Fig. 4.5). These results suggest that PI3-kinase activity does not affect CaSR- 
independent axon growth from early, stage 20 nodose neurons.
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4.23 CaSR activation in stage 20 nodose neuron results in Akt phosphorylation
Akt is a major downstream target of activated PI3-Kinase, and has previously been 
shown to play a role in mediating both neurotrophic factor-promoted neuronal survival 
(Alonzi et al., 2001; Andjelkovic et al., 1998; Ashcroft et al., 1999) and axon elongation 
(Yoshimura et al., 2005). To provide further evidence for the participation of PI3-kinase in 
CaSR-promoted axon growth from early neurotrophin-independent axon growth, I 
investigated whether activation of the CaSR in stage 20 nodose neurons leads to Akt 
phosphorylation. Stage 20 nodose neurons were cultured in the absence of BDNF in medium 
containing 0.7mM Ca2+ for 4 hours prior to stimulation with lpM Gd3+. The cells were lysed 
5, 10, 30 and 60 minutes after stimulation by Gd3+, and extracted proteins were run on 
denaturing gels and Western blotted to membranes. Control (non-stimulated) and BDNF- 
treated cultures were lysed alongside Gd3+-stimulated neurons at the 5 minute time point. The 
upper panel of figure 4.6A shows a representative Western Blot of cell lysates probed with an 
antibody against phospho-Akt, and the lower panel shows the same filter after stripping and 
reprobing with an antibody against tubulin to allow normalisation of the phospho-Akt signal 
to protein concentration within the lysate. Addition of lpM Gd3+ resulted in a rapid, transient 
increase in the levels o f phospho-Akt that returned to basal levels within 30 minutes after the
*> I
addition of Gd . Scanning and quantitative analysis of ECL films, followed by normalization 
of phospho-Akt levels to tubulin, revealed that the addition of lpM Gd3+ to cultures increased
o I
the levels of phospho-Akt by some 30% compared to control cultures 10 mins after Gd 
treatment (Fig. 4.6B). BDNF had no apparent effect on phospho-Akt levels. These findings 
suggest that Gd3+-induced CaSR activation leads to Akt phosphorylation, which is consistent 
with PI3-Kinase activation as a result of CaSR activation.
4.2.4 Effects of PI3-kinase, GSK3 and MEK1/2 inhibitors on CaSR-promoted, BDNF- 
independent axon growth from stage 23 nodose neurons
In addition to studying the effects of pharmacological inhibitors on CaSR-promoted 
neurite growth from nodose neurons during the earliest stages of neurotrophin-independent 
axon growth at stage 20, I also studied the effects of these reagents at stage 23, a later time 
point in the period of neurotrophin independence. These neurons were cultured in BDNF-free 
medium containing 0.7 mM Ca2+and lpM of the potent CaSR agonist Gd3+ in the presence 
and absence of pharmacological inhibitors of PI3-kinase, GSK3 and MEK1/2. Measurement
O i
of axon lengths after 24 hours showed that, as in the case of stage 20 neurons, lpM Gd 
caused a greater than five-fold increase in axon length compared with non-stimulated control
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neurons (Fig. 4.7A), and all three inhibitors caused highly significant reductions in the length 
of Gd3+-stimulated neurons (p< 0.0001 in all cases, ANOVA with Fisher’s ad hoc). As for 
stage 20 neurons, the greatest decrease in Gd3+-stimulated axon growth was brought about by 
the PI3-kinase inhibitor LY294002, although the reduction was even greater than at stage 20 
(90% shorter and less than control cultures containing BDNF alone, Fig. 4.7C). The MEK1/2 
inhibitor PD98059 caused a similar reduction in axon length to that observed in stage 20 
neurons (Fig. 4.7C). However, in marked contrast to stage 20 neurons where the GSK3 
inhibitor Bio caused a 30% reduction in axon length, Bio caused an 80% reduction in axon 
length at stage 23 (Fig. 4.7B). As in stage 20 cultures, neuron counts carried out 24 hours 
after plating revealed there were no significant differences in survival under all experimental 
conditions at stage 23 (Fig. 4.8). These results suggest that both PI3-kinase signalling and 
GSK3 signalling play major roles in CaSR-enhanced, neurotrophin-independent axon growth 
from stage 23 nodose neurons, with a lesser role played by MEK1/2-ERK1/2 signalling. 
These results also demonstrate that neither PI3-kinase, GSK3 nor MEK1/2 are required for 
neurotrophin-independent survival at this stage of development.
4.2.5 Effects of PI3-kinase, GSK3 and MEK1/2 inhibitors on CaSR-promoted, BDNF- 
dependent axon growth from stage 27 nodose neurons
The data in chapter 3 clearly demonstrates that both BDNF and elevated [Ca2+]0 
promote axon extension from stage 27 and older nodose neurons, although CaSR activation 
by its physiological ligand does not appear to promote significant axon elongation in the 
absence of BDNF (Figs. 3.12 and 3.13). The identity of the intracellular signalling pathways 
that transduce CaSR and trkB activation into enhanced axon outgrowth from nodose neurons 
at these later developmental stages were investigated using a similar experimental approach to 
that used to investigate BDNF-independent CaSR signalling in relation to enhanced de novo 
axon growth in sections 4.2.1 and 4.2.4. At stage 27, nodose neurons were cultured for 24 
hours in BDNF-supplemented medium containing 0.7 mM Ca2+and lpM of the potent CaSR 
agonist Gd3+ in the presence and absence of pharmacological inhibitors of PI3-kinase, GSK3
*> j
and MEK1/2. Measurement of axon lengths after 24 hours showed that lpM Gd caused an 
almost five-fold increase in axon length compared with neurons grown with BDNF alone 
(Fig. 4.9A). In marked contrast to CaSR-promoted, BDNF-independent axon growth from 
stage 23 neurons, CaSR-promoted, BDNF-dependent axon growth from stage 27 neurons was 
not significantly reduced by either the PI3-kinase inhibitor LY294002 or MEK1/2 inhibitor 
PD98059 (Fig. 4.9C). However, the inhibition of GSK3 by Bio was able to reduce the extent
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of BDNF- and Gd - enhanced axon growth from stage 27 nodose neurons to less than that 
seen in cultures without Gd3+ (Fig 4.9B). Neuron counts carried out 24 hours after plating 
revealed there were no significant differences in survival under all experimental conditions at 
this time (Fig 4.10). These results suggest that at stage 27, when maximal axonal growth is 
dependent on both BDNF and activation of the CaSR, GSK3 plays a critical role in axonal 
extension, but that neither PI3-kinase nor MEK1/2 are required.
4.2.6 Effects of PI3-kinase, GSK3 and MEK1/2 inhibitors on CaSR-promoted, BDNF- 
dependent axon growth from stage 33 nodose neurons
By stage 33, BDNF is required to promote the survival of the majority of nodose 
neurons over a 24 hour culture period (Fig. 4.11). Since most neurons die in the absence of 
BDNF, cultures for assessing the extent of axon growth in the absence of BDNF were 
supplemented with the pan-caspase inhibitor, Boc-D-FMK. At a concentration of IOjiM, this 
caspase inhibitor was as effective as BDNF in supporting the survival of stage 33 nodose
^  I
neurons over a 24 hour culture period in medium containing 1.3 mM Ca (Fig. 10). Neither 
LY294002, Bio nor PD98059 affected the survival of stage 33 nodose neurons incubated for 
24 hours in BDNF-supplemented medium (Figs. 4.11 A, B and C, respectively). There was 
negligible axon growth from stage 33 neurons cultured in the absence of BDNF, and BDNF- 
promoted axon growth in medium containing 1.3 mM Ca2+ was completely unaffected by 
either LY294002 or PD98059 (Figs. 4.12A and C). However, as in stage 27 cultures, the 
GSK3 inhibitor Bio totally abrogated BDNF-promoted axon growth when neurons were
cultured in medium that activated the CaSR (Fig. 4.12B). These results suggest that BDNF-
•  •  •  •  •  2+  •promoted axon growth from neurons grown in medium containing sufficient Ca to activate
the CaSR is critically dependent on GSK3 signalling.
Essentially similar results were obtained when stage 33 neurons were cultured in
BDNF-supplemented medium containing 0.7 mM Ca2+and lpM Gd3+. In these cultures, Bio
virtually eliminated BDNF- and activated CaSR-promoted axon growth and neither
LY294002 nor PD98059 reduced BDNF- and activated CaSR-promoted axon growth (Fig.
4.13B and C). Paradoxically, LY294002 promoted a consistent and significant increase in
axon length in cultures supplemented with BDNF and lpM Gd3+ (p< 0.0001, ANOVA with
Fisher’s ad hoc). Whereas neither Bio, LY294002 nor PD98059 affected the survival of stage
33 neurons cultured for 24 hours in BDNF-supplemented medium containing 0.7 mM
Ca2+and lpM Gd3+, the percent survival in BDNF-supplemented medium containing 0.7 mM
Ca2+and lpM Gd3+ was significantly greater than in BDNF-supplemented medium containing
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0.7 mM Ca2+ without Gd3+ (Fig. 4.14, p< 0.01, ANOVA with Fisher’s ad hoc). This latter 
observation raises the possibility that activation of the CaSR might contribute to the survival 
of nodose neurons at this stage of development.
To further examine the role of GSK3 signalling in BDNF-promoted axon outgrowth 
from older nodose neurons cultured in medium containing 1.3 mM [Ca2+]0, I co-transfected 
stage 30 nodose neurons with a YFP expression plasmid together with a plasmid expressing 
either wild type GSK3 or dominant-negative GSK3. Control cultures were co-transfected with 
the YFP plasmid and an empty pcDNA3.1 expression plasmid. All cultures were 
supplemented with 10 ng/ml BDNF. YFP expressing co-transfected neurons were counted 
after 24 hours and 48 hours in culture, and the percentage survival of YFP expressing neurons 
at 48 hours was calculated relative to the number of YFP-positive neurons counted at 24 
hours.
Neither over-expression of wild type GSK3 nor expression of dominant-negative 
GSK3 significantly affected the survival of stage 30 nodose neurons after 48 hours in culture 
compared to control transfected neurons (Fig. 4.15 A). Measurements of axon length 24 hours 
after transfection revealed no significant differences between neurons over-expressing wild 
type GSK3 and control transfected neurons. However, expression of dominant-negative 
GSK3 significantly decreased mean total axon length by approximately 60% compared to 
control transfected neurons (Fig. 4.15B, p< 0.0001, ANOVA with Fisher’s ad hoc). These 
results support the importance o f GSK in BDNF-promoted axon growth from BDNF- 
dependent nodose neurons grown in medium containing physiological levels of extracellular 
calcium.
To further prove a role for GSK3 in transducing CaSR activation in the presence of 
BDNF into enhanced axon growth, I briefly exposed stage 30 nodose neurons, that had been 
cultured for 4 hrs in medium containing 0.7mM Ca2+, to the specific and potent CaSR agonist, 
Calhex, that has only recently become commercially available. After 5,15 and 30 minute time 
points, I lysed the neurons and prepared the lysate for Western blotting. As discussed in 
chapterl, the activity of GSK3 is regulated either by serine phosphorylation on residue 9 of 
GSK3P or residue 21 of GSK3a, or by tyrosine phosphorylation of residue 216 of GSK3p or 
residue 279 of GSK3a.. Serine phosphorylation leads to inactivation of GSK3 proteins, 
whereas tyrosine phosphorylation promotes GSK3a and P activity (Jope and Johnson, 2004). I 
therefore probed Western blot filters with antibodies against either serine phosphorylated 
GSK3a/p or tyrosine phosphorylated GSK3a/p. Filters were also stripped and re-probed for 
tubulin to ensure lysates contained equal quantities of protein. Figure 4.16A demonstrates that
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Calhex induced tyrosine phosphorylation of GSK3a/p within 5 minutes and this enhanced 
tyrosine phosphorylation persisted for at least 30 minutes. In contrast, Calhex did not induce 
serine phosphorylation of GSK3a/p (Fig. 4.16B). This data suggests that tyrosine 
phosphorylation of GSK3 is an important step in the signal transduction pathway that 
connects CaSR activation to enhanced axon growth.
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Figure 4.1: The effects of GSK3, PI3-Kinase and MEK1/2 inhibitors on axon outgrowth from stage 20 
nodose neurons cultured in media containing a low calcium concentration plus lpM Gd3+.
Stage 20 nodose neurons were cultured without BDNF, in media containing 0.7mM Ca2+. With the exception o f  
control cultures, culture m edia was supplemented with either lpM  Gd3+ alone or lpM  Gd3+ plus either lOpM o f  
the GSK inhibitor, B io, 50pM  o f  the PI3-Kinase inhibitor, L Y 294002 or 10 |iM  o f  the MEK1/2 inhibitor, 
PD98059. Fluorescent im ages for analysis o f  process growth were captured after a 24 hr culture period.
A: lpM  Gd3+ increased mean total axon length in media containing a low  calcium concentration.
B: Bio reduced mean total axon length in the presence o f  lpM  Gd3+.
C: In the presence o f  lp M  Gd3+, L Y 294002 and PD 98059 decreased mean total axon length compared to 
neurons cultured with Gd3+ alone, 
n = 150 neurons per condition from 3 different experiments. Data presented are the mean ±  SEM. *** denotes 
p < 0.0001 after statistical comparisons with control (A ) or G d 3+ (B and C) (AN O V A  with Fisher's ad hoc).
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Figure 4.2: The effects of GSK3, PI3-Kinase and MEK1/2 inhibitors on the survival of stage 20 nodose 
neurons cultured in media containing a low calcium concentration plus lpM Gd3* .
Stage 20 nodose neurons were cultured for 24 hours, in the absence o f  BDNF, in media containing 
0.7mMCa2+. With the exception o f  control cultures, culture media was supplemented with either lpM  Gd3+ 
alone or lpM  Gd3+ plus either lOpM  o f  the GSK inhibitor, B io, 50pM  o f  the PI3-Kinase inhibitor, 
LY 204002 or 10 pM  o f  the M EK 1/2 inhibitor, PD 98059. Neurons were counted 3 hrs after plating and after 
24 hrs in culture, allow ing percentage neuronal survival at 24 hrs to be determined. There were no 
significant differences in survival between control cultures and cultures supplemented with Gd3+ alone or 
Gd3+ plus either B io , LY or PD. Data are the mean +/- SEM from three separate cultures containing 
triplicate dishes for each condition.
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Figure 4.3: The effects of GSK3, PI3-Kinase and MEK1/2 inhibitors on the survival of and axon 
outgrowth from stage 20 nodose neurons cultured in media containing 0.7mM [Ca2+]0.
Stage 20 nodose neurons w ere cu ltu red  fo r 24 hours, in the absence o f  BD N F, in m edia containing 0.7m M  
[Ca2+]0 . W ith the excep tion  o f  contro l cultures, culture m edia was supplem ented w ith either 10pM  o f  the 
G SK  inhibitor, B io, 5 0 |iM  o f  the P I3-K inase inhibitor, LY 294002 or 10 (iM o f  the M EK1/2 inhibitor, 
PD98059. N eurons w ere  coun ted  3 hrs afte r p la ting  and  after 24  hrs in culture, allow ing percentage neuronal 
survival at 24 hrs to  be  determ ined. F luorescen t im ages o f  surviving neurons w ere also captured after 24hrs in 
culture, so tha t the  ex ten t o f  axon elongation  could  be determ ined.
A: Percentage neuronal surv ival a t 24  hours. T here w ere no significant differences in survival betw een any 
o f  the cultu re conditions. D ata are the  m ean + /- SEM  from  three separate cultures containing triplicate 
dishes for each  condition .
B: A verage to ta l axon  length  o f  neurons cu ltured  in each condition. B io, LY  or PD  did  not effect neuritic 
process ou tg row th  in  the  absence o f  G d3+. n=  150 neurons per condition from  3 different experim ents. 
D ata are p resen ted  as the  m ean  ±  SEM .
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Figure 4.4: The effects of modulating PI3-Kinase signalling on the survival of and extent of axon 
outgrowth from cultured stage 20 nodose neurons cultured in media containing 1.3mM [Ca2+J0 .
Stage 20 nodose neurons were cultured in the absence o f  neurotrophins, in media containing 1.3mM  
[Ca2+]0 . Electroporation w as used to co-transfect neurons with the expression vector pcDNA3.1 containing 
cDNA encoding YFP together with either empty pcDNA3.1 (control), pcDNA3.1 containing the cD N A  
encoding constitutively active PI3-Kinase (active) or pcDNA3.1 containing the cD N A  encoding a dominant 
negative PI3-Kinase (D N ). Co-transfected YFP expressing neurons were counted 24 hrs after plating and 
after 48 hrs in culture, allow ing percentage neuronal survival at 48 hrs to be determined. Fluorescent images 
o f  YFP expressing neurons for subsequent analysis o f  process growth were captured after a 24 hr culture 
period.
A: Over-expression o f  constitutively active PI3-Kinase did not significantly effect the survival o f  stage 20  
nodose neurons. In contrast, over-expression o f  dominant-negative PI3-Kinase signficantly increased the 
survival o f  cultured stage 20 nodose neurons compared to control cultures .
B: Over-expression o f  dominant-negative PI3-Kinase significantly decreased mean total axon length o f  
stage 20 nodose neurons compared to control cultures, whereas over-expression o f  constitutively active 
PI3-Kinase increased the extent o f  axon outgrowth, 
n = 90 neurons per condition from 3 different experiments. Data presented are the mean ± SEM. *** 
denotes p <  0 .0001, ** denotes p <  0.001 and * denotes p< 0.01 after statistical comparisons with control 
(ANO VA with Fisher's ad hoc). 115
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Figure 4.5: The effects of modulating PI3-Kinase signalling on the survival of and extent of axon 
outgrowth from stage 20 nodose neurons cultured in conditions that minimally activate the CaSR.
Stage 20 nodose neurons were cultured in the absence of neurotrophins, in media containing 0.7mM 
[Ca2+]0. Electroporation was used to co-transfect neurons with the expression vector pcDNA3.1 containing 
cDNA encoding YFP together with either empty pcDNA3.1 (control), pcDNA3.1 containing the cDNA 
encoding constitutively active PI3-Kinase (active) or pcDNA3.1 containing the cDNA encoding a dominant 
negative PI3-Kinase (DN). Co-transfected YFP expressing neurons were counted 24 hrs after plating and 
after 48 hrs in culture, allowing percentage neuronal survival at 48 hrs to be determined. Fluorescent images 
of YFP expressing neurons for subsequent analysis of process growth were captured after a 24 hr culture 
period.
A: Over-expression of constitutively active PI3-Kinase or dominant-negative PI3-Kinase did not alter the 
survival of stage 20 nodose neurons compared to control cultures .
B: Over-expression of constitutively active PI3-Kinase or dominant-negative PI3-Kinase did not alter the 
mean total length of axons projecting from stage 20 nodose neurons compared to control cultures, 
n = 90 neurons per condition from 3 different experiments. Data presented are the mean ± SEM.
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Figure 4.6: G d3+ rapidly and transiently phosphorylates Akt in stage 20 nodose neurons cultured  
in media containing a low concentration o f  calcium .
Stage 20 nodose neurons were cultured in media containing 0.7mM [Ca2+]0 for 4 hrs. With the 
exception of control and BDNF only cultures, neurons were stimulated by the addition of lpM Gd3+. 
Cells treated with Gd3+ were lysed, and the lysate prepared for western blotting, either 5, 10, 30 or 60 
minutes after stimulation. Control and BDNF only cultures were lysed alongside the cultures for the 5 
minute Gd3+ stimulation time point.
A: Western blots demonstrating that increased levels of phosporylated Akt were present in stage 20 
nodose neurons following 5 and 10 minute exposure to Gd3+. Phosphorylated Akt appeared to return 
to basal levels within 30 minutes o f Gd3+ treatment. Filters were re-probed with an antibody against 
P-III tubulin to allow normalization and quantification of the phospho-Akt signal.
B: Graphical representation of the normalised levels of phospo-Akt following densitometric analysis of 
the western blots shown in A. Increased levels of phosp-Akt, a known target for activated PI3- 
Kinase, after Gd 3+ stimulation raises the possibility that PI3-Kinase may exert neuritic outgrowth 
promoting activity at least partially via activation of Akt.
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Figure 4.7: T he effects o f  G S K 3, P I3-K in ase and M E K 1/2 inhibitors on the extent o f  axon outgrowth from  
stage 23 nodose n eu ron s cu ltured  in m edia containing a low calcium  concentration in the presence o f  
lp M  Gd3*.
Stage 23 nodose neurons were cultured without BD N F in media containing 0.7mM  [Ca2+]0With the exception o f  
control cultures, culture m edia was supplemented with either lpM  Gd3+ alone or lpM  Gd3+ plus either lOpM o f  
the GSK inhibitor, B io, 50pM  o f  the PI3-Kinase inhibitor, LY294002 or 10 pM  o f  the MEK1/2 inhibitor, 
PD98059. Fluorescent im ages for analysis o f  process growth were captured after a 24 hr culture period.
A: lpM  Gd3+ increased mean total neurite length in media containing a low  calcium concentration.
B: Bio reduced mean total neurite growth in the presence o f  lp M  Gd3+.
C: In the presence o f  Gd3+, L Y 294002 and PD 98059 decreased mean total neurite length compared to neurons 
cultured with Gd + alone.
n = 150 neurons per condition from 3 different experiments. Data presented are the mean ±  SEM. *** denotes 
p < 0.0001 after statistical com parisons with control (A ) or G d 3+ (B and C) (ANO VA with Fisher's ad hoc).
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Figure 4.8: The effects of GSK3, PI3-Kinase and MEK1/2 inhibitors on the survival of stage 23 
nodose neurons cultured in media containing a low calcium concentration in the presence of lpM  
Gd3*.
Stage 23 nodose neurons were cultured for 24 hours, in the absence o f  BDNF, in media containing 0.7mM  
[Ca2+]0 . With the exception o f  control cultures, culture media was supplemented with either lpM  Gd3+ 
alone or lpM  Gd3+ plus either lOpM  o f  the GSK inhibitor, B io, 50|iM  o f  the PI3-Kinase inhibitor, 
LY 294002 or 10 pM  o f  the M EK 1/2 inhibitor, PD 98059. Neurons were counted 3 hrs after plating and 
after 24 hrs in culture, allow ing percentage neuronal survival at 24 hrs to be determined. There were no 
significant differences in survival between control cultures and cultures supplemented with Gd3+ alone or 
Gd3+ plus either B io , LY or PD. Data are the mean +/- SEM from three separate cultures containing 
triplicate dishes for each condition.
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Figure 4.9: T he effects o f  G S K 3, P I3-K in ase and M E K 1/2 inhibitors on the extent o f  axon outgrowth  
from stage 27 n odose n eu ron s cu ltured  in m edia containing a low calcium  concentration in the presence 
o f  BD N F and G d3*.
Stage 27 nodose neurons were cultured with 10 ng/ml BD N F in media containing 0.7mM  [Ca2+]0. With the 
exception o f  B D N F only cultures, culture m edia was supplemented with either lpM  Gd3+ alone or lpM  
Gd3+ plus either lOpM  o f  the GSK inhibitor, B io, 50pM  o f  the PI3-Kinase inhibitor, LY294002 or 10 pM o f  
the MEK1/2 inhibitor, PD 98059. Fluorescent im ages for subsequent analysis o f  process growth were captured 
after a 24 hr culture period.
A: lpM  Gd3+ increased m ean total axon length in media containing a low  calcium concentration and BDNF  
B: Bio dramatically reduced mean total axon length in the presence o f  BDNF plus Gd3+.
C: In the presence o f  B D N F plus Gd3+, L Y 204002 did not effect axon outgrowth whereas PD98059  
increased mean total axon length compared to neurons cultured with BDNF plus Gd3+ alone, 
n = 150 neurons per condition from 3 different experiments. Data presented are the mean ± SEM. *** denotes 
p < 0.0001 after statistical comparisons with BD N F alone (A ) or BDNF plus G d 3+ (B), whereas ** denotes p 
< 0.001 compared to B D N F plus G d 3+ (A N O V A  with Fisher's ad hoc). 120
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Figure 4.10: The effects of GSK3, PI3-Kinase and MEK1/2 inhibitors on the survival of stage 
27 nodose neurons cultured in media containing a low calcium concentration in the presence 
of BDNF and lpM  Gd3+.
Stage 27 nodose neurons were cultured for 24  hours, in the presence o f  10 ng/ml BDNF, in media 
containing 0.7m M  [Ca2+]0. With the exception o f  BDNF only cultures, culture media was 
supplemented with either lp M  Gd3+ alone or lpM  Gd3+ plus either 10pM o f  the GSK inhibitor, Bio, 
50|iM  o f  the PI3-Kinase inhibitor, LY 294002 or 10 pM o f  the MEK1/2 inhibitor, PD98059. 
Neurons were counted 3 hrs after plating and after 24 hrs in culture, allowing percentage neuronal 
survival at 24  hrs to be determined. There were no significant differences in survival between 
BDNF containing cultures and B D N F containing cultures supplemented with lpM  Gd3+ alone or 
lpM
Gd3+ plus B io, LY  or PD. Data are the mean +/- SEM from three separate cultures containing 
triplicate dishes for each condition.
121
A
12 0  -i
100 -
Control B D N F Caspase BD N F  
Inhibitor +  
LY
C
120 n
100 -
Control B D N F Caspase BDNF  
Inhibitor + 
PD
B
120 i
Control BDNF Caspase BDNF  
Inhibitor + 
Bio
Figure 4.11: T h e effects o f  B D N F , caspase inhibitors and G SK 3, PI3-K inase and M EK 1/2 inhibitors 
on the survival o f  stage 33  nodose neurons cultured in m edia containing 1.3m M  [Ca2+]0 .
Stage 33 nodose neurons were cultured in media containing 1.3mM[Ca2+]0. With the exception o f  control 
cultures, culture m edia w as supplemented with either 10 ng/ml BDNF alone, 10pM caspase inhibitors alone, 
or 10 ng/ml BDNF plus either lOpM o f  the G SK inhibitor, B io, 50pM  o f  the PI3-Kinase inhibitor, 
LY294002 or 10 pM  o f  the M EK1/2 inhibitor, PD 98059. Neurons were counted 3 hrs after plating and after 
24 hrs in culture, allow ing percentage neuronal survival at 24 hrs to be determined.
A, B and C: Stage 33 nodose neurons required BD N F to support in vitro survival. In the absence o f  BDNF, 
caspase inhibitors also supported the survival o f  stage 33 nodose neurons over a 24 hour culture period. 
Neither B io (A ) , LY (B ) or PD (C ) affected die survival o f  stage 33 nodose neurons cultured with 10 ng/ml 
BDNF.
Data are the mean + /- SEM  from three separate cultures containing triplicate dishes for each condition.
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Figure 4.12: T he effects o f  B D N F and G SK 3, PI3-K inase and M EK 1/2 inhibitors on the extent o f  axon  
outgrowth from  stage 33  nodose neurons cu ltured  in m edia containing 1.3m M  [Ca2+]0.
Stage 33 npdose neurons were cultured either in the presence o f  lOpM caspase inhibitors, or with 10 ng/ml 
BDNF, in m edia containing 1.3mM [Ca2+]0. Som e BDNF containing cultures were supplemented with either 
lOpM o f  the GSK inhibitor, B io, 50pM  o f  the PI3-Kinase inhibitor, LY294002 or 10 pM o f  the MEK1/2 
inhibitors, PD 98059. Fluorescent im ages for subsequent analysis o f  axon growth were captured after a 24 hr 
culture period.
A, B and C: Stage 33 nodose neurons required BDNF to promote significant axon outgrowth in media containing 
1.3mM Ca2+
A: The GSK3 inhibitor, B io, dramatically reduced BD N F promoted axon outgrowth.
B: The PI3-Kinase inhibitor, L Y 294002, and (C ) the MEK inhibitor, PD 98059, did not significantly modulate 
BDNF promoted axon outgrowth from stage 33 nodose neurons cultured in media containing 1.3mM Ca2+. 
n = 150 neurons per condition from 3 different experiments. Data presented are the mean ± SEM. *** denotes p 
< 0.0001 after statistical comparisons with BD N F (AN O V A  with Fisher's ad hoc).
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Figure 4.13: The effects o f  G SK 3, P13-Kinase and M EK 1/2 inhibitors on the extent o f  axon outgrowth from  
stage 33 nodose neurons cultured in m edia containing a low  calcium  concentration in the presence o f  BDNF  
and lp M  Gd3*.
Stage 33 nodose neurons were cultured with 10 ng/ml BDNF in media containing 0.7mM [Ca2+]0. With the 
exception o f  BDNF only cultures, culture media was supplemented with either lpM  Gd3+ alone or lpM  
Gd3+ plus either lOpM o f  the GSK inhibitor, Bio, 50pM  o f  the PI3-Kinase inhibitor, LY294002 or 10 pM o f  the 
MEK1/2 inhibitor, PD98059. Fluorescent images for subsequent analysis o f  process growth were captured after a 24 
hr culture period.
A: lpM  Gd3* increased mean total axon length in media containing a low calcium concentration plus BDNF.
B: Bio dramatically reduced mean total axon length in the presence o f  BDNF plus Gd3+.
C: In the presence o f  BDNF plus Gd3+, LY 294002 promoted axon growth. In contrast PD98059 had no
affect on the extent o f  axon outgrowth compared to neurons cultured in the presence o f  BDNF plus Gd3+ alone, 
n = 150 neurons per condition from 3 different experiments. Data presented are the mean ± SEM. *** denotes p < 
0.0001 after statistical comparisons with BDNF alone (A) or BDNF plus Gd 3+ (B and C) (ANOVA with Fisher's ad 
hoc). 1 2 4
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Figure 4.14: The effects of GSK3, PI3-Kinase and MEK1/2 inhibitors on the survival of stage 
33 nodose neurons cultured in media containing a low calcium concentration in the presence 
of BDNF and lpM Gd3+.
Stage 33 nodose neurons were cultured for 24 hours, in the presence o f  10 ng/ml BDNF, in media 
containing 0.7m M  [Ca2+]0. With the exception o f  BDNF only cultures, culture media was 
supplemented with either lp M  Gd3+ alone or lpM  Gd3+ plus either lOpM o f  the GSK inhibitor, Bio, 
50pM  o f  the PI3-Kinase inhibitor, LY 294002 or 10 pM o f  the MEK1/2 inhibitor, PD98059. 
Neurons were counted 3 hrs after plating and after 24 hrs in culture, allowing percentage neuronal 
survival at 24  hrs to be determined. There were no significant differences in survival between 
BDNF containing cultures supplemented with Gd3+ alone or Gd3+ plus Bio, LY or PD, although 
Gd3+ plus B D N F appeared to enhance survival compared to BDNF alone. Data are the mean +/- 
SEM from three separate cultures containing triplicate dishes for each condition. * denotes p <
0.01 after statistical comparisons between BDNF and BDNF plus G d 3+ (ANOVA with Fisher's ad 
hoc).
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Figure 4.15: T he effects o f  m odulating G SK 3 signalling on the survival o f  and process outgrowth from  
stage 30 nodose neurons cu ltured  in m edia containing 1.3m M  C a2+.
Stage 30 nodose neurons were cultured with 10 ng/ml BDNF in media containing 1.3mM [Ca2+]0. 
Electroporation w as used to co-transfect neurons with the expression vector pcDNA3.1 containing cDNA  
encoding YFP together with either empty pcDNA3.1 (control), pcDNA3.1 containing the cD N A  encoding 
wild type GSK3 (GSK3 WT) or pcDNA3.1 containing the cD N A  encoding a dominant negative GSK3 
(GSK3 DN). Co-transfected YFP expressing neurons were counted 24 hrs after plating and after 48 hrs in 
culture, allowing percentage neuronal survival at 48 hrs to be determined. Fluorescent images o f  YFP 
expressing neurons for subsequent analysis o f  process growth were captured after a 24 hr culture period.
A: Over-expression o f  either wild type GSK3 or dominant-negative GSK3 did not significantly alter the 
survival o f  cultured stage 30 nodose neurons compared to control cultures .
B: Over-expression o f  dominant-negative GSK3 significantly decreased mean total neurite length o f  
stage 30 nodose neurons compared to control cultures, whereas over-expression o f  wild type GSK3 did 
not significantly effect the extent o f  neurite outgrowth compared to control cultures, 
n = 90 neurons per condition from 3 different experiments. Data presented are the mean ±  SEM. *** 
denotes p <  0.0001 after statistical comparison with control (ANO VA with Fisher's ad hoc). 126
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Figure 4.16: The specific C aSR  agonist Calhex rapidly phosphorylates GSK3 on its regulatory 
tyrosine residue, but not its regulatory serine residue, in stage 30 nodose neurons cultured in 
media containing a low concentration o f calcium.
Stage 30 nodose neurons were cultured in media containing 0.7mM [Ca2+]0 for 4 hrs. With the 
exception of control cultures, neurons were stimulated by the addition of 25nM Calhex. Cells were 
lysed, and the lysate prepared for western blotting, either 5, 10, 30 or 60 minutes after stimulation. 
Control cultures (NF) were lysed alongside the cultures for the 5 minute Gd3+ stimulation time point. 
A: Western blots demonstrating that increased levels of tyrosine phosporylated GSK3 were present in 
stage 30 nodose neurons following 5, 15 and 30 minute exposure to Calhex.
Filters were re-probed with an antibody against p-III tubulin.
B: Western blots demonstrating no increased phosporylation of GSK3 on its serine residue when stage 
30 nodose neurons are exposed to the CaSR agonist Calhex.
Filters were re-probed with an antibody against P-III tubulin.
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Figure 4.17: Sum m ary o f the effects o f GSK3, PI-3 Kinase and MEK1/2 inhibitors on the extent of  
axon outgrowth from  stage 20, 23, 27 and 33 nodose neurons cultured in media containing a low  
calcium concentration in the presence o f lp M  Gd3+
Mean total axon length data from figures 4.12, 4.14,4.16 and 4.18 is shown. For clarity, data has been 
normalised to mean total axon length o f neurons cultured with lpM Gd3+ at each stage.
The GSK3 inhibitor, Bio, significantly reduced the ability of Gd3+ to promote axon outgrowth at all stages. 
The inhibitory effects o f Bio on Gd3+ promoted axon elongation increases between stage 20 and stage 33. 
The PI3-kinase inhibitor, LY294002, significantly reduced the ability of Gd3+ to promote axon outgrowth at 
stages 20 and 23. However, LY294002 does not interfere with the ability of Gd3+ to increase axon length at 
stage 27 and potentiated the effects o f Gd3+ at stage 33.
The MEK1/2 inhibitor, PD98059, significantly reduced the ability of Gd3+ to enhance axon length at stages 
20 and 23, but not stages 27 or 33.
n = 150 neurons per condition from 3 different experiments for each developmental stage. Data presented 
are the mean ± SEM. *** denotes p < 0.0001 after statistical comparisons with G d3+ alone (stages 20 and 
23) or BDNF plus Gd 3+ (stage 27 and 33), whereas ** denotes p < O.OOlcompared to BDNF plus G d 3+ 
(ANOVA with Fisher's ad hoc).
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4.3 Discussion
The aim of this chapter was to use pharmacological inhibitors of PI3-kinase, GSK3 
and MEK1/2 to determine whether any of these signalling proteins are involved in 
transducing signals from the activated CaSR into enhanced axon growth. These three 
signalling proteins were chosen for investigation because they have been shown to play a role 
in modulating neurotrophic factor-dependent neurite growth by either regulating 
actin/microtubule polymerization dynamics in the growth cone or regulating the activity of 
transcription factors that promote the transcription of mRNAs encoding structurally important 
proteins within extending neuronal processes.
In this chapter, I have used the physiologically relevant CaSR agonist, Ca , and the
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non-physiologically relevant, but potent, CaSR agonists, Gd and Calhex to activate the 
CaSR in cultured nodose neurons. For clarity and ease of interpretation, the data obtained 
with the most widely used agonist, Gd3+, at each developmental stage are summarised in 
figure 4.17.
4.3.1 PI3-kinase, MEK1/2 and GSK3 signalling are not required for either BDNF- 
independent or BDNF-dependent survival of nodose neurons
PI3-kinase- and GSK3-mediated signalling have previously been shown to play a role 
in regulating the survival of both neurotrophic factor dependent neurons and neuronal cell 
lines under conditions that trigger apoptosis (Andjelkovic et al., 1998; Ashcroft et al., 1999; 
Bijur and Jope, 2001; Klesse et al., 1999; Pap and Cooper, 1998; Rodriguez-Viciana et al., 
1994). It was, therefore, surprising that inhibiting these signalling proteins did not effect the 
survival of either newly differentiated, neurotrophic factor-independent or later stage, BDNF- 
dependent, placode-derived cranial sensory neurons of the chicken embryo. The great 
majority of studies on the roles of PI3-Kinase and GSK3 in mediating neuronal survival have 
utilised neuronal cell lines and rodent sympathetic neurons, neural-crest-derived sensory 
neurons and motoneurons. It is possible, therefore, that placode-derived cranial sensory 
neurons of the chicken embryo utilise different signalling pathways to promote survival 
compared to the rodent neurons and cell lines hitherto studied. However, in accordance with 
previously published data (Creedon et al., 1996; Klesse et al., 1999), inhibition of MEK1/2 
by PD98059 did not effect the survival of cultured chick nodose neurons, either in the 
presence or absence of BDNF. The fact that the signalling protein inhibitors used in this study 
did not significantly effect neuronal survival makes the effects of PI3-kinase, MEK1/2 and 
GSK3 inhibitors on activated CaSR-promoted axon growth far easier to interpret.
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43.2 Signalling pathways that mediate CaSR-promoted de novo axon growth
In accordance with the data in chapter 3, lpM Gd 3+ was able to promote robust de 
novo axon growth from neurotrophic factor-independent stage 20 and 23 nodose neurons. 
Blocking the function of PI3-Kinase by LY294002 had a profound inhibitory effect on 
activated CaSR-promoted axon outgrowth at both stages. In contrast, LY294002 did not 
reduce the length of axons projecting from stage 20 nodose neurons cultured in medium 
containing 0.7mM Ca2+, culture conditions that do not significantly activate the CaSR. 
Interestingly, LY294002 was able to reduce the length of axons projecting from stage 23 
nodose neurons stimulated with 1 pM Gd3+ to below those of neurons cultured in 0.7mM Ca2+ 
alone. This may reflect an ability of 0.7mM [Ca2+]0 to activate the CaSR sufficiently to 
promote limited axon elongation.
Further confirmation that PI3-Kinase plays an important role in activated CaSR- 
promoted axon growth in the absence of BDNF was obtained by transfecting stage 20 neurons 
with plasmids expressing either constitutively active or dominant-negative PI3-Kinase and 
culturing the neurons in medium containing either 0.7mM or 1.3mM Ca2+. Over-expression of
constitutively active PI3-Kinase significantly increased axon length in medium containing
2+  • •1.3mM Ca , whereas over-expression of dominant-negative PI3-Kinase reduced axon length
in the same medium. The over-expression of either protein did not alter the length of axons
extending from nodose neurons cultured in medium containing 0.7mM Ca . Additional
evidence that PI3-kinase is involved in activated CaSR-promoted axon growth is provided by
the demonstration that Akt, a major downstream target of activated PI3-Kinase, is rapidly
phosphorylated after the addition of lpM Gd to cultures of stage 20 nodose neurons. Taken
together the data presented in this chapter demonstrate that PI3-Kinase plays an important role
in transducing activation of the CaSR into enhanced BDNF-independent axon growth. Whilst
this finding is in accordance with the observations that PI3-Kinase can be activated
downstream of G protein-coupled receptor stimulation in non-neuronal cells (De Camilli et
al., 1996) and PI3-kinase signalling promotes neurotrophic factor-dependent axon growth
(Aoki et al., 2005; Jiang et al., 2005; Shi et al., 2003; Yoshimura et al., 2005; Zhou et al.,
2004) this is the first demonstration that PI3-Kinase signalling promotes de novo axon
growth.
Inhibiting either MEK1/2 or GSK3 also significantly decreased the extent of Gd3+- 
promoted axon elongation from stage 20 and 23 nodose neurons. MEK1/2 inhibition reduced 
Gd3+-promoted axon growth by around 50% at both stage 20 and 23. Inhibiting GSK3 with
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Bio reduced Gd3+-promoted axon growth by 30% at stage 20 and eliminated it at stage 23. At 
both stages, LY294002 was a more potent inhibitor of Gd3+-enhanced axon growth than either 
PD98059 or Bio, indicating that, of the three signalling proteins investigated, PI3-kinase plays 
the most important role in transducing activation of the CaSR into enhanced de novo axon 
growth.
Although, ERK signalling in response to neurotrophic factors has previously been 
shown to induce local axon assembly and to promote the transcription of mRNAs involved in 
axon growth by activating the transcription factors CREB and NFATc (Atwal et al., 2000; 
Lonze and Ginty, 2002; Nguyen and Di Giovanni, 2008; Xing et al., 1996; Xing et al., 1998), 
I have demonstrated for the first time that ERK activation also promotes de novo axon 
growth. The activation o f Akt and ILK by PI3-kinase has previously been shown to lead to the 
phosphorylation of GSK3 and subsequent growth cone extension and axon elongation (Zhou 
et al., 2004; Jiang et al., 2005; Zhou and Snider, 2006). In addition, the ERK1/2 MAPK 
pathway has also been shown to phosphorylate GSK3 via MAPKAP Kinase-2 (Jope and 
Johnson, 2004; Stambolic and Woodgett, 1994; Stokoe et al., 1992). Together with my data, 
these previous findings may suggest that PI3-kinase and ERK are upstream of GSK3 
phosphorylation in the signal transduction pathway that leads to enhanced axon growth 
following CaSR activation. However, in these previous studies, activated PI3-Kinase and 
ERK1/2 lead to the phosphorylation of GSK3 on its regulatory serine residue and resulted in 
the inactivation of GSK3. Inactivation of GSK3 by serine phosphorylation has previously 
been implicated in promoting axon growth (Jiang et al., 2005; Zhou and Snider, 2006; Zhou et 
al., 2004). In contrast, my data clearly shows that inhibition of GSK3 by Bio, an inhibitor that 
blocks ATP binding to GSK3 and prevents phosphorylation of downstream substrates, has a 
detrimental effect on activated CaSR-promoted axon growth in the absence of BDNF. This 
suggests that stimulation of GSK3 activity rather than its inactivation is an important step in 
coupling CaSR stimulation to de novo axon growth. This novel finding and the nature of 
GSK3 activation is discussed further in section 4.3.3, below.
My data raise the possibility that the serine threonine kinase, Akt is a downstream 
target of PI3-kinase following CaSR activation. As mentioned above, previously published 
literature has suggested that GSK3 is a major target of Akt in pathways that regulate axon 
growth and that Akt phosphorylates GSK3 on its regulatory serine residue to inhibit its 
activity and promote microtubule polymerization. In light of the data obtained by using Bio in 
my experiments it seems unlikely that GSK3 is the target of activated CaSR stimulated Akt. 
Further experiments are therefore needed to identify the substrates of Akt following CaSR
133
activation and to determine whether these substrates are linked to signalling pathways that can 
promote axon growth. In addition to regulating microtubule dynamics via Akt, PI3-kinase can 
also promote filopodial and lamellipodial extension by modulating actin polymerization 
kinetics by pathways that include activation of either Cdc42 or Rac (Zhou and Snider, 2006). 
Future Western blot experiments are needed to determine whether either Cdc42 or Rac 
activation occurs following CaSR activation. If this is the case, further culture experiments 
need to be performed to find out whether activation of these small GTPases is necessary for 
CaSR-promoted axon growth.
4.3.3 Signalling pathways that mediate CaSR-promoted BDNF-dependent axon growth
Surprisingly, PI3-kinase did not appear to play a role in transducing CaSR and trkB 
activation into enhanced axon elongation from stage 27 chick nodose neurons. Moreover, 
LY294002 enhanced axon growth from stage 33 nodose neurons cultured with lpM Gd in 
the presence of BDNF, raising the possibility that PI3-Kinase activation at this stage inhibits 
axon growth. This finding is at odds with the well characterised role of PI3-Kinase in 
mediating neurotrophic factor-promoted neuronal process outgrowth from various types of 
rodent neurons and cell lines (Aoki et al., 2005; Jiang et al., 2005; Nusser et al., 2002; 
Yoshimura et al., 2005; Zhou et al., 2004). Curiously, inhibiting PI3-kinase in stage 33 
nodose neurons cultured in medium containing 1.3mM Ca2+ plus BDNF did not affect axon 
length. This anomaly may be due to the fact that Gd3+ is a more potent activator of the CaSR,
•  •  •  9+and hence promotes greater axon growth, than its main physiological ligand, Ca . 
Alternatively, it is possible that activation of the CaSR by both agonists is qualitatively 
different, resulting in the recruitment of different G proteins and the activation of different 
intracellular signalling cascades. Limited evidence already exists to suggest that different 
agonists may activate the CaSR in qualitatively different ways (Ward, 2004). Whilst the lack 
of involvement of PI3-Kinase signalling in BDNF-promoted axon growth from later stage 
nodose neurons is surprising, it may indicate that signalling pathways that mediate 
neurotrophin-promoted process outgrowth from chick placode-derived cranial sensory 
neurons differ from those in rodent neurons and cell lines.
In contrast to its role in mediating CaSR-enhanced axon growth at early 
developmental stages, MEK1/2-ERK signalling did not appear to be involved in BDNF and 
activated CaSR-promoted axon growth at stages 27 and 33. This finding is also surprising, 
since ERK signalling has previously been shown to be involved in regulating neuronal 
process outgrowth in response to neurotrophic factors (Atwal et al., 2000; Lonze and Ginty,
134
2002; Nguyen and Di Giovanni, 2008; Xing et al., 1996; Xing et al., 1998). Once again, 
previously published data has been taken from studies involving rodent neurons and cell lines, 
and it may be that signalling pathways differ in the chick or the particular placode-derived 
sensory neurons studied.
My data clearly show that GSK3 is an extremely important component of the 
signalling cascades that convert CaSR activation in the presence of BDNF into enhanced axon 
elongation. Bio was able to reduce the mean length of axons projecting from stage 27 and 33 
nodose neurons cultured with BDNF and lpM Gd3+ to below that of neurons cultured in 
BDNF alone. Although this suggests that Bio can completely block axon growth promoted by 
CaSR activation as well as inhibiting growth promoted by trkB activation, the experimental 
design used in my studies precludes a definitive determination of whether GSK3 transduces 
signals downstream of either the activated CaSR or activated trkB, or both. Bio was also able 
to completely abolish BDNF-promoted growth from stage 33 neurons cultured in medium 
containing 1.3mM Ca2+. Once again, although this strongly suggests that GSK3 is involved in 
transducing trkB activation into enhanced axon growth, the experimental design cannot 
determine to what extent GSK3 also signals downstream of the activated CaSR to promote 
axon elongation, since 1.3mM Ca2+ significantly activates the CaSR. The pivotal role of 
activated GSK3 in transducing CaSR stimulation in the presence of BDNF into enhanced 
axon growth was further established by transfection experiments at stage 30 using either wild 
type GSK3 or dominant-negative GSK3 expression plasmids. Whilst over-expression of wild 
type GSK3 did not increase the length of axon growing from stage 30 nodose neurons 
cultured in medium containing 1.3mM Ca2+, the expression of dominant-negative GSK3 
greatly reduced the length of axons in the same culture medium.
As discussed above, inhibition of GSK3 activity by serine phosphorylation is normally 
associated with neurotrophic factor-promoted neurite growth. My novel data clearly 
demonstrate that in chick nodose neurons it is GSK3 activation that promotes axon growth. 
GSK3 activity is normally tightly controlled by a balance of inhibitory serine phosphorylation 
and stimulatory tyrosine phosphorylation (Jope and Johnson, 2004). To determine whether 
CaSR activation did indeed lead to tyrosine phosphorylation of GSK3,1 carried out Western 
blots of cell lysates extracted from stage 30 nodose neurons that had been stimulated by 
25mM of the potent and specific, commercially available CaSR agonist, Calhex, in medium 
containing 0.7mM Ca2+ and lacking BDNF. Western blots clearly demonstrated that Calhex 
induced a rapid phosphorylation of GSK3 on its regulatory tyrosine residue without affecting 
the phosphorylation status of the regulatory serine residue.
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Whilst my data suggest that CaSR activation promotes neurite growth from later stage, 
BDNF-dependent nodose neurons by a signalling pathway that involves GSK3 activation by 
tyrosine phosphorylation, several pertinent questions need addressing to further characterise 
this signalling pathway. For example, experiments need to be performed with Bio using an 
experimental design that will allow a clear distinction between the roles of CaSR activation 
and trkB activation in promoting neurite growth from later stage nodose neurons. It will also 
be important to determine whether trkB activation in absence of CaSR stimulation also leads 
to tyrosine phosphorylation and activation of GSK3 in the absence of serine phosphorylation. 
In addition, the recently available potent and specific CaSR antagonist, Calindol, will be 
useful to specifically isolate axon growth-promoting signalling pathways initiated by either 
trkB activation or CaSR activation.
The novel observation that tyrosine phosphorylation and stimulation of GSK3 activity 
is a key step in transducing CaSR and/or trkB activation into enhanced axon growth from 
BDNF dependent chick cranial sensory neurons, begs the question of what is the identity of 
the tyrosine kinase that is responsible for activation of GSK3. One candidate is the soluble 
intracellular tyrosine kinase, src. Although src has previously been shown to be activated 
following neurotrophin receptor stimulation (Reichardt, 2006) there are no reports that CaSR 
activation can modulate its activity. Further Western blot experiments are needed to determine 
if activation of either the CaSR or trkB can promote src phosphorylation in BDNF dependent 
chick cranial sensory neurons. If this proves to be the case, experiments with specific src 
inhibitors could be used to investigate whether src activation downstream of either CaSR or 
trkB activation is necessary for enhanced axon elongation.
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Summary
The data in this chapter demonstrate a clear switch in the signalling pathways that are 
involved in promoting axon elongation from chick nodose neurons from early BDNF- 
independent stages of de novo axon growth to later BDNF-dependent stages of axon growth. 
PI3-Kinase is the key signalling protein that links CaSR activation to enhanced axon growth 
at the earliest developmental stages, whereas GSK3 is the major signalling protein associated 
with later CaSR- and trkB-promoted axon elongation. Importantly, my data demonstrates that 
activation of GSK3 by tyrosine phosphorylation is a crucial step leading to enhanced axon 
growth in later stage chick nodose neurons. Further experiments are warranted to fully 
characterise this novel developmental switch the intracellular signalling network that governs 
axonal growth.
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General Discussion
Until recently, the CaSR has been studied in the context of systemic [Ca 2+]o homeostatis. 
Although the widespread expression of the CaSR in the nervous system has been known for 
many years, the first role for the CaSR in the nervous system was only recently established by 
the demonstration that activation of the CaSR in SCG neurons during a narrow developmental 
window in the immediate perinatal periods enhances NGF-promoted axonal growth and 
branching in vitro and the finding that sympathetic innervation is defective in newborn mice 
lacking the CaSR gene (Vizard et al., 2008).
My work has extended the role of the CaSR in regulating axonal growth to the earliest stages 
of neuronal development. I have demonstrated that activation of the CaSR is required for the 
neurotrophin-independent extension of axons from the placode-derived neurons of the nodose 
ganglion at the time in development when these neurons are extending axons towards their 
targets. Nodose neurons have distant targets and exhibit an especially fast rate of axonal 
growth at this stage of development. In contrast, the placode-derived neurons of the 
vestibular ganglion, which have nearby targets and extend axons at a much slower rate to 
these targets, express lower levels of the CaSR than nodose neurons, and activity of the CaSR 
in these neurons has no affect on axon growth rate. Because of the hypercalcaemic milieu of 
the embryo, these findings imply that differences in the level of CaSR expression in early 
placode-derived neurons plays a role in governing intrinsic differences in the rates at which 
axons grow from these neurons to their targets. However, high levels of CaSR expression are 
not sufficient to confer fast axonal growth since overexpression of CaSR in neurotrophin- 
independent vestibular neurons did not enhance axonal growth rate. One reason for this might 
be because the signalling mechanisms downstream of the receptor are not active at this stage 
of development in these neurons, since overexpression the CaSR at later stages in 
development significantly increased axon growth from BDNF-dependent vestibular neurons. 
The fact that we found CaSR upregulated mRNA expression in nodose neurons during 
development while it stayed at the same levels thoughout development in vestibular neurons 
also points at a missing signalling mechanism in early stages. One further experiment to 
confirm different levels of CaSR expression in nodose and vestibular neurons are semi- 
quantitative western blots, where there should be a visible upregulation in CaSR protein in 
nodose neurons but not in vestibular neurons during development.
The technical difficulty using electroporation, is that placode-derived chicken neurons at 
these early stages in development are very sensitive to electroporation. The overall growth
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rate decreased significantly compared to non-electroporated neurons. I can exclude that the 
reporter we used for transfection -YFP- to have a toxic effect on the neurons, since I also 
earned out transfections without the reporter and stained the neurons with a CaSR antibody. 
Even though transfected neurons could not be identified visually, the overall count and 
analysis of these neurons showed an increase or decrease in growth, respectively, but still an 
overall decrease in neurite length compared to non-transfected neurons.
To confirm that the CaSR dominant negative is effective, since it had to be cloned into the 
chicken construct, we could use two different approaches. Either by electroporation of nodose 
neurons and then running a western blot afterwards, looking for the CaSR downstream 
signalling. This approach is technically impossible, as by using this method there will not be 
enough protein to detect any downstream signalling. Another approach could be to look at a 
stable cell line expressing the CaSR wild type or dominant-negative constructs. I should find 
enhanced activated signalling downstream the wild type expressing cell line, while I should 
find reduced signalling in the dominant-negative expressing cell line. Overexpressing both 
constructs at the same time should bring signalling back to control levels.
An important issue will be to determine the physiological relevance of these in vitro 
observations. To this end, experiments are currently in progress to pharmacologically 
manipulate CaSR function in ovo, to see if such manipulations affect axonal growth rate and 
target innervation by nodose and vestibular neurons. These experiments involve administering 
the CaSR antagonist to stage 15 embryos, a time in development when neuroblasts have 
differentiated into neurons and axons start to extend towards their targets. Embryos are 
subsequently fixed at later stages and whole-mount neurofilament antibody staining carried 
out to visualize the respective nerves and measure their lengths. If my in vitro findings are 
relevant for in vivo development, I would predict that the CaSR antagonist would affect the 
growth of nodose but not vestibular axons. In ovo electroporation of DN CaSR has been also 
been attempted to address the physiological relevance of my in vitro observations, but 
electroporation of the respective placodes was either not successful or the very few cases in 
which placodes transfected, the embryos did not survive long enough to carry out the analysis.
After nodose ganglion axons reach their targets, the neurons become dependent on BDNF 
for survival, and BDNF promotes the growth and branching of the axons in vitro, which may 
reflect a role o f BDNF in facilitating the terminal branching and ramification of these axons in 
their targets. Manipulation of CaSR in cultured nodose neurons at this stage of development 
has also demonstrated that activation of the CaSR is crucial for BDNF-promoted axonal 
growth and branching. Studies to investigate the signalling pathways that mediate CaSR
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dependent axonal growth in developing nodose neurons has not only provided the first 
evidence for the intracellular molecular mechanisms by which CaSR affects axonal growth, 
but have revealed a completely unexpected switch in the signalling pathways that are required 
for axonal growth at neurotrophin-independent and BDNF-dependent stages of development. 
To investigate axon growth after target innervation and to examine the possibility of a cross­
talk in CaSR and Trk signalling, I carried out initial experiments to see if the CaSR is 
signalling together with or independently of the Trk receptor. Culturing neurons in the 
presence of high and low [Ca2+]o, but in the absence of BDNF (but in the presence of caspase 
inhibitor Boc-D-FMK), did not show differences in axon growth in stage 30 nodose neurons. 
Neurons cultured in low [Ca2+]o but in the presence and absence of BDNF increased axon 
growth in the cultures containing BDNF, but only up to half the length as I found the high and 
low [Ca 2+]o in the presence of BDNF.
This experiment suggests that the CaSR and Trk receptor need to be activated 
simultaneously, but whether the signalling pathways are linked can not be answered through 
this approach.
Experiments using selective pharmacological inhibitors have revealed that PI3-kinase 
signalling is required for neurotrophin-independent axon growth and GSK3 signalling is 
required for BDNF-dependent growth. One of the greatest technical obstacles in the further 
analysis of CaSR signalling at these neurons during these early stages of development is the 
extremely limited availability of nodose neurons for biochemical studies. Indeed, because of 
the very small size o f this ganglion, Western blot analysis was technically impossible up until 
the very end of the phase of neurotrophin-independence. Nonetheless, I was able to provide 
confirmatory evidence for CaSR-dependent PD-kinase signalling at this stage of 
development, and was able to demonstrate that CaSR activates GSK3 by a non-canonical 
mechanism that involves tyrosine phosphoryation of the enzyme during the stage of BDNF 
dependence. While I provided additional supportive evidence for these two signalling 
pathways in regulating axonal growth at these respective stages of development by 
transfecting the neurons with plasmids expressing mutated signalling proteins, nodose 
neurons turned out to be very sensitive to electroporation, in that the overall growth rate 
dropped significantly compared to non-electroporated neurons.
GSK3 has previously been reported to be constitutively active within the cell, and 
increases axon growth through its inactivation following signalling events that lead to 
phosphorylation on serine 9 (Armstrong et al., 2001; Fang et al., 2000; Hughes et al., 1993; Li 
et al., 2000; Stambolic and Woodgett, 1994). In marked contrast, my work shows in
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embryonic chicken nodose neurons that inactivation of GSK3 with the pharmacological 
inhibitor Bio, leads to decreased axon growth. Furthermore, GSK3 activation has been shown 
to be further enhanced by phosphorylation on tyrosine 216 (Jope and Johnson, 2004), and my 
data clearly indicate that CaSR-dependent phosphorylation of GSK3-a on tyrosine 216 results 
in embryonic nodose neurons enhances axonal growth. How GSK3 is phosphorylated on this 
tyrosine residue in nodose neurons is not clear. I did experiments to see if the src tyrosine 
kinase is involved in CaSR signalling, and found that while src phosphorylation is increased 
by CaSR activation, either by elevated [Ca2+]o or by the CaSR agonist Calhex, the src 
inhibitor PP2 did not decrease the level of phospho-tyrosine GSK3, suggesting that activation 
of src is not required for CaSR-dependent phosphorylation of GSK3 in nodose neurons.
While activation of the CaSR enhances the growth rate of nodose ganglion axons during the 
stages of neurotrophin independence and BDNF dependence, it is unlikely that the 
extracellular calcium and the CaSR play any direct role in axon guidance. This is because 
there is no evidence for and no reason to expect the presence of Ca2+ gradients in the 
extracellular fluid in the embryo that could differentially activate the CaSR across the growth 
cone. Rather, the relative hypercalcaemia of the embryo would likely granule cell growth 
cones to BDNF has been shown to be due to TrkB-dependent Ca2+-permeant TRPC channel 
opening (Li et al., 2005). Although BDNF is unlikely to be a long-range cue for early nodose 
neurons, since TrkB is not expressed by these neurons at the stage when their axons are 
growing to their targets (Robinson et al., 1996), it may play a role in local guidance of growth 
lead to constitutive activation of the CaSR in all locations on the surface of cells that express 
it. It is possible, however, that constitutive activation of the CaSR could indirectly affect the 
molecular mechanisms involved in axon guidance by affecting the sensitivity of such 
mechanisms to extracellular signals that govern growth cone direction. For example, since 
gradients of intracellular Ca2+ within the growth cone can influence growth cone turning, if 
CaSR affects the mean [Ca2+]i in the growth cone as a result of stimulating release of Ca2+ 
from intracellular stores, for example, this might affect the sensitivity of the molecular 
mechanisms that transduce [Ca2+]i gradients into directional responses of the growth cone to 
extracellular signals that bring about [Ca2+]i gradients in the growth cone. In future work it 
will be interesting to test the possibility that activation of the CaSR affects the sensitivity of 
growth cones to chemoattractants and chemorepellents. For example, BDNF-induced chemo- 
attractive turning of cerebellar cones in their target fields later in development. If so, it would 
be interesting to investigate if turning responses of growth cones to BDNF gradients is 
affected by the level of CaSR activation.
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Appendix
Appendix
SDS polyacrylamide gel electrophoresis 
Sample buffer
Electrophoresis buffer
10% separating gel(lOml)
4% stacking gel( 5ml)
Transfer buffer
lOOmM Tris pH 6.8 (Sigma)
2% SDS (Serva)
10% Glycerol
0.5% Bromphenol
5% p- Mercaptoethanlol (Sigma)
250mM Tris (Sigma)
1.9M glycine (Merck)
0.1% SDS (Serva)
4.05ml H20
2.6 ml 1.5M Tris pH 8.8, 0.4% SDS 
0.65ml 30% Acrylamide (Biorad)
5 pi TEMED (Biorad)
50pl 10%APS (Biorad)
3.05 H20
1.3ml 0.5 M Tris pH 6.8, 0.4% SDS 
0.65 ml 30% Acrylamide (Biorad)
5 pi TEMED (Biorad)
50pl 10% APS (Biorad)
20mM Tris (Sigma)
150mM Glycine (Merck)
0.1% SDS (Serva)
10% Methanol (Merck)
PBS Tween PBS
0.1% Polyoxyethylene sorbitan monolaurate 
(Sigma)
Blocking solution
4% stacking gel (5ml)
Transfer buffer
PBS Tween
Blocking solution
Stripping buffer
PBS Tween 
5% Milk Powder
3.05 ml H20
1.3ml 0.5M Tris pH 6.8, 0.4% SDS
0.65ml 30% Acrylamide/Bis solution (Biorad)
5 pi TEMED
50pl 10% APS (Biorad)
20mM Tris (Sigma)
150mM Glycine (Merck)
0.1% SDS (Serva)
10% Methanol (Merck)
PBS
0.1% Polyoxyethylene sorbitan monolaurate 
(Sigma)
PBS Tween 
5% milk powder
5mM Na2HP4
2% SDS (Serva) and freshly added:
0.02% p-Mercaptoethanol (Sigma)
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Poly-omithine Solution
9.2g boric acid (Sigma) was dissolved in 1L (IH2O and adjusted to PH 8.4 with NaOH.
500mg poly-DL-omithine hydrobromide (Sigma) was dissolved in the borate solution and 
filter serilized using a 0.2pm Acrocap filter unit (Pall Corporation). The poly- ornithine 
solution was stored in two 500 ml bottles at 4°C for up to 2 weeks.
Trypsin
50mg Trypsin (Worthington) was dissolved in 5ml Ca 2+ / Mg 2+ free PBS (Gibco, Invitrogen) 
, filter sterilized and stored at 50pl aliquots at -20°C
Siliconised pipettes
Glass Pasteur pipettes (Fisher Scientific) were placed in a large beaker which was filled with 
dH20 up to 3A length of the pipettes and left for 2 mins. The (IH2O was removed and replaced 
with dichlorodimethylsaline (BDH) and left for 30 mins. The pipettes where then washed 5 
times with dH20, a further 2 times with sterile PBS then placed in pipette boxes and 
autoclaved.
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